Prof. Pia Raanani

המטולוגיה סגל אקדמי קליני
Prof. Pia Raanani
External phone: 03-9377906
Fax: 03-9240145

Prof. Pia Raanani - Clinical Full Professor in Hematology

 

CURRICULUM VITAE

 

 

Name:              Pia        Raanani   Clinical Associate Professor                5655050-2   

                        (first)      (last)         (academic Degree)                             I.D.    no.

Faculty/Dept: Sackler School of Medicine, Tel-Aviv University

Place of work: Rabin Medical Center, Beilinson Hospital, Israel

Hospital/Dept: Head, Division of Hematology, Rabin Medical Center, Beilinson Hospital

Phone No.:03-9377906

Home address: 11, Efter  st., Tel-Aviv, 69362  

Mobile phone no.: 050-4065447                                   

Phone no.: 03-6995525

E-mail: praanani@012.net.il

Date & Place of birth: 11.6.1960          Israel

                                 (date)             (country)

Zahal (Israeli) Military Service: 26.10.1978 - 25.10.1980

Marital status: divorced                     No. of children:    -

 

 

A. EDUCATION

 

Period of Study (dates)

 

____________

Name of University (city, country)

__________

Subject

 

 

_____________

Degree or professional

License

_____________

Date Awarded

 

 

_____________

1980-1986

Hebrew University Jerusalem

Medicine

B.Sc

 

 

M.D.

1984

(cum laude)       

 

1989

 

Title of Master's Thesis: None

Name of Supervisors: None

 

Title of Doctoral Dissertation: Does complete revascularization by conventional method truly provide the best possible results?

 

Name of Supervisors: Professor Daniel A. Goor; Dr. Jacob Lavee

 

Date of receiving specialization certificate:

September 1992 - Internal Medicine

March 1995     - Hematology

 

 

B. FURTHER STUDIES

 

Period of study (dates)

 

 

 

 

Name of university (including city and country if not in Israel)

 

Subject

 

 

 

 

 

Degree or professional license

 

 

 

Date awarded

 

 

 

 

 

1.1988-5.1990

Tel-Aviv University

Postgraduate Medical School-Faculty of Medicine

      

5.1990

 

 

 

 

6.1995

Royal Postgraduate Medical School,  London, U.K.

 

Advances in Hematology

 

 

 

 

 

 

6.1997

Royal Postgraduate Medical School, London, U.K.

Advances in Hematology

 

 

 

 

C. ACADEMIC & PROFESSIONAL ACTIVITIES & ACHIEVEMENTS

    C1. ACADEMIC EXPERIENCE

 

Period (dates)

 

 

Name of institution (city, country)

Department

 

 

 

Rank/function

 

 

 

1.1991-7.1991

 

 

 

 

Beilinson Medical Center, Petah-Tikva, Israel

Laboratory of Hemostasis

Head: Prof. Judith Lahav

Basic sciences

 

 

 

 

8.1996-8.1997

 

 

 

 

 

Hammersmith Hospital-Royal Postgraduate Medical School

Hematology-Leukaemia Research Unit

Head: Prof. John Goldman

Reaserch  in Minimal Residual Disease in leukemia

Suprevisor: Dr. N.C.P Cross-Head of MRD laboratory

2006 ®

The Cochrane Collaboration

Cochrane Haematological Malignancies Group (CHMG)

 

Editor

2007-2010

Tel-Aviv University

Senate

Representative of Senior Lecturers in the Senate

2007-2010

Tel-Aviv University

Sackler School of Medicine

Representative of Senior Lecturers in the Faculty Council

2008-2014

Tel-Aviv University

Sackler School of Medicine

Member in the Research Funds Committee

 

2009 -2014

 

"Harefuah" - journal of the Israel Medical Association

Editorial Board

Editor

 

 

 

5.2010 ®

Tel-Aviv University

Sackler School of Medicine   

Clinical Associate Professor in Hematology

 

 

9.2010 -9.2014

 

Tel-Aviv University

Sackler School of Medicine   

Chairman of Hematology Department

 

 

1.2011®

 

Tel-Aviv University

Sackler School of Medicine

Member in the Scientific Committee of the Cancer Biology Research Center

 

 

12.2011®

Tel-Aviv University

The Djerassi Oncology Center

Member in the Scientific Committee of

 

 

 

 

5.2012 ®    American Society of Hematology                      Invited abstract reviewer                                                    

                                                                                                for 54th ASH meeting

 

7.2012 ®    Acta Haematologica       Editorial Board           Editor

 

2013–2016   Tel-Aviv University       Senate                         Deputee Representative                                                                                              of Associate Professors                                                                                                     in the Senate

 

2013 – 2016    Rabin Medical Center   Institutional review board (IRB)      Member

 

2014 ®           IMAJ –Israel Medical

                        Association Journal        Editorial Board                                Editor

 

5.2014®

Tel-Aviv University

 

  The Varda and Boaz Dotan                 Member in

   Research Center in                             Scientific

  Hemato-oncology                               Committee

 

9.2014 ®        Tel-Aviv University    Sackler School of Medicine                                                                                                                Research Funds Committee              Chairman

 

2.2015 ®        Cardio-oncology           Editorial Board                                 Editor

 

2015 ®           Tel-Aviv University      Department of Human                      Adjunct

                                                                         Genetics and Biochemistry                Professor

2015 ®           MD Anderson             Society of Hematologic Oncology                                                                             (SOHO)                                                         Ambassador

2017                            Harvard                     Buisness School Course                     Strategy for

                                                                                                                                 Health Care

                                                                                                                     Delivery

 

 

 

 

C2. PROFESSIONAL  EXPERIENCE

 

Period (dates)

 

 

 

Name of Institution (city, country)

 

 

   Department

 

 

 

Rank/Function

 

 

 

8.1988-8.1992

 

 

 

 

Beilinson Medical Center, Petah-Tikva, Israel

Internal Medicine

Resident

 

 

 

9.1992-3.1995

 

 

 

 

Sheba Medical Center, Tel-Hashomer, Israel

Hematology

Resident

 

 

 

4.1996-3.2002

 

 

 

 

Sheba Medical Center, Tel-Hashomer, Israel;

Rabin Medical Center, Campus Beilinson, Israel

Hematology

Senior Hematologist

 

 

 

 

 

 

 

3.2002 – 11.2004

Sheba Medical Center, Tel-Hashomer, Israel

 

Hematology

Head, Leukemia Service

11.2004 – 1.2007

Rabin Medical Center, Campus Beilinson, Israel

Hematology

Head, Leukemia Unit

 

2.2005 – 2.2008

 

 

 

1.2007®

Israeli Society of   Hematology and Blood Transfusions

 

Davidoff Cancer Center, Rabin Medical Center

Hematology

 

 

 

Hematology

Secretary

 

 

 

Establishment & Head of the Hemato-oncology Hospitalization  Unit

 

10.2011-11.2011

Memorial Sloan Kettering Cancer Center

Leukemia Service-Department of Medicine

Chief: Prof. Tallman

Visiting Professor

 

 

 

 

 

10.2013®               Rabin Medical Center    Hematology          Head of the Division                                           

 

C3. ACTIVE PARTICIPATION IN SCIENTIFIC MEETINGS

 

Year

Subject  (Role)

Place

3.1990

The Israeli Society of Internal Medicine, Ramat-Gan.

Life threatening hypophosphatemia in a patient with Philadelphia chromosome positive CML in acute blastic crisis.

P. Raanani, M. Lahav, M. Prococimer, E. Theodor  (Speaker)

 

Israel

11.1993

The Israeli Society of Hematology, Tel-Aviv.

Salvage combination chemotherapy for acute leukemia using high dose Ara-C and mitoxantrone. Experience of the Sheba Medical Center.

P. Raanani., O. Shpilberg, M. Bercowicz, O. Sofer, I. Hardan, A. Chetrit, I. (Speaker)

 

Israel

3.1996

The Israeli Society of Hematology, Natanya.

Salvage combination chemotherapy for acute leukemia using high dose Ara-C and mitoxantrone. Experience of the Sheba Medical Center: 1991-1995.

P. Raanani., O. Shpilberg, M. Bercowicz, O. Sofer, I. Hardan, A. Avigdor, A. Chetrit, I. Ben-Bassat (Speaker)

 

Israel

9.1997

The Israeli Society of Hematology and Blood Transfusion,            Dead Sea

Competitive PCR-The method and clinical applications.

P. Raanani,  N.Cross, J.Goldman - Institute of Hematology,            Sheba Medical Center, Tel-Hashomer, Hammersmith Hospital,

London    (Speaker)                                                                                    

 

Israel

10.1999

The Israeli Society of Hematology and Blood Transfusion,         Dead Sea

Engraftment associated hypophosphatemia - the role of cytokine release and steep leukocyte rise post stem cell transplantation.

P. Raanani, I. Levi, O. Shpilberg, F. Holzman, I. Grotto, F. Brok-Simoni, A. Avigdor, M. Berkowicz, I. Hardan, A. Kneller and I. Ben-Bassat. (Speaker)

 

 

2.2001

Annual meeting of the Cancer  Biology Research Center , Eilat

The role of cytokines and leukocyte rise in the development of hypophosphatemia after PBSCT.

P. Raanani, I. Levi, F. Holzman, I. Grotto,                      F. Brok-Simoni, A. Avigdor, J. Davidson, O. Shpilberg, and   I. Ben-Bassat. (Speaker)

 

Israel

1.2003

The Israeli Society of Hematology and Blood Transfusion,          Tel-Aviv

A high rate of BCR-ABL negativity by FISH & multiplex RT-pcr  but not by real-time RT-PCR can be achieved in cml patients treated with imatinib. 

P. Raanani, I. Ben-Bassat, S. Gan, L. Trakhtenbrot, Z. Mark, S. Itskovich,  N. Amariglio, F. Brok-Simoni, I. Hardan, A. Kneler, A. Shimoni, A. Nagler (Speaker)

 

Israel

4.2003

Annual meeting of the Cancer  Biology Research Center , Kfar Blum

Monoclonal antibodies in the treatment of hematological malignancies.

P. Raanani and I. Ben-Bassat (Speaker)

 

Israel

1.2004

The Israeli Society of Hematology and Blood Transfusion,          Tel-Aviv

Hasford score may predict for the dynamics of imatinib induced reduction of bcr-abl transcripts in chronic phase cml – should an old score be used for a new drug?

P. Raanani, I. Ben-Bassat, S. Itskovich,  S. Gan, Y.Morgulis, O. Ashur-Fabian, A. Kneller, I. Hardan, F. Brok-Simoni, A.Simon, G. Rechavi, N. Amariglio, A. Nagler (Speaker)

 

Israel

4.2004

The Israeli Society of Hematology and Blood Transfusion,          Dead sea

Philadelphia positive T lymphoblastic leukemia – acute leukemia or cml blast crisis?

P. Raanani, I. Ben-Bassat, L. Trachtenbrrot, A. Avigdor, F.Brok-Simoni, N. Amariglio, A. Nagler (Speaker)

 

Israel

4.2004

Annual meeting of the Cancer  Biology Research Center , Kfar Blum

Detection of minimal residual disease in myeloid leukemias – methods and their clinical significance.

P. Raanani, I. Ben-Bassat, A. Nagler (Speaker)

 

Israel

11.2007

The Israeli Society of Hematology and Blood Transfusion,          Avenue Convenetion and Event Center

Immunoglobulin prophylaxis in patients undergoing hematopoietic stem cell transplantation – systematic review and meta-analysis.

P. Raanani,  A. Gafter-Gvili, M. Paul, I. Ben-Bassat, L. Leibovici, O. Shpilberg (Speaker)

 

Israel

4.2008

Annual Meeting of the European Group for Blood and Marrow Transplantation - EBMT 2008

Immunoglobulin prophylaxis in patients undergoing hematopoietic stem cell transplantation: systematic review and meta-analysis.
P. Raanani, A. Gafter-Gvili, M. Paul, I. Ben-Bassat, L. Leibovici, O. Shpilberg (Speaker)

 

Italy

   11.2009        The Israeli Society of Hematology and Blood Transfusion        Israel Management of adult patients with ALL                                                                      in first  complete remission: systematic review and meta-analysis.

R. Ram, A. Gafter-Gvili, L. Vidal, M. Paul, I. Ben-Bassat,                                    O. Shpilberg, P. Raanani   (Speaker) 

    5.2011         A Joint Meeting of the CBRC and the Department of Hematology  Israel Tel-Aviv University: Should personalized medicine be the standard of care in Hematology in the third millenium? Biological and clinical aspects   (Member of steering committee)

    5.2011         A Joint Meeting of the CBRC and the Department of Hematology  Israel Tel-Aviv University: Cure in CML in the 3rd millenium – a target or a dream?   (Speaker)      

9.2011     Meeting in celebration of 30 years since the establishment of the   Israel

Cancer Biology Research Center (CBRC)

(Member of steering committee)

                                                     

7.2011   10th Anniversary of the Cochrane Haematological Malignancies  Germany

               Group                                                                                            

               Systematic reviews in hematological malignancies

               Pia Raanani (Speaker) 

 

6.2012    CBRC – Hematology Department Joint Discussion Forum:           Israel

         Drug Development in Cancer, June 21 2012

         (Member of steering committee)

 

11.2012  Tel-Aviv University–Mayo Clinic Cancer Centre Alliance              Israel

    Symposium

         (Member of steering committee)

 

11.2012  Tel-Aviv University–Mayo Clinic Cancer Centre Alliance              Israel

    Symposium

    The role of Systematic Reviews and Meta-analyses in Hematological                     Malignancies

    Pia Raanani (Speaker) 

 

12.2012      54th Annual Meeting of the American Society of Hematology       USA

                    Health Services and Outcome Research (Moderator)

 

6.2013         2013 Biennial Retreat of  theCancer Biology Research Center     Israel

                    (Member of steering committee)

 

6.2014        Cancer Prevention and Intervention 2014 Conference                   Israel

                   (Member of steering committee)

 

6.2014        Cancer Prevention and Intervention 2014 Conference                   Israel

                   Can leukema be cured in 2014?

                   P. Raanani (Speaker) 

 

2.2015        IMCO – International Meeting on CardioOncology:                      Israel

Towards a Comprehensive Cardiac – Cancer Care

(Member of steering committee)

 

2.2015        IMCO – International Meeting on CardioOncology:                      Israel

Towards a Comprehensive Cardiac – Cancer Care

                   Can leukema be cured in 2014?

                   P. Raanani  (Speaker) 

 

 

 

C4. MEMBERSHIP IN PROFESSIONAL SOCITIES

 

Year

Society

Country

1987®

Israeli Society of Medicine

Israel

1989®

Israeli Society of Internal Medicine

 

Israel

1993®

2.2004 – 2.2007

Israeli Society of Hematology

Secretary of the Israeli Society of Hematology and Blood Transfusions

Israel

1999 – 2003

5.2012 ®                  

American Society of Hematology

Invited Abstract Reviewer of the American Society of Hematology

 

USA

 

 

2007 ®

European  Hematology Association 

Europe

 

2009 ®

American Society of Hematology

USA

 

 

USA

2015®                                    Society of Hematologic Oncology (SOHO)   USA

 

 

D1. DOCTORAL STUDENTS SUPERVISED BY CANDIDATE

 

Years

Name of student

Subject

Academic Institute

Ph.D/M.D

In collaboration with

2008 - 2012

Adelina Ovcharenko

Molecular mechanisms involved in the occurrence of extramedullary disease following targeted therapies for hematological malignancies

Felsenstein Medical Research Center

Ph.D

Prof. Nadir Arber, Dr. Galit Granot, Prof. Ofer Shpilberg

From 2014

Adi Zelig

The influence of bone mineral density at diagnosis on other manifestations of bone disease and on patients' survival in multiple myeloma -A historical cohort study

Institute of Hematology, Rabin Medical Center

M.D

Dr. Eli Muchtar

From 2014 (2012 – 2014 suprevised by Prof. Ofer Shpilberg)

Saar Shapira

Sensitivity of CML stem cells to tyrosine kinase inhibitors

Felsenstein Medical Research Center

Ph.D

Prof. Nadir Arber, Dr. Galit Granot

From 2014 (2013 – 2014 suprevised by Prof. Ofer Shpilberg)

Ala Aladin Samara

Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma

Felsenstein Medical Research Center

Ph.D

Dr. Smadar Avigad, Dr. Galit Granot

From 2015

Gili Kroitoro

Early Identification of Myelodysplatic Syndrome among Patients with Unexplained Anemia Based on Laboratory Indices from the Years Predating the Diagnosis

Institute of Hematology, Rabin Medical Center   

M.D

Dr. Erel Joffe

 

 

 

 

D2. MEMEBERSHIP IN COLLOQUIUM OF M.D. STUDENTS

1.Member, colloquium committee for  M.D. thesis of the student Gil Shlomovitz (supervisor Prof. Yohai Birenbaum): “In vitro ultrasound augmented pharmacological thrombolysis – what is the correct timing of the ultrasound irradiation?” , Tel-Aviv University

2. Member,  colloquium committee for M.D thesis of the student Orit Mimon (Supervisor Prof. Michael Lishner): “Replication pattern in polycythemia vera and essential thrombocytosis, comparison between patients treated with hydroxyurea and untreated patients”, Tel-Aviv University

3. Head, colloquium committee for M.D. thesis of the student Eliahu Rakach

(Supervisors Prof. Raphael Katan and Dr. Ofer Marimsky): "Imatinib mesylate- a breakthrough in the treatment of GIST: long term follow-up”, Tel-Aviv University

4.      Member,  colloquium committee for M.D thesis of the student Uri Inbal (Supervisors Prof. Hillele Halkin and Dr. Daniel Kurnik and Dr. Ronen Loebstein): “The effect of low dose vitamin K supplementation on warfarin anticoagulation among vitamin K deficient patients”, Tel-Aviv University

5.      Member,  colloquium committee for M.D thesis of the student Joseph Landman (Supervisors Dr. Maya Koren-Michowitz and Dr. Yoram Cohen and Prof. Arnon Nagler): “The relation between JAK2-V617F mutation load in polycythemia vera patients and the clinical chracteristics of their disease” , Tel-Aviv University

6.      Member,  colloquium committee for M.D thesis of the student Ido Matia from the Technion (Supervisors Dr. Ayelet Barak and Dr. Rachel Bar-Shalom): “The value of FDG-PET/CT during complete remission in identifying relapse of pediatric lymphoma” , Technion, Haifa

7.      Head, colloquium committee for M.D thesis of the student Zvi Sirotkin (Supervisors Prof. Sara Apter and Dr. Abraham Avigdor):"Primary mediastinal large B-cell lymphoma: the impact of adding rituximab on the outcome of patients treated with VACOP-B or CHOP, clinical and imaging prognostic factors", Tel-Aviv University

8.      Member,  colloquium committee for M.D thesis of the student Einat Mader (Supervisors Dr. Giora Shubinsky and Dr. Itai Levi): “Diagnosis and Characterization of Myelodysplsatic Syndrome by Flow Cytometry Immunophenotyping”, Ben-Gurion University of the Negev

{C}9.      {C}Member, colloquium committee for  M.D. thesis of the student Amit Ben-Hayman (supervisors Dr. Amit Gil-Ad and Dr. Michael Taler): “In vitro effect of sertaline as an antiproliferative and chemosensitizing agent in T-cell lymphoma/leukemia(Jurkat) cell” , Tel-Aviv University

10.  Head, colloquium committee for M.D thesis of the student Shani Bergman Frank: " Lymphocytes Reconstitution Following Hematopoietic Stem Cell Transplantation - Clinical Implications", Tel-Aviv University

{C}11.  {C}Head, colloquium committee for  M.D. thesis of the student Shani Saborai Litvak (supervisors Prof. Moshe Mittelman and Dr. Ophira Ben-Tal): “Myelodysplatic syndrome – have the clinical characteristics changed over the years?” , Tel-Aviv University

{C}12.  {C}Member, colloquium committee for  M.D. thesis of the student Michael Frumer (supervisor: Prof. Eldad Dan): “Evaluation the follow-up by PET/CT of Hodgkin’s lymphoma patients, who are in remission after first-line of therapy, compared with the follow-up by clinical examination” , Technion, Haifa

13.  Member, colloquuium committee for M.D thesis of the student Yoav Binenbaum (supervisors Dr. Izhar Hardan and Prof. Gideon Rechavi): “Discontinuation of anti-leukemic treatment followoing combination therapy with imatinib and alpha interferon in chronic phase CML: Molecular mechanisms that characterize the responding patients”, Tel-Aviv University

14.  Head, colloquium committee for  M.D. thesis of the student Aviv Aharon (Supervised by Prof. Moshe Mittelman): “Thrombocytopenia causes and bleeding– A retrospective analysis” ”, Tel-Aviv University

15.  Member, colloquuium committee for M.D thesis of the student Gigozinsky Michal (supervisors Dr. Ronit El-Hasid, Prof. Btia Stark and Prof. Shai Izraeli): “Characteristics and outcomes of treatment of childhood ALL in Israel”, Tel-Aviv University

 

 

E. M.A/M.Sc Students

Years

Name of student

Subject

Academic Institute

In collaboration with

2008 - 2011

Saar Shapira

The effect of nilotinib on the signal transduction cascade leading to down  regulation of telomerase activity in K562 cells sensitive and resistant to imatinib

Felsenstein Medical Research Center

Prof. Ofer Shpilberg, Dr. Dr. Galit Granot

 

                                                                                                                                                         

 

E. GRANTS &AWARDS

     

Year

 

 

 

Name of Institution (city, country)

 

 

Award

1984

 

 

 

The Hebrew University, Faculty of Medicine, Jerusalem

List of excellent students

1985

 

 

 

The Hebrew University, Faculty of Medicine, Jerusalem

Scholarship for excellency

1986

 

 

 

The Hebrew University, Faculty of Medicine, Jerusalem

List of excellent students

1991

 

 

 

Beilinson Medical Center, Petah-Tikva

$1200.-  to fund research in the Laboratory of Hemostasis

1995

 

 

 

 

 

The Israel Cancer Association

$700 .- to fund participation in the course "Advances in Haematology" at the Hammersmith Hospital, U.K.

 

 

1996

 

 

 

 

The Israel Cancer Association

10,000 NIS.- Grant to fund a continuing education in the field of hemato-oncology and bone marrow transplantation at the Hammersmith Hospital, London, U.K

1996

 

 

 

 

 

 

 

 

The British Council, Tel-Aviv

A one year scholarship of 1,250 GBP.- per month.

The British Council and the Barclay Family Cancer Research Foundation-Scholarship for Oncological Research- to undertake a research in the field of CML and bone marrow transplantation at the Hammersmith Hospital, London, U.K

1998

Tel-Aviv University

$3,000 grant.

The Zoss & Fanny Safoon grant for research on the subject of : “Quantitative RT-PCR for quantifucation of bcr-abl transcripts in chronic myeloid leukemia (CML)”

 

 

1999

Israel Cancer Association

35,000 NIS grant for research on:

Cytokine mediated Engraftment syndrome and hypophosphatemia in patients undergoing high dose chemotherapy with peripheral blood stem cell support for hematological malignancies

1999

Israel Cancer Association

6,500 NIS grant

For participation in ASH 1999 where a poster on the subject: "Cytokine mediated Engraftment syndrome and hypophosphatemia in patients undergoing high dose chemotherapy with peripheral blood stem cell support for hematological malignancies" was presented

 

2000

Israel Cancer Association

23,000 NIS grant

The role of cytokines and the "cytokine release syndrome" in the development of adverse effects during treatment with anti CD20 (rituximab) in general and in the development of the "1St Dose reaction" in particular

 

2001

Tel-Aviv University

Excellent Lecturer in Hematology for the year 2000

 

2002

Israel Cancer Association

2,800 NIS grant

for training  in quantitative Real-Time RT-PCR for follow-up of CML patients in the laboratory of minimal residual disease in Hammersmith Hospital, Lomdon

2004

Tel-Aviv University

Excellent Lecturer in Hematology for the 3 years 2001-2003

 

 

2008

The Barclay Family Cancer Research Foundation

30,000.00 GBP grant to be allocated for research studies under the direction of Dr. Pia Raanani. Dedicated mainly for the research on: "Molecular mechanisms involved in the occurrence of extramedullary disease following targeted therapies for hematological malignancies". Dr. Pia Raanani   - Principal Investigator

 

2009

Beilinson Medical Center, Petah-Tikva (Research Authority)

30,000 NIS grant for research on: "The role of colony stimulating factors administered for prevention and treatment of infectious complications in patients with acute  myelogenous leukemia-a meta –analysis". (Research conducted by Dr. Pia Raanani- Principal Investigator, grant donated to young investigator - Dr. Ronit Gurion)

 

 

 

2010             Tel-Aviv University                   32,000 NIS grant for research on: "The

                     (Research Authority)                 effect of nilotinib and dasatinib on

                                                                        telomerase activity in BCR-ABL                                                                                                                   positive K562 cells" (The Meirbaum/

the Safoon grants) – Principal    Investigator

 

2010            Tel-Aviv University                    $ 5,000 grant for Ph.D student Adelina

(The Cancer Biology                   Ovcharenko-Mermelshtein for the research, entitled: “Molecular mechanisms involved in the occurrence of extramedullary disease following targeted therapies for hematological malignancies“- Research conducted by Prof. Pia Raanani- Principal Investigator

 Research Center)

2010     Tel-Aviv University               18,325 NIS grant for research on: “Molecular mechanisms involved in the occurrence of extramedullary disease following targeted therapies for hematological malignancies”

                                                            (Van Bits, Cancer Research  Center)- Principal Investigator

 

2013    Tel-Aviv University                37,000 NIS grant for research on: “Molecular

(Research Authority)              mechanisms invovled in the occurrence of extramedullary disease following targeted 

therapies for hematological malignancies” (The Fenster Foundation  Grant for Leukemia Research) - Principal Investigator

 

2012 Kupat Holim Clalit                    50,000 NIS grant for Research on: "The effect     of active adherence encouraging intervention on adherence to TKI treatment in CML- a multi center study (TAKE-IT)"- Principal Investigator

 

2013  Israel Cancer Association       45,000 NIS grant for Research on: "Regulatory                

mechanisms involved in Pyk2 expression following novel agents' treatment for hematological malignancies"- Principal Investigator

 

2013 Israeli Society of Hematology   30,000 NIS grant for Research on: "The effect     of active adherence encouraging intervention on adherence to TKI treatment in CML- a multi center study (TAKE-IT)"- Principal Investigator

 

2014 Dotan Center for Research        350,000 NIS grant/year for 2 years on: “Targeting mantle cell lymphoma with nanomedicines” (Prof. Dan Peer – principal-investigator; Prof. Pia Raanani – co-investigator)

In Hemato-oncology

2015 Pfizer Pharmaceuticals Israel    63,000$ for  Investigator-Initiated Research (“IIR”) grant for 2 years (2016 – 2017) a non-human Research study entitled “Pathogenesis of Tyrosine Kinase Inhibitors (TKIs) Associated Vascular Disease in Chronic Myeloid Leukemia (CML): An in vitro Model”- Principal Investigator

 

2015 ARIAD Pharmaceuticals Inc.   50,000$ for  Investigator-Initiated Research (“IIR”) grant for Research study entitled “Subclinical markers of tyrosine kinase inhibitor associated vascular disease in chronic myeloid leukemia: An exploratory multicenter cohort study” - Principal Investigator

 

 

LIST  OF  SCIENTIFIC  PUBLICATIONS

 

 

A. BOOKS & MONOGRAPHS

1.      Dr. Pia Raanani & Prof. Isaac Ben-Bassat

      Anemia - It Is in Our Blood

      Prolog Publishers, 2004 (112 pages)

 

 

B.1. ORIGINAL ARTICLES

Published

 

  1. Lavee J., Rath S., Hoa T.Q., Raanani P.,  Ruder A., Modan., Neufeld H.N., Goor D.A.                                                                                                                      Does complete revascularization by the conventional method truly provide the best  possible results? Analysis of results and comparison with revascularization of infarct  prone segments (systemic segmental myocardial revascularization):The Sheba Study.                                                                                                                 Journal of Thoracic and Cardiovascular Surgery, Vol. 92, pp. 279-290, 1986 (journal IF =  3.354; journal 5-Year IF = 3.505; journal rank = 16 of 75)

 

  1. Lahav M., Regev A., Raanani P., Theodor E.                                              Intermittent administration of furosemide vs. continuous infusion preceded by a   loading dose for congestive heart failure.                                                                 Chest, Vol. 102, pp. 725-731, 1992

      (journal IF =  4.143 ; journal 5-Year IF = 4.311 ; journal rank = 6 of 34)

 

 

3.      Arber N., Zajicek G., Shamir R., Kenet G., Raanani P., Nordenberg J., Sidi Y. Bromobenzene accelerates hepatocyte streaming in rats.                         Gastroenterology, Vol. 103, pp. 1273-1276, 1992

(journal IF =  11.673; journal 5-Year IF = 12.424; journal rank = 1 of 50)

 

4.      Singer R., Levinsky H., Sagiv M., Raanani P., Weissenberg R., Lahav M. Spermatogenesis and sialic acid content and sialytransferase activity in testis, epididimisand prostate of gossypol treated male rats.                                             Advances in Contraceptive Delivery Systems, Vol. 7, pp. 201-209, 1992

(journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

5.      Singer R., Weissenberg R.,Lahav M., Sagiv M.,  Raanani P., Kyser S,  Cohen A, Levinsky H.                                                                                                        Sialic acid and sialytransferase activity in testis, epididymis and prostate of rats: developmental stages.                                                                                 Advances in Contraceptive Delivery Systems, Vol. 8, pp. 247-252, 1992

(journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

6.      Varon D., Handsher R., Dardik R., Gitel S., Raanani P., Heim M., Martinowitz U. Response of hemophilic patients to poliovirus vaccination:correlation with HIV serology and with immunological parameters.                                                            

      Journal of Medical Virology, Vol. 40, pp. 91-95, 1993

(journal IF =  2.831; journal 5-Year IF = 2.739; journal rank = 14 of 25)

 

7.      Singer R.,  Levinsky H., Kyzer S., Cohen A., Sagiv M., Raanani P., Lurie B., Lahav M.

Effect of procarbazine/clomiphene citrate on sialyltransferase activity in testis/epididymis of rats.

Advances in Contraceptive Delivery Systems, Vol 9, pp 107-111, 1993

(journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

8.      Raanani P., Shpilberg O., Berezin M., Ben-Bassat I.                                            Acute leukemia relapse presenting as central diabetes insipidus.                             Cancer, Vol. 73, pp. 2312-2316, 1994

(journal IF =  4.632; journal 5-Year IF = 4.865; journal rank = 28 of 132)

 

9.      Weissenberg R., Lahav M., Raanani P., Singer R., Regev A., Sagiv M., Giler S., Theodor E.                                                                                                             Clomiphene citrate reduces procarbazine-induced sterility in a rat model.                   British Journal of Cancer, Vol. 71, pp. 48-51, 1995

            (journal IF =  4.635; journal 5-Year IF = 4.322; journal rank = 27 of 132)

 

10.  Shpilberg O., Haddad N., Sofer O., Raanani P., Berkowicz M., Chetrit A.,       Carter A., Ramot B., Tatarski I., Ben-Bassat I.                                                          Postremission therapy with two different dose regimens of cytarabine in adults with acute myelogenous leukemia.                                                              Leukemia-Research, Vol. 19, pp. 893-897, 1995

            (journal IF =  2.561; journal 5-Year IF = 2.278; journal rank = 67 of 132)

 

11.  Bessler H., Singer R., Raanani P., Levinsky H., Lahav M., Cohen A.M.                              Interferon alpha-2b modulates beta-galactoside alpha-2,6-sialyltransferase gene expression in rat testes.                                                                                            Biology of Reproduction, Vol. 53, pp. 1474-1477, 1995

            (journal IF =  3.670; journal 5-Year IF = 3.766; journal rank = 2 of 25)

 

12.  Singer R., Cohen A., Levinsky H., Raanani P., Luria B.B., Weissenberg R.,   Lahav M.                                                                                                                               Effect of interferon alpha IIb on the activity of sialyltransferase in testis homogenates of adult rats.                                                                                                                 Archives of Andrology, Vol. 35, pp. 1-3, 1995

            (journal IF =  0.808; journal 5-Year IF = 0.777; journal rank = 2 of 5)

 

13.  Berkowicz M., Toren A., Rosner E., Biniaminov M., Rosenthal E., Gipsh N., Berman S., Hardan I., Mandel M., Amariglio N., Mark Z., Sofer O., Raanani P., Kenet G., Neuman Y., Sharon N., Brok-Simoni, F., Rubnov V., Ben-Bassat I, Rechavi G.

Translocation (2;14)(p13;q32) in CD10+CD13+ acute lymphatic leukemia.                                                                                                                     Cancer Genetics and Cytogenetics, Vol. 83, pp. 140-143, 1995

      (journal IF =  1.559; journal 5-Year IF = 1.581; journal rank = 99 of 132)

 

14.  Raanani P.,  Rosner E., Bercowicz M., Ben-Bassat I.                                 t(12;20)(q13;p11.2)- a new translocation involving the 12q13 breakpoint in acute nonlymphoblastic leukemia.                                                                                      Cancer Genetics and Cytogenetics, Vol. 89, pp. 118-119, 1996

            (journal IF =  1.559; journal 5-Year IF = 1.581; journal rank = 99 of 132)

 

15.  Raanani P., Bercowicz M., Rosner E., Rosenthal E., Berman S., Rechavi G.,   Ben- Bassat I.                                                                                                           Translocation t(3;17)(q23;q21)  - a new translocation in acute lymphoblastic       leukaemia.                                                                                                                      British Journal of Haematology, Vol. 95, pp. 131-134, 1996

            (journal IF =  4.490; journal 5-Year IF = 3.733; journal rank = 12 of 63)

 

16.  Oren R.,  Zajicek G., Maaravi Y., Kenet G., Karmely F., Hubert A.,
 Raanani P.,  Arber N.   

Methimazole slows hepatocyte streaming in rats.                                                                 Digestive Diseases and Sciences, Vol. 42, pp. 1433-1437, 1997

(journal IF =  1.319; journal 5-Year IF = 1.582; journal rank = 41 of 50)

 

17.  Raanani P.,  Dazzi F.,  Sohal J.,  Szydlo R.M., van Rhee F., Reiter A., Lin F., Goldman J.M. and  Cross N.C.P.  

The rate and Kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation.                                                                                                             British Journal of Haematology, Vol. 99, pp. 945-950, 1997

(journal IF =  4.490; journal 5-Year IF = 3.733; journal rank = 12 of 63)

 

18.  Dreiher J, Shpilberg O, Raanani P, Chetrit A, Ben-Bassat I.

The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.                                                      Leukemia  Research Vol. 22, pp 997-1002,  1998 (Written by mistake as Raamami)

             (journal IF =  2.561; journal 5-Year IF = 2.278; journal rank = 67 of 132)

 

19.  Reiter A., Marley S.B., Hochhaus H., Sohal .J, Raanani P, Hehlmann R., Gordon M.Y., Goldman J.M., Cross N.C.P.                                                                                  

       BCR-ABL positive primitive progenitors in chronic   myelogenous leukemia patients in complete cytogenetic remission after treatment with interferon-a.

       British Journal of Hematology. Vol. 102 pp. 1271-1278, 1998

      (journal IF =  4.490; journal 5-Year IF = 3.733; journal rank = 12 of 63)

 

20.  Raanani P., Shpilberg O., Bercowicz M., Sofer O., Hardan I., Chetrit A., 
 Ben-Bassat I.                                                                                                                 Salvage therapy of relapsed and primary resistant acute leukemia with high dose mitoxantrone and cytarabine.                                                                          leukemia Research , Vol 23 pp 695-700, 1999                                                    (journal IF =  2.561; journal 5-Year IF = 2.278; journal rank = 67 of 132)

 

21.  Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M, Ben-Bassat I.

Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug.                                                                                                                             British Journal of Hematology Vol 108 pp 391-393, 2000                                                    (journal IF =  4.490; journal 5-Year IF = 3.733; journal rank = 12 of 63)

 

22.  Goldstein G, Shpilberg O, Raanani P, Chetrit A, Ben-Bassat I

Acute lymphoblastic leukemia in adults treated with German multicenter study group protocols.

Harefuah  Vol 139 pp 255-9, 328, 327, 2000                                                                     (journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

  1. Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I

High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease.

Harefuah  Vol 139 pp 174-9, 248, 247, 2000                                                          (journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

  1. Raanani P, Segal E, Levi I, Bercowicz M, Berkenstat H, Avigdor A, Perel A,   Ben-Bassat I.

Diffuse alveolar hemorrhage in acute promyelocytic lLeukemia patients treated with Atra - a manifestation of the basic disease or the treatment.

      Leukemia & Lymphoma  Vol 37 pp 605-610, 2000 

     (journal IF =  1.512; journal 5-Year IF = 1.461; journal rank = 41 of 63)

 

  1. Raanani P, Levi I, Holzman F, Grotto I, Brok-Simoni F, Avigdor A, Davidson J, Shpilberg O, Ben-Bassat I.

      Engraftment-associated hypophosphatemia--the role of cytokine release and steep leukocyte rise post stem cell transplantation.

Bone Marrow Transplantation  Vol. 27, pp :311-317, 2001                                          (journal IF =  3.000; journal 5-Year IF = 2.542; journal rank = 25 of 63)

 

  1. Avigdor A., Raanani P., Levi I., Hardan I., Ben-Bassat I.

Extramedullary progression despite a good response in bone marrow in patients treated with thalidomide for multiple myeloma.

Leukemia & Lymphoma Vol 42, pp 683-687, 2001                                                                      (journal IF =  1.512; journal 5-Year IF = 1.461; journal rank = 41 of 63)

 

{C}27.  {C}Levy-Nissenbaum O., Sagi-Assif O., Raanani P., Avigdor A., Ben-Bassat I., Witz I.P.

      Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukaemia.

 Cancer Letters  Vol. 199, pp185-192, 2003                                                       (journal IF =  3.398; journal 5-Year IF = 3.193; journal rank = 49 of 132)

 

{C}28.  {C}Levy-Nissenbaum O. , Sagi-Assif  O. , Kapon D. , Hantisteanu S. , Burg T., Raanani  P., Avigdor A. , Ben-Bassat I. ,  Witz I.P. 

Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in     myeloid leukemia and other malignant cells.

Oncogene Vol.  22, pp. 7649–7660, 2003                                                             (journal IF =  6.440; journal 5-Year IF = 6.371; journal rank = 14 of 132)

 

{C}29.  {C}Shimoni A., Hardan I., Avigdor A., Yeshurun M., Raanani P., Ben-Bassat I., Nagler A.

       Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma.

British Journal of Haematology  Vol.  122 , pp 457 – 464, 2003                                (journal IF =  4.490; journal 5-Year IF = 3.733; journal rank = 12 of 63)

 

  1. Levy-Nissenbaum O., Sagi-Assif O., Raanani P., Avigdor A., Ben-Bassat I., Witz I.P.

     cDNA microarray analysis reveals an overexpression of the dual-specificity    

     MAPK phosphatase PYST2 in acute leukemia.

     Methods in Enzymology Vol. 366, pp 103-113,  2003

    (journal IF =  2.122; journal 5-Year IF = 1.886; journal rank = 31 of 60)

 

{C}31.  {C}Raanani P.,  Ben-Bassat I., Gan S., Trakhtenbrot L., Mark Z. , Ashur-Fabian S. , Itskovich S. , Brok-Simoni F., Rechavi G., Amariglio N., Nagler A.. Assessment of the response to imatinib in chronic myeloid leukemia patients – comparison between the FISH, multiplex and real-time RT-PCR methods.

 European Journal of Haematology Vol. 73, pp 243 – 250, 2004                  (journal IF =  2.163; journal 5-Year IF = 2.056; journal rank = 34 of 63)

 

  1. Raanani P .,Trakhtenbrot L., Rechavi G., Rosenthal E., Avigdor A., Brok-   

Simoni F., Leiba M.,  Amariglio N., Nagler A., Ben-Bassat I.

Philadelphia chromosome positive T- lymphoblastic leukemia: acute leukemia or  chronic  myelogenous leukemia blastic crisis.

      Acta Haematologica Vol. 113, pp 181-189, 2005

    (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

{C}33.  {C}Raanani P., Shasha Y., Peri C., Metser U., Naparstek E., Apter S., Nagler A., Polliack A., Ben-Bassat I., Even-Sapir E.

Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?

     Annals of Oncology Vol. 17, pp 117-122, 2006                                               (journal IF =  4.875; journal 5-Year IF = 4.805; journal rank = 23 of 132)

 

{C}34.  {C}Apter S., Shemesh J., Raanani P., Portnoy O., Thaler M., Zissin R., Ezra D., Rozenman J., Pfeffer R., Hertz M.

 Cardiovascular calcifications after radiation therapy for Hodgkin lymphoma: computed tomography detection and clinical correlation.
Coronary artery disease  Vol 17, pp 145-151, 2006                                            (journal IF =  1.556; journal 5-Year IF = 1.596; journal rank = 33 of 54)

 

{C}35.  {C}Tecuceanu N., Dardik R., Rabizadeh E., Raanani P., Inbal A.

A family with hereditary thrombocythaemia and normal genes for thrombopoietin and c-Mpl.

British Journal of Haematology Vol 135, pp 348-351, 2006                             (journal IF =  4.490; journal 5-Year IF = 3.733; journal rank = 12 of 63)

 

{C}36.  {C}Ashur-Fabian O., Adamsky K., Trakhtenbrot L., Cohen Y., Raanani P, Hardan I., Nagler A., Rechavi G., Amariglio N.

Apaf1 in chronic myelogenous leukemia (CML) progression: reduced Apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis.
 Cell Cycle Vol 6, pp 589-594,  2007                                                                  (journal IF =  3.314; journal 5-Year IF = not applicable; journal rank = 31 of 156)

 

{C}37.  {C}Ram R., Gafter-Gvili A., Okon E., Pazgal I., Shpilberg O., Raanani P.

Gelatinous transformation of bone marrow in chronic myeloid leukemia    during treatment with imatinib mesylate: a disease or a drug effect?

    Acta Haematologica Vol 119, pp 104-107, 2008                                                      (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

{C}38.  {C}Mashiah A., Wolach O., Sandbank J., Uziel O., Raanani P., Lahav M.

Lymphoma and leukemia cells possess fractal dimensions that correlate with their biological features.

Acta Haematologica Vol 119, pp 142-150, 2008                                               (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

{C}39.  {C}Raanani P., Gafter-Gvili A., Paul M., Ben-Bassat I., Leibovici L., Shpilberg O.

Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation.
      Cochrane Database of Systematic Reviews Vol 4,  Art. No.: CD006501, 2008                                                                                                         (journal IF =  4.654; journal 5-Year IF = not applicable; journal rank = 27 of 100)

 
{C}40.  {C}Ram R., Gafter-Gvili A., Yeshurun M., Paul M., Raanani P., Shpilberg O.
       Prophylaxis regimens for GVHD: systematic review and meta-analysis.
       Bone Marrow Transplantation Vol 43, pp 643-653, 2009 
      (journal IF =  3.000; journal 5-Year IF = 2.542; journal rank = 25 of 63)
 
{C}41.  {C}Raanani P., Gafter-Gvili A., Paul M., Ben-Bassat I., Leibovici L., Shpilberg O.

       Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: Systematic review and meta-analysis.

       Journal of Clinical Oncology Vol 27, pp 770-781, 2009                              (journal IF =  15.484; journal 5-Year IF = 13.753; journal rank = 5 of 132)

 

{C}42.  {C}Gafter-Gvili A., Ram R., Gurion R., Paul M., Yeshurun M., Raanani P.,   Shpilberg O.

ATG plus cyclosporine reduces all-cause mortality in patients with Severe aplastic Anemia – Systematic Review and Meta-Analysis.

Acta Haematologica  Vol 120, pp 237-243, 2009                                           (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

{C}43.     Ram R., Bonstein L., Gafter-Gvili A,. Ben-Bassat I., Shpilberg O., Raanani P.

Rituximab-associated acute thrombocytopenia: An under-diagnosed phenomenon.

American Journal of Hematology  Vol 84, pp 247-250, 2009                              (journal IF =  1.949; journal 5-Year IF = 1.914; journal rank = 36 of 63)

 

 

    44.     Raanani P., Gafter-Gvili A., Paul M., Ben-Bassat I., Leibovici L., Shpilberg O.

Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma - systematic review and meta-analysis.
Leukemia & Lymphoma  Vol 50, pp 764-772, 2009

(journal IF = 1.512; journal 5-Year IF = 1.461; journal rank = 41 of 63)

 

    45.     Ram R., Gafter-Gvili A., Raanani P., Yeshurun M., Shpilberg O., Dreyer J., Peck A., Leibovici L., Paul M.

Surveillance of infectious complications in hemato - oncological patients.

Israel Medical Association Journal  Vol 11, pp 133-137, 2009

(journal IF =  0.577; journal 5-Year IF = 0.583; journal rank = 42 of 100)

 

    46.     Gurion R., Gafter-Gvili A., Paul M., Vidal L., Ben-Bassat I,. Yeshurun M,. Shpilberg O., Raanani P.

Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy systematic review and meta analysis.

 Haematologica  Vol 94, pp 712-719, 2009                                                    (journal IF =  5.516; journal 5-Year IF = 4.758; journal rank = 9 of 63)

 

47.     Magen-Nativ H., Ram R., Yeshurun M., Gafter-Gvili A., Raanani P., Shpilberg O.

Total therapy based treatment for multiple myeloma - a single center experience.

     Annals of Hematology Vol 89, pp 53-59, 2010 

   (journal IF =  2.342; journal 5-Year IF = 1.914; journal rank = 31 of 63)

 

48.  Gurion R., Vidal L., Gafter-Gvili A., Belnik Y., Yeshurun M., Raanani P.,
Shpilberg O.

The role of hypomethylating agents in the treatment of patients with myelodysplastic syndrome - systematic review and meta-analysis.

        Haematologica Vol 95, pp 303-310, 2010

   (journal IF =  5.978; journal 5-Year IF = 5.513; journal rank = 9 of 62)

 

 

49.  Mor R., Uziel O., Shpilberg O., Lahav J., Raanani P., Bakhanashvili M., Rabizadeh  E., Zimra Y., Lahav M., Granot G.

The effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL positive) cells sensitive and resistant to imatinib.

        Experimental Hematology Vol 38, pp 27-37, 2010

   (journal IF =  3.203; journal 5-Year IF = 3.490; journal rank = 24 of 62)

 

 

50.  Ram R., Gafter-Gvili A., Vidal L., Paul M., Ben-Bassat I., Shpilberg O., Raanani P.

Management of adult patients with acute lymphoblastic leukemia in first    complete remission: systematic review and meta-analysis.

        Cancer  Vol 116, pp 3447 – 3457, 2010 

   (journal IF =  5.238; journal 5-Year IF = 5.517; journal rank = 23 of 143)

 

51.  Gafter-Gvili A., Leader A., Gurion R., Vidal L., Ram R., Shacham-Abulafia A., Ben-Bassat I., Lishner M., Shpilberg O., Raanani P.

High-dose imatinib for newly diagnosed chronic phase chronic myeloid     leukemia patients-systematic review and meta-analysis.

        American Journal of Hematology Vol 86, pp 657 – 662, 2011

 (journal IF =5; journal 5-Year IF = 4.041; HEMATOLOGY journal rank  = 13 of 70; Quartile in Category – Q1; no. of citations: 15)

 

52.  Gurion R., Belnik-Plitman Y., Gafter-Gvili A., Paul M., Vidal L., Ben-Bassat I., Shpilberg O., Raanani P.

Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia.

Cochrane Database of Systematic Reviews Vol 9,  Art. No.: CD008238, 2011

(journal IF =  6.035; journal 5-Year IF = 6.539; MEDICINE, GENERAL & INTERNAL   journal rank = 13 of 154; Quartile in Category – Q1; no. of citations: 2)

 

 

53.  Pfreundschuh M., Kuhnt E., Trümper L., Osterborg A., Trneny M., Shepherd L., Gill D.S., Walewski J., Pettengell R., Jaeger U., Zinzani P.L., Shpilberg O., Kvaloy S., de Nully Brown P., Stahel R., Milpied N, López-Guillermo A., Poeschel V., Grass S., Loeffler M., Murawski N.; MabThera International Trial (MInT) Group.

Collaborators: Jäger G., Jäger U, Ruckser R., Thaler J., Bell R., Cannell P., Cartwright K.D, Enno A., Fay K., Filshie R., Gibson J., Gill D., Green M., Grigg A., Hertzberg M.S., Horvath N., Irving I., Kanourakis G., Leahy M., Lowenthal R.M., Ma D., Norman E., Prosser W., Schwarer A., Smith C.L., Tileay C.R., Underhill C., Wolf M., Alves  de Souza Scheliga A., Belch A., Bence-Bruckler I., Burnell M., Cantin G., Charpentier D., Crump M., Desjardins P., Findlay B., Gapski J., Howson-Jan K., Imrie K., Matthews J.H., Pressnail B., Sheperd L., Stevens R., Stewart D., Tompkins K., Voralia M., White D., Bolomská I., Jankovská M., Kubáckova K., Matuska M, Papajík T., Pytlík R., Siffnerová H., Trneny M., Vásová I., Vozobulová V, Zák P., Boesen A.M., de Nully Brown P., Hansen M., Plesner T., Lehtinen T., Pyrhönen S., Teerenhovi L., Colombat P., Maisonneuve H., Milpied N., Andreesen R., Aulitzky W., Berdel W., Bodenstein H., Brugger W., Clemens M., deWit M., Döhner H., Dörken B., Eimermacher H., Franke A., Frickhofen N., Haas R., Herold M., Hiddemann W., Ho A., Höffken K., Hoelzer D., Huber C., Kneba M., Mergenthaler H.G., Metzner B., Mantovani L, Nerl C, Peest D, Pfreundschuh M, Pielken HJ, Reiser M, Schlimok G, Schmitz N, Trümper L, Steinhauer HB, Uppenkamp M, Verbeek W, Berrebi A, Cohen A, Kornberg A, Raanani P, Rachmilevitz E, Shpilberg O, Yehuda B, Yukla M, Amadori S, Falini B, Fanin R, Foa R, Gobbi M, Mazza P, Zaccaria A, Zinzani PL, Ekanger R, Johnsen H, Kvaløy S, Maisenhølder M, Östenstad B, Telhaug R, Dmoszyńska A, Hellmann A, Hołowiecki J, Jedrzejczak W, Robak T, Sułek K, Utracka-Hutka B, Walewski J, Caballero Barrigón D, Conde García E, Díaz Mediavilla J, Guillermo AL, Adriansson M, Andreassen L, Cavallin-Ståhl E, Erlanson M, Fredén S, Hagberg H, Hedenus M, Johansson JE, Kimby E, Lauri B, Lindblom A, Österborg A, Rådlund A, Rylander H, Betticher D, Ghielmini M, Hitz F, Mingrone W, Pless M, Stahel R, Widmer LA, Cunningham D, Dyer JS, Evely R, Hancock B, Hatton C, Haynes A, Hoskin P, Johnson P, Lister A, Marcus R, Milligan DW, Morris TC, Pettengell R, Pettitt A, Poynton C, Tighe J, Wimperis J.

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Lancet Oncology  Vol 12, pp 1013-1022, 2011

(journal IF =  26.509; journal 5-Year IF = 28.181; ONCOLOGY journal rank = 3 of 213; Quartile in Category – Q1;  no. of citations:187)

 

54.  Ram R., Wolach O., Vidal L., Gafter-Gvili A., Shpilberg O., Raanani P.

Adolescents and young adults with acute lymphoblastic leukemia have a better

outcome when treated with pediatric-inspired regimens: systematic review and

meta-analysis.

American Journal of  Hematology Vol 87, pp 472 – 478, 2012

(journal IF =  5; journal 5-Year IF = 4.041; HEMATOLOGY journal rank =   13 of 70; Quartile in Category – Q1;   no. of citations: 30)

 

55.  Shapira S., Granot G, Mor-Tzuntz R., Raanani P., Uziel O., Lahav M., Shpilberg O.

Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells.

Cancer Letters Vol. 323, pp 223 – 231, 2012

(journal IF =  5.992; journal 5-Year IF = 5.174; ONCOLOGY journal rank = 23 of 213; Quartile in Category – Q1; no. of citations: 3)

 

56.  Gurion R., Belnik-Plitman Y., Gafter-Gvili A., Paul M., Vidal L., Ben-Bassat I., Shpilberg O., Raanani P.

Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia - update of

Cochrane Database of Systematic Reviews Vol 9,  Art. No.: CD008238, 2011

Cochrane Database of Systematic Reviews Vol 6,  Art. No.: CD008238, 2012

(journal IF =  6.035; journal 5-Year IF = 6.539; MEDICINE, GENERAL & INTERNAL   journal rank = 13 of 154; Quartile in Category – Q1; no. of citations: 3)

 

 

57.  Ram R., Farbman L., Leibovici L., Raanani P., Yeshurun M., Vidal L., Gafter-Gvili A., Peck A., Shpilberg O., Paul M.

  Characteristics of initial compared with subsequent bacterial infections among

  hospitalised haemato-oncological patients.

  International Journal of Antimicrobial Agents Vol. 40, pp 123 – 126, 2012

(journal IF =  4.097; journal 5-Year IF = 4.349; INFECTIOUS DISEASES   journal rank = 16 of 83; Quartile in Category – Q1; no. of citations: 9)

 

{C}58.  {C}Gurion R., Gafter-Gvili A., Vidal L., Leader A., Ram R., Shacham-Abulafia A., Paul M., Ben-Bassat I., Shpilberg O., Raanani P.

Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come?

  Systematic review and meta-analysis.

  Haematologica Vol 98, pp 95-102, 2013

  (journal IF =  6.671; journal 5-Year IF = 5.877; HEMATOLOGY journal rank  = 4 of 70; Quartile in Category – Q1;  no. of citations: 13)

 

59.  Vidal L., Gafter-Gvili A., Gurion R., Raanani P., Dreyling M., Shpilberg O. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.

  Cochrane Database of Systematic Reviews Vol 9,  Art. No.: CD009045, 2012

 (journal IF =  6.035; journal 5-Year IF = 6.539; MEDICINE, GENERAL & INTERNAL   journal rank = 13 of 154; Quartile in Category – Q1; no. of citations: 0)

 

 

60.  Ram R., Magen-Nativ H., Vidal L., Herscovici C., Peck A,. Raanani P., Shpilberg O., Yeshurun M.

Toxicity of autologous hematopoietic cell transplantation in patients with

multiple myeloma - comparison between two different induction regimens.

Clinical Transplantation Vol. 26, E549-54, 2012

(journal IF =  1.844; journal 5-Year IF = 1.761; SURGERY journal rank = 77 of 199; Quartile in Category – Q2; no. of citations: 0)

 

61.  Muchtar E., Vidal L., Ram R., Gafter-Gvili A., Shpilberg O., Raanani P.

The role of maintenance therapy in acute promyelocytic leukemia in first   complete remission. Systematic review and meta-analysis.

  Cochrane Database of Systematic Reviews Vol 3,  Art. No.: CD009594, 2013

(journal IF =  6.035; journal 5-Year IF = 6.539; MEDICINE, GENERAL & INTERNAL   journal rank = 13 of 154; Quartile in Category – Q1; no. of citations: 0)

 

{C}62.  Ovcharenko A., Granot G., Shpilberg O.,  Raanani P.

Retinoic acid induces adhesion and migration in NB4 cells through Pyk2 signaling.

Leukemia Research Vol. 37 , pp 956 – 962, 2013

(journal IF =  2.606; journal 5-Year IF = 2.507; HEMATOLOGY journal rank = 38 of 70; Quartile in Category – Q3; no. of citations: 3)

 

63.  Itchaki G., Gafter-Gvili A., Lahav M., Vidal L., Raanani P, Shpilberg O., Paul M.

Anthracycline-containing regimens for treatment of follicular lymphoma in    adults.

Cochrane Database Systematic Reviews Vol 7, Art. No.: CD008909, 2013

(journal IF =  6.035; journal 5-Year IF = 6.539; MEDICINE, GENERAL & INTERNAL   journal rank = 13 of 154; Quartile in Category – Q1; no. of citations: 2)

 

64.  Gafter-Gvili A., Paul M., Bernstine H., Vidal L., Ram R., Raanani P., Yeshurun M., Tadmor B., Leibovici L., Shpilberg O., Groshar D.                                                                                      The Role  of 18F-FDG PET/CT for the diagnosis of infections in patients with   hematological malignancies and  persistent febrile neutropenia

 Leukemia Research Vol 37, pp 1057 – 1062, 2013

(journal IF =  2.606; journal 5-Year IF = 2.507; HEMATOLOGY journal rank = 38 of 70; Quartile in Category – Q3; no. of citations: 4)

 

65.  Ovcharenko A., Granot G., Shpilberg O.,  Raanani P.

Enhanced adhesion/migration and induction of Pyk2 expression K562 cells     following imatinib exposure

   Leukemia Research Vol 37, pp 1729 – 1736, 2013

(journal IF =  2.606; journal 5-Year IF = 2.507; HEMATOLOGY journal rank     = 38 of 70; Quartile in Category – Q3; no. of citations: 4)

 

66.  Paul M., Ram R. ,Kugler E., Farbman L., Peck A., Leibovici L., Lahav M., Yeshurun M., Shiplberg O., Herscovici C, Wolach O., Itchaki G., Bar-Nathan M., Vidal L., Gafter-Gvili A., Raanani P.

Subcutaneous vs. intravenous G-CSF for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial.

   American Journal of Hematology  Vol 89, pp 243 – 248, 2014

(journal IF =  5; journal 5-Year IF = 4.041; HEMATOLOGY journal rank  =     13 of 70; Quartile in Category – Q1; no. of citations: 3)

 

67.  Muchtar E., Raanani P., Yeshurun M., Shpliberg O. , Magen-Nativ H.

Myeloma in scar – an under reported phenomenon or an emerging entity in the novel agents' era? Single center series report.

Acta Haematologica Vol 132, pp 39 - 44,  2014

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 2)

 

68.  Muchtar E., Ram R., Raanani P., Yeshurun M., Oniashvili N., Shpilberg O., Magen H.

First line and salvage therapy with total therapy 3-based treatment for multiple

myeloma-An extended single center experience.

Leukemia Research  Vol 38, pp 1401-1406, 2014

(journal IF =  2.606; journal 5-Year IF = 2.507; HEMATOLOGY journal rank        = 38 of 70; Quartile in Category – Q3; no. of citations: 0)

 

69.  Shepshelovich D., Edel Y., Goldvaser H., Dujovny T., Wolach O., Raanani P. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study.

British Journal of Clinical Pharmacology  Vol 79, pp 685 - 691, 2014

(journal IF =  3.83; journal 5-Year IF = 3.878; PHARMACOLOGY & PHARMACY journal rank = 48 of 253; Quartile in Category – Q1; no. of citations: 0)

 

70.  Hershkovitz-Rokah O., Modai S., Pasmanik-Chor M., Toren A., Shomron N., Raanani P., Shpilberg O., Granot G.

MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.

Cancer Letters Vol 356, pp 597 – 605, 2015

  (journal IF =  5.992; journal 5-Year IF = 5.174; ONCOLOGY journal rank =   23 of 213; Quartile in Category – Q1; no. of  citations: 10)

 

71.  Kugler E., Levi A., Goldberg E., Zaig E., Raanani P., Paul M.

The association of central venous catheter placement timing with infection rates in patients with acute leukemia.

Leukemia Research  Vol 38, pp 1401-1406, 2014

  (journal IF =  2.606; journal 5-Year IF = 2.507; HEMATOLOGY journal rank        = 38 of 70; Quartile in Category – Q3; no. of citations: 2)

 

72.  Wolach O., Itchaki G., Bar-Natan M., Yeshurun M., Ram R., Herscovici C.,    Shpilberg O., Douer D., Tallman M., Raanani P.

High dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia – is more better or more of the same?

Hematological Oncology Vol 34, pp 28 - 35, 2016                                                                            (journal IF =  3.494; journal 5-Year IF = 2.533; HEMATOLOGY journal rank = 24 of 70; Quartile in Category – Q2; no. of citations: 0)

 

73.  Hershkovitz-Rokah O., Modai S., Pasmanik-Chor M., Toren A., Shomron N.,    Raanani P., Shpilberg O, Granot G.

Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.

Cancer Letters Vol 360, pp 245 – 256, 2015

(journal IF =  5.992; journal 5-Year IF = 5.174; ONCOLOGY journal rank =   23 of 213; Quartile in Category – Q1; no. of  citations: 5)

 

 

74.  Hazan-Halevy I., Rosenblum D., Weinstein  S., Bairey O. , Raanani P., Peer D.               Cell-specific uptake of mantle cell lymphoma- derived exosomes by B-lymphocytes in a cholesterol dependent pathway.

  Cancer Letters Vol 364, pp 59 – 69, 2015

 (journal IF =  5.992; journal 5-Year IF = 5.174; ONCOLOGY journal rank =    23 of 213; Quartile in Category – Q1; no. of  citations: 4)

 

 

75.  Gafter-Gvili A., Ribakovsky E., Mizrahi N., Avigdor A.,  Aviv A., Vidal L., Ram R., Perry C., Avivi I., Kedmi M., Nagler A., Raanani P., Gurion R.

Infections associated with bendamustine - retrospective multicenter study.  Leukemia and Lymphoma Vol 57, pp 63 – 69 ,2016

(journal IF =  3.093; journal 5-Year IF = 2.704; HEMATOLOGY journal rank = 28 of 70; Quartile in Category – Q2; no. of  citations: 0)

 

 

76.  Vidal L., Shpilberg O., Gurion R., Monsef I., Raanani P., Ram R., Gafter -Gvili A.                                                                                                                                      CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma – a meta-analysis of randomized controlled trials.

Acta Oncologica Vol 55, pp 77 – 84, 2016

(journal IF =  3.73; journal 5-Year IF = 3.417; ONCOLOGY journal rank = 66 of 213; Quartile in Category – Q2; no. of  citations: 0)

 

{C}77.  {C}Yeshurun M., Shpilberg O., Herscovici C., Shargian L., Dreyer J., Peck A., Israeli M., Levy-Assaraf M., Gruenewald  T., Mechoulam R., Raanani P., Ram R.                                                                                                                        Cannabidiol for the prevention of graft-versus-host-disease after allogeneic hematopoietic cell transplantation: results of a phase II study

Biology of Blood and Marrow Transplantation Vol 21, pp 1770 - 1775, 2015

 (journal IF =  3.98; journal 5-Year IF = 3.992; TRANSPLANTATION journal rank = 4 of 25; Quartile in Category – Q1; no. of  citations: 0)

 

{C}78.  {C}Shahal-Zimra Y., Rotem Z., Chezar J., Oniashvili N., Leader A., Raanani P., Rabizadeh E.

Adult pre B-cell acute lymphoblastic leukemia with unusually large proportion of bone marrow CD45 bright/high SSc blasts.

Cytometry, part B (Clinical Cytometry) 2015 Sep 28. [Epub ahead of

print]

(journal IF =  2.822; journal 5-Year IF =2.323  ; MEDICAL LABORATORY TECHNOLOGY journal rank =    6 of 30; Quartile in Category – Q1; no. of  citations: 0)

 

79.  Shacham-Abulafia A., Itchaki G., Yeshurun M., Paul M., Peck A., Leader A., Shpilberg O., Ram R., Raanani P.

High intensity induction chemotherapy is feasible for elderly patients with          acute myeloid leukemia.

      Acta Haematologica  Vol 135, pp 55-64, 2016

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 0)

 

80.  Muchtar E. Gatt M., Rouvio O., Ganzel C., Lavi N., Shochat T.,Cohen Y., Avivi I., Raanani P., Magen H.

Efficacy and safety of salvage therapy using Carfilzomib for relapsed or  refractory multiple myeloma patients: a multicentre retrospective observational study.

       British Journal of  Haematology  Vol 172, pp 89-96, 2016

   (journal IF =  5.401; journal 5-Year IF = 5.151; HEMATOLOGY journal rank    = 10 of 70; Quartile in Category – Q1; no. of  citations: 1)

 

81.  Muchtar E.,  Magen H.,  Itchaki G.,  Cohen A.,  Rosenfeld R,  Shochat T.,  Kornowski R.,  Iakobishvili Z.,  Raanani P.                                                         Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis.                                                                                          Leukemia Research  Vol 41, pp 56 – 61, 2016

(journal IF =  2.606; journal 5-Year IF = 2.507; HEMATOLOGY journal rank        = 38 of 70; Quartile in Category – Q3; no. of citations: 0)

 

 

82.  Weinstein S., Toker I.A., Emmanuel R., Ramishetti S., Hazan-Halevy I., Rosenblum D., Goldsmith M., Abraham A., Benjamini O., Bairey O., Raanani P., Nagler A., Lieberman J., Peer D.                                                                         Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.                                                                                                         Proceedings of the  National Academy of Sciences  U S A (PNAS) Vol 113, pp E16-22, 2016

(journal IF =  9.423; journal 5-Year IF = 10.285; MULTIDISCIPLINARY   SCIENCES  journal rank    = 4 of 63; Quartile in Category – Q1; no. of  citations: 1)

 

83.  Vidal L., Gurion R., Ram R., Raanani P., Bairey O., Robak T., Gafter-Gvili A., Shpilberg O.

  Chlorambucil for the treatment of patients with chronic lymphocytic leukemia

  (CLL) - a systematic review and meta-analysis of randomized trials.                                                                                             

  Leukemia and Lymphoma. 2016 Mar 16:1-11. [Epub ahead of print]

(journal IF =  3.093; journal 5-Year IF = 2.704; HEMATOLOGY journal rank = 28 of 70; Quartile in Category – Q2; no. of  citations: not availabel yet)

 

84.  Al-Ali HK., Griesshammer M., le Coutre P., Waller CF., Liberati AM., Schafhausen P, Tavares R., Giraldo P., Foltz L., Raanani P., Gupta V., Tannir B., Perez Ronco J., Ghosh J., Martino B., Vannucchi AM.

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.                                                                    Haematologica 2016 May 31. [Epub ahead of print]

(journal IF =  6.671; journal 5-Year IF = 5.877; HEMATOLOGY journal rank  = 4 of 70; Quartile in Category – Q1;  no. of citations: not availabel yet)

 

 

85. Muchtar E.,  Zelig  A., Robenshtok E., Shochat T., Oniashvili  N., Amitai I., Raanani P., Magen H.

Bone Mineral Density Utilization in Patients with Newly Diagnosed Multiple Myeloma: a Single Center Experience.

Hematological Oncology 2016 June 21[Epub ahead of print]

 (journal IF =  3.494; journal 5-Year IF = 2.533; HEMATOLOGY journal rank = 24 of 70; Quartile in Category – Q2; no. of citations: not available yet)

 

86.  Mittelman M., Filanovsky K., Ofran Y., Rosenbaum H., Raanani P., Braester A.,  Goldschmidt N., Kirgner I., Herishanu Y., Perri C., Ellis M., Oster HS.; Israel Myelodysplastic Syndrome Working Group (MDS-WG).

Azacitidine-lenalidomide (ViLen) combination yields a high response rate in

higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.     

Annals of Hematology Vol 95, pp 1811 – 1818, 2016.

(journal IF =  3.022; journal 5-Year IF = 2.751; HEMATOLOGY journal rank        = 31 of 70; Quartile in Category – Q2; no. of citations: 0)

 

87.  Gurion R., Raanani P., Vidal L., Leader A.,  Gafter-Gvili A.                                First line treatment with the newer tyrosine kinase inhibitors in chronic myeloid leukemia is associated with a deep and durable molecular response – systematic review and meta-analysis

Acta Oncologica Vol 55, pp1077-1083, 2016

(journal IF =  3.73; journal 5-Year IF = 3.417; ONCOLOGY journal rank = 66 of 213; Quartile in Category – Q2; no. of  citations: 0)

 

 

88.  Gover-Proaktor A., Granot G., Shapira S.,  Raz O.,  Pasvolsky O., Nagler A.,  Lev D.L.,  Inbal A.,  Lubin I.,  Raanani P.,  Leader A.

Ponatinib reduces viability, migration, and functionality of human endothelial

cells.

Leukemia and Lymphoma Vol 58, pp 1455 – 1467, 2016

(journal IF =  3.093; journal 5-Year IF = 2.704; HEMATOLOGY journal rank = 28 of 70; Quartile in Category – Q2; no. of  citations: 0)

 

 

  1. Grisariu S., Vaxman I., Gatt M., Elias S., Avni B., Arad A., Pasvolsky O., Raanani P., Paltiel O.

Enteroviral infection in patients treated with rituximab for non- Hodgkin lymphoma: a case series and review of the literature.

Hematological Oncology 2016 Oct 13

(journal IF =  3.494; journal 5-Year IF = 2.533; HEMATOLOGY journal rank = 24 of 70; Quartile in Category – Q2; no. of citations: not available yet)

 

  1. Gafter-Gvili A., Gurion R., Raanani P.,  Shpilberg O., Vidal L.

Bendamustine-associated infections-systematic review and meta-analysis of

randomized controlled trials.

Hematological Oncology 2016 Oct 13

(journal IF =  3.494; journal 5-Year IF = 2.533; HEMATOLOGY journal rank = 24 of 70; Quartile in Category – Q2; no. of citations: 0)

 

91.  Leader A.,  Zelikson-Saporta R., Pereg D.,  Spectre G.,  Rozovski U., Raanani P., Hermoni D., Lishner M.

The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence.

(journal IF =  5.61; journal 5-Year IF = 5.263; MEDICINE, GENERAL & INTERNAL journal rank = 14 of 155; Quartile in Category – Q1; no. of citations: not available yet)

 

 

     Accepted

92.  Gurevich A., Tzadok S., Rosenberg A., Inbal A., Bar-Natan M., Wolach O., Raanani P.

Extended small dose platelet transfusions in multi-transfused hemato-oncological patients:   a single center experience.

Accepted to: Acta Haematologica

  

 

 

 

 

 

 

B.2. CASE REPORTS

 

Published

1.       Raanani P., Levi Y., Varon D., Gitel S., Martinowitz U.                                   Congenital afibrinogenemia with bleeding, bone cysts and antibodies to fibrinogen. Harefuah Vol. 121, pp. 291-293, 1991                                                                          (journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

2.       Raanani P., Lahav M., Prokocimer M., Poles L., Theodor E.                                   Life threatening hypophosphataemia in a patient with Philadelphia chromosome positive chronic myelogenous leukaemia in acute blastic crisis.                                    Postgraduate Medical Journal Vol. 68, pp. 283-286, 1992                                         (journal IF =  1.218; journal 5-Year IF = 1.232; journal rank = 56 of 100)

 

3.       Raanani P., Kunicevki M., Sidi Y.                                                                          Fever and lymphadenopathy in a 33 year old patient with discoid lupus erythematosus. Clinico-pathological conference.                                                                                Harefuah Vol. 124, pp. 854-660, 1993                                                                 (journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

4.       Bar-Dayan Y., Raanani P.,  Levy Y., Aharon A., Likumovich P., Skurnik Y.              Acute renal failure and fatal respiratory failure in leukemic hyperleukocytosis                                     (clinical conference).                                                                                             Harefuah Vol. 132, pp. 63-67, 1997                                                                            (journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

5.       Raanani P., Thaler M., Keller N., Ben-Bassat I.                                                             Skin lesions in a patient with hairy cell leukaemia.                                                    Postgraduate Medical Journal Vol. 73, pp. 375-377, 1997                                        (journal IF =  1.218; journal 5-Year IF = 1.232; journal rank = 56 of 100)

 

6.       Kreiss Y., Schwartz E., Kaminski N., Raanani P., Schiby G.., Zvas Z., Sidi Y.

 Unique pulmonary presentation of intravascular large cell lymphoma.                   

 Respiratory Medicine Vol. 92, pp. 1087-1089, 1998                                                (journal IF =  2.235; journal 5-Year IF = 2.146; journal rank = 28 of 75)

 

7.       Rachmani R., Avigdor A., Youkla M., Raanani P., Zilber M., Ravid M.,
Ben-Bassat I.

Thrombotic thrombocytopenic purpura complicating chronic myelogenous      leukemia. A report of two successfully treated patients.

Acta Haematologica Vol. 100, pp. 204-206, 1998                                                            (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

8.       Levi I., Raanani P., Shalmon B., Schiby-Brilliant R., Ben-Bassat I.                               Acute neutrophilic dermatosis induced by all-trans-retinoic acid treatment for acute promyelocytic leukaemia.

Leukemia & Lymphoma  Vol. 34, pp. 401-404, 1999                                                 (journal IF = 1.512; journal 5-Year IF = 1.461; journal rank = 41 of 63)

 

9.       Sharabi Y., Raanani P., Shenkar A, Thaler M., Grossman E.

Plasma cell dyscrasia with polyneuropathy - POEMS syndrome presenting with

vasculitic skin lesions and responding to combination chemotherapy

Leukemia & lymphoma  Vol. 40, pp. 209-213, 2000                                                      (journal IF = 1.512; journal 5-Year IF = 1.461; journal rank = 41 of 63)

 

10.     Gayer G., Zandman-Goddard G., Raanani P., Hertz M., Apter S.

Widespread abdominal venous thrombosis in paroxysmal nocturnal    hemoglobinuria diagnosed on CT.

Abdominal Imaging Vol. 26,  pp. 414-419, 2001                                                          (journal IF = 1.213; journal 5-Year IF = 1.258; journal rank = 60 of 87)

 

11.     Raanani P., Goldman J.M., Ben-Bassat I.

Depigmentation in a chronic myeloid leukemia patient treated with STI-571

Journal of Clinical Oncology Vol 20, pp. 869 – 870, 2002                                          (journal IF =  15.484; journal 5-Year IF = 13.753; journal rank = 5 of 132)

 

12.     Levi I.,  Dinour D.,  Ben-Bassat I.,   Raanani P.

Acute myeloid leukemia associated with nephrotic syndrome.

Leukemia & Lymphoma Vol 4 , pp.  1133-1136, 2002                                              (journal IF = 1.512; journal 5-Year IF = 1.461; journal rank = 41 of 63)

 

13.     Gurion R., Groshar D., Schindel A., Shpilberg O., Raanani P.

18F-fluorodeoxyglucose-avid mammary mass in a patient with insulin-dependent diabetes mellitus and Hodgkin's lymphoma: relapse or pitfall?

The Israel Medical Association Journal Vol 8, pp 838-839, 2006                              (journal IF =  0.577; journal 5-Year IF = 0.583; journal rank = 42 of 100)

 

14.     Sapoznikov B., Morgenstern S., Raanani P., Aviram A., Rabizadeh E., Prokocimer M., Niv Y.

Follicular lymphoma with extensive gastrointestinal tract involvement: follow-  up by capsule endoscopy.
Digestive Diseases and Sciences  Vol 52, pp 1031 – 1035,  2007                              (journal IF =  1.319; journal 5-Year IF = 1.582; journal rank = 41 of 50)

 

15.     Gafter-Gvili A., Ram R., Gafter U., Shpilberg O., Raanani P.

Renal failure associated with tyrosine kinase inhibitors – case report and review of the literature.

Leukemia Research Vol 34, pp. 123-127, 2010

(journal IF =  2.390; journal 5-Year IF = 2.160; journal rank = 34 of 62)

 

 

16.     Wolach O, Yeshurun M, Amariglio N, Shpilberg O, Raanani P.

Acute promyelocytic leukemia with a smoldering course associated with

therapy-related myelodysplastic syndrome.

Acta Haematologica Vol 126, pp 152 – 156,  2011

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 1)

 

17.     Muchtar E, Paul M, Horowitz A, Shpilberg O, Raanani P.

Persistent carbapenem-resistant Klebsiella pneumoniae bacteremia in a patient

with acute lymphoblastic leukemia.

Israel Medical Association Journal : IMAJ Vol 14, pp 195 – 197, 2012

(journal IF =  0.879; journal 5-Year IF = 1.014; MEDICINE, GENERAL & INTERNAL journal rank = 98 of 151; Quartile in Category – Q3;  no. of citations: 1)

 

18.     Shacham – Abulafia A., Nagar R., Ram E., Levavi H., Vidal L., Shpilberg O., Raanani P.

     Burkitt Lymphoma of the Ovary: Case Report and Literature Review

    Acta Haematologica Vol 129, pp 169 – 174,  2013

 

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 0)

 

19.     Shepshelovich D., Shpilberg O., Lahav M., Itchaki G., Raanani P., Cohen A.

Hodgkin Lymphoma and Hypothermia: Case Report and Review of the Literature.

Acta Haematologica Vol 131, pp 227 – 230, 2014

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 1)

 

20.     Shepshelovich D., Oniashvili N., Parnes D., Klein A., Muchtar E., Yeshaya J., Aviram A., Rabizadeh E., Raanani P.                                                                              Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.

    Cancer Genetics  Vol 208, pp 575-579, 2015

(journal IF =  2.333; journal 5-Year IF = 2.805; ONCOLOGY  journal rank = 135 of 213; Quartile in Category – Q3; no. of citations: 0)

 

21.     Wasserstrum Y., Raanani,P., Kornowski R., Iakobishvili Z.

 Concomitant treatment with ibrutinib and amiodarone causing reversible heart failure syndrome.

Israel Medical Association Journal  Vol 18, pp 433- 434, 2016

(journal IF =  0.879; journal 5-Year IF = 1.014; GENERAL & INTERNAL MEDICINE  journal rank = 99 of 105; Quartile in Category – Q3; no. of citations: 0)

 

 

 

 

B.3. REVIEW ARTICLES

Published

 

1.       Raanani P., Martinowitz U.                                                                                             Chronic fatigue syndrome - review.                                                                         Harefuah, Vol. 127, pp. 467-471, 1994                                                                         (journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

2.       Raanani P., Shpilberg O., Ben-Bassat I.                             

2-chlorodeoxyadenosine(2-CdA) therapy in hairy cell leukemia - review.         Harefuah, Vol. 126, pp. 673-676, 1994                                                                         (journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

3.       Raanani P., Ben-Bassat I.

Immune-mediated Complications during interferon therapy in hematological patients.

Acta Haematologica, Vol. 107, pp. 133-144 ,2002                                                      (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

4.       Raanani P.,  Ben-Bassat I..

Detection of Minimal Residual Disease in Acute Myelogenous Leukemia.

Acta Haematologica  Vol. 112, pp 40-54, 2004                                                 (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

 

{C}5.       Raanani P., Shpilberg O., Ben-Bassat I.

Extramedullary disease and targeted therapies for hematological   malignancies - is the association real?
Annals of Oncology  Vol. 18, pp 7-12, 2007                                                              (journal IF =  4.875; journal 5-Year IF = 4.805; journal rank = 23 of 132)

 

6.       Shpilberg O, Ben-Bassat I, Raanani P.

Targeted and tailored therapy in hemato-oncology: vision for the 21st century.

The Israel Medical Association Journal Vol. 8, pp 843-844, 2006                            (journal IF =  0.577; journal 5-Year IF = 0.583; journal rank = 42 of 100)

 

7.       Ben-Bassat I, Raanani P, Gale RP.

Graft-versus-leukemia in chronic lymphocytic leukemia.
Bone Marrow Transplantation Vol 39, pp441-446,  2007                                          (journal IF =  3.000; journal 5-Year IF = 2.542; journal rank = 25 of 63)

 

{C}8.       Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P.

The late adverse events of rituximab therapy – rare but there!

     Leukemia & Lymphoma Vol 50, pp 1083-1095, 2009
  (journal IF = 1.512; journal 5-Year IF = 1.461; journal rank = 41
     of 63)
 
 
{C}9.       {C}Ram R, Gafter-Gvili A, Shpilberg O, Raanani P. 
                          Allogeneic hematopoietic cell  transplantation for adult patients with acute    leukemia: the role of meta-analyses. 
     Acta Haematologica Vol. 125, pp 39-46, 2011

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 1)

 

{C}10.     {C}Gafter-Gvili A, Ram R, Raanani P, Shpilberg O. 
                          Management of aplastic anemia: the role of systematic reviews and meta-analyses. 
     Acta Haematologica Vol. 125, pp 47-54, 2011

 (journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 3)

 

 
{C}11.     {C}Gurion R, Shacham-Abulafia A, Shpilberg O, Raanani P. 
The use of myeloid colony-stimulating factors in hematologic malignancies:          the  role of systematic reviews and meta-analyses. 
     Acta Haematologica Vol. 125, pp 68-79, 2011

 (journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 3)

 

12.     Raanani P, Granot G, Ben-Bassat I

Is cure of chronic myeloid leukemia in the third millennium a down to earth target (ed) or a castle in the air?

Cancer Letters Vol. 352, pp 21 – 27, 2014

(journal IF =  5.992; journal 5-Year IF = 5.174; ONCOLOGY journal rank =    23 of 213; Quartile in Category – Q1; no. of  citations: 1)

 

13.     Leader A., Raanani P.

Adherence-related issues in adolescents and young adults with hematological disorders.

  Acta Haematologica Vol. 132, pp 348 - 362, 2014

   (journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank   = 62 of 70; Quartile in Category – Q4; no. of citations: 0)

 

14.    Pasvolsky O., Leader A., Iakobishvili Z., Wasserstrum Y., Kornowski R., Raanani P.

 Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid

  Leukemia

 Cardio-Oncology Vol  1: 5, 2015 DOI 10.1186/s40959-015-0008-5

(No IF yet)

 

15.       Wasserstrum Y., Kornowski R., Raanani P., Leader A., Pasvolsky O., Iakobishvili Z.,

Hypertension in cancer patients treated  with anti-angiogenic based regimens Cardio-Oncology Vol  1: 6, 2015 DOI 10.1186/s40959-015-0009-4

(No IF yet)

 

16.  Asheknazy S., Dreyer J., Raanani P., Leader A.

Adherence to oral treatment in hemato-oncology

Harefuah, Vol. 156, pp. 254-258, 2017

 

C.      CHAPTERS IN BOOKS

      Published

 

1.      Ram R., Vidal L., Gurion R., Raanani P., Shpilberg O.: Evidence-based guided interventions in acute leukemia. In: Antica M (Ed): Acute leukemia - the scientist's perspective and challenge. InTech, 2011, pp 349 -370

 

2.      Raanani P., Gurion R., Gafter-Gvili A., Ben-Bassat I.,  Shpilberg O.: The role          of hematopoietic growth factors in aplastic anemia: an evidence-based perspective. In: Molineux G, Foote MA, Arvedson T (Eds): Twenty years of G-CSF. Springer Basel, 2012, pp 195 - 210

 

    

3.      Saar N., Raanani P., Rozovski U.: Prognostic and Predictive Indicators in Treatment Naïve Patients with Chronic Lymphocytic Leukemia:
Is It Prime Time to Stratify Patients According to IGHV Mutation Status?                     In: Chronic Lymphocytic Leukemia: Diagnosis, Treatment Options and Prognosis" - Nova Science Publishers 2016

 

 

D.1.  INVITED PAPERS IN SCIENTIFIC MEETINGS

Raanani P

Systematic reviews in haematological malignancies

Evidence-based Reviews in Haemato-Oncology: 10th Anniversary of the Cochrane Haematological Malignancies Group, Cologne, 2011.

D.2. PAPERS PRESENTED AT SCIENTIFIC MEETINGS AND PUBLISHED    AS PROCEEDINGS

 

1.      Martinowitz U., Verroust F., Raanani P., Varon D., Lemay D., Heim M.  

TENS enhanced joint recovery in hemophiliacs with hemarthrosis.                           Tenth congress of the International Society of Hematology, September 1989, Jerusalem, Israel.

 

2.      Raanani, P., Lahav M., Prococimer M., Theodor E.                                                  Life threatening hypophosphatemia in a patient with Philadelphia chromosome positive CML in acute blastic crisis.                                                                                           The Israeli Society of Internal Medicine, March 1990, Ramat-Gan, Israel.

 

3.      Martinowitz U., Verroust F., Raanani P., Varon D., Lemay D., Heim M. 

 

TENS enhanced joint recovery in hemophiliacs with hemarthrosis.                              XIX International Congress of the World Federation of Hemophilia                         International Congress of World Federation of Hemophilia, August 1990, Washington D.C., U.S.A.

 

4.      Lahav M., Raanani P., Weissenberg R., Regev A., Sagiv M., Singer R.                         Prevention of procarbazine induced sterility by clomiphene - a rat model.

American Society of Hematology, 33rd annual meeting, December 1991, Denver, Colorado, U.S.A.

 

5.      Lahav M., Raanani P., Weissenberg R., Regev A., Sagiv M., Singer R.                  Time dependence for the protective effect of clomiphene from procarbazine induced sterility.                                                                                                                 American Society of Hematology, 34th annual meeting, December 1992, Anaheim, California, U.S.A.

 

6.    Singer R., Lahav M., Sagiv M., Raanani P., Lurie B., Cohen A., Magazanik A., Levinski H.                                                                                                              Sialic acid content and sialyltransferase activity in rats and epididmis of male rats.

     The 27th National Congress of the Israel Society of Clinical   Biochemistry, January 1993, Tel-Aviv, Israel

 

7.       Levinsky H., Singer R., Cohen A., Lurie B., Weissenberg R., Sagiv M., Raanani P., Regev A., Lahav M.                                                                                                          The effect of clomiphene citrate and procarbazine on sialytransferase activity in testis and epididmis of the adult rat.                                                                                  Annual meeting of the Israel Society of Fertility, April 1993, Tel-Aviv, Israel

 

8.       Shamir R., Kenet G., Raanani P., Zajicek G, Arber N.                                               Increased turnover of intra-hepatic bile ducts induced by bromobenzene.                    American Gastroenterology Association, American Association for the Study of Liver Diseases, May 1993. Boston, Massachusettes, U.S.A.

 

9.       Raanani P., Shpilberg O., Bercowicz M., Sofer O., Hardan I., Chetrit A.,
Ben-Bassat I.                                                                                                        

Salvage combination chemotherapy for acute leukemia using high dose Ara-C and mitoxantrone. Experience of the Sheba Medical Center.                                       

The Israeli Society of Hematology, November 1993 , Tel-Aviv, Israel

 

10.     Hardan I., Sofer O., Shpilberg O., Ra'anani P., Ben-Bassat I.

Safety of stringent prophylactic platelet transfusion (PT) policy for lymphoma patients treated by high dose chemotherapy (HDC) and autologous stem cell support (ASCS(

20th Annual Meeting of the European Group for Bone Marrow Transplantation and the 10th Meeting of the Nurses Group, March 1994, Harrogate, England, UK

 

11.     Levinsky H., Singer R., Cohen A., Raanani P., Regev A., Kyzer S., Lahav M.         The effect of clomiphene citrate and cyclophosphamide activity in extract of kidney and liver of the rat.                                                                                                              The 29th National Congress of the Israel Society of Clinical Biochemistry, January 1995, Tel-Aviv, Israel

 

12.     Raanani P., Shpilberg O., Bercowicz M., Sofer O., Hardan I., Chetrit A., Avigdor A., Ben-Bassat I.                                                                                                      Salvage combination chemotherapy for acute leukemia using high dose Ara-C and mitoxantrone. Experience of the Sheba Medical Center: 1991-1995.                                       The Israeli Society of Hematology, March 1996, Natanya, Israel

 

13.     Weissenberg R., Lahav M., Raanani P., Madgar I.

Prevention of procarbazine - induced sterility by clomiphene isomers and  tamoxifen: A rat model

VIth International Congress of Andrology, May 1997, Salzburg, Austria

14.         Dazzi F., Raanani P., van Rhee F., Olavarria E., Szydlo R.M., Apperley J.,   Goldman, J.M., Cross N.C.P.                                                                                 RT-PCR for BCR-ABL transcripts in CML patients receiving DLI as treatment for relapse after BMT: differing patterns of molecular response.                                       EBMT-European Group for Blood and Bone Marrow Transplantation-23 Annual meeting, March 1997, Aix-les-bains, France

 

15.         Raanani P., Cross N., Goldman J.                                                              Competitive PCR-The method and clinical applications.                                                The Israeli Society of Hematology and Blood Transfusion, September 1997, Dead Sea Israel.

 

16.         Dazzi F., Raanani P., van Rhee F., Olavarria O., Murphy K.M., Philpott N.J., Apperley J.F., Cross N.C..P, Goldman J.M.                                                                                Responses to donor lymphocyte infusion in CML patients in relapse after BMT may be partial and transient: further evidence for a dose-response effect.                                                                                                                  American Society of Hematology, 39th annual meeting, December 1997, San Diego, California, U.S.A.

 

17.         Raanani P., Dazzi F., Sohal J., Szydlo R.M., van Rhee F., Reiter A., Lin F., Apperley J.F., Goldman J.M., Cross N.C.P.                                                                                       The incidence, kinetics and durability of response to donor leukocyte transfusions for CML patients who relapse after BMT.                                                                                  

American Society of Hematology, 39th annual meeting, December 1997, San Diego, California, U.S.A.

 

18.     Raanani P., Shpilberg O., Gilis S., Avigdor A., Hardan I., Berkowicz M., Sofer O., Lossos I., Chetrit A., Ben-Yehuda D., Ben-Bassat I.                                                        Salvage therapy of refractory acute leukemia with high-dose mitoxantrone and cytarabine.                                                                                                           American Society of Hematology, 39th annual meeting. December 1997, San Diego, California, U.S.A.

 

19.     Dazzi F., Raanani P., van Rhee F., Szydlo R. M., Olavarria E., Kaeda J., Apperley     J.F., Cross N.C.P., Goldman J.M.                                                                                         Donor lymphocyte infusion (DLI) for relapse of CML after allo-BMT: comparison of two regimens.                                                                                      EBMT-European Group for Blood and Bone Marrow Transplantation- 24th Annual Meeting, March 1998, Courmayeur, Italy

 

20.     Kaeda J.S., Dazzi .F., Baker P., Raanani .P, Knafer E., Apperley J.F.,
 Cross N.C.P., Goldman J.M.                                                                                                       Escalating doses of DLI identify a subset of CML patients in relapse after allografting in whom only a partial or transient response is achieved.   

EBMT-European Group for Blood and Bone Marrow Transplantation-

24th Annual Meeting, March 1998, Courmayeur, Italy

 

21.     Hardan I., Avigdor A., Attias D., Raz H.,  Berkowitcz M., Raanani .P, Sareli R.,  Levy I., Ben-Bassat I.                                                                                                       

High dose melphalan and etoposide (VP-16) with autologous stem cell support for newly diagnosed multiple myeloma (MM) patients- a phase II study.

EBMT-European Group for Blood and Bone Marrow Transplantation- 24th

Annual Meeting, March 1998, Courmayeur, Italy

 

22.     Raanani P., Levi I. , Shpilberg O., Holzman F. , Grotto I. , Simoni F. , Avigdor A., Berkowicz M.  , Hardan I., Ben-Bassat I..

Engraftment associated hypophosphatemia - the role of cytokine release and steep leukocyte Rise post stem cell transplantation.

American Society of Hematology, 41st  annual meeting, December 1999, New-Orleans, U.S.A.

 

23.     Raanani P., Levi I., Shpilberg O., Holzman F., Grotto I., Brok-Simoni F., Avigdor A., Berkowicz M., Hardan I., Kneller A.  and Ben-Bassat I..

Engraftment associated hypophosphatemia - the role of cytokine release and steep leukocyte rise post stem cell transplantation.

The Israeli Society of Hematology and Blood Transfusion, October 1999,  Dead Sea, Israel

 

24.     Raanani P., Levi I., Holzman F., Grotto I., Shpilberg O., Brok-Simoni F., Avigdor A., Berkowicz M., Hardan I., Kneller A., Ben-Bassat I.

The role of cytokines and leucocyte rise in the development of hypophosphataemia after pbsct.

26th Annual Meeting European Group for Blood and Marrow Transplantation and    16th Meeting of the Nurses Group, March 2000, Innsbruck, Austria

 

25.     Raanani P., Levi I., Holzman F., Grotto I., Brok-Simoni F., Avigdor A., Berkowicz M., Davidson J., Shpilberg O., Ben-Bassat I.

The role of cytokines and leukocyte rise in the development of hypophosphatemia after PBSCT.

Cancer Biology Research Center – annual meeting February 2001, Eilat

 

26.     Hardan I., Kneller A., Avigdor A., Raz H., Berkowicz M., Sareli R., Shimoni A.,    Levi I., Raanani P., Ben-Bassat I.
Rescue of multiple myeloma patients with disease progression after autologous PBSC transplantation.

27th Annual Meeting European Group for Blood and Marrow Transplantation and 17th Meeting of the Nurses Group, March 2001

 

 

27.     Levy-Nissenbaum O.,  Sagi-Assif O.,  Kapon D., Hantisteanu S.,  Raanani P.,

Avigdor A.,  Ben-Bassat I.,  Witz I.P.

High Expression of the Dual-Specificity Phosphatase PYST2 in Leukocytes Derived from AML Patients.

American Society of Hematology, 43rd  annual meeting, December 2001, Orlando, U.S.A.

 

28.     Shimoni A. , Hardan I., Avigdor A., Yeshurun M., Raanani P., Ben-Bassat I.,

Nagler A.

Post-transplant Rituximab reduces relapse risk after allogeneic and

autologous stem-cell transplantation (SCT) in high-risk aggressive lymphoma.

American Society of Hematology, 44th  annual meeting, December 2002, Philadelphia, U.S.A.

 

29.     Cohen A., Polliack A. ,Ben-Bassat I.,Avigdor A., Bennett M.,Berkowicz M., Attias D., Dann E., Hatskelzon L.,Levi I., Libster D.,Rahmani R,  Raanani P., Rowe JM, Shtalrid M., Yerushalmi R.,Yeshurun M.

Results of a Phase II study employing a combination of fludarabine, cyclophosphamide and Rituximab (FCR) as primary therapy for patients with advanced follicular lymphoma (FL): The Israel Cooperative Lymphoma Group.

American Society of Hematology, 44th  annual meeting, December 2002, Philadelphia, U.S.A.

 

30.     Raanani P., Ben-Bassat I., Gan S., Trakhtenbrot L., Mark Z., Itskovich S.,  Amariglio N., Brok-Simoni F., Hardan I., Kneler A., Shimoni A., Nagler A.

A  high rate of BCR-ABL negativity by FISH & multiplex RT-PCR  but not by real-time RT-PCR can be achieved in cml patients treated with imatinib.

The Israeli Society of Hematology and Blood Transfusion, January 2003, Tel-

Aviv

 

31.     Raanani P., Ben-Bassat I., Gan S., Trakhtenbrot L., Mark Z., Itskovich S.,  Amariglio N., Brok-Simoni F., Hardan I., Kneler A., Shimoni A., Nagler A.

A high rate of bcr-abL negativity by fish & multiplex rt-pcr  but not by real-time RT-PCR can be achieved in cml patients treated with imatinib 

Research conference Tel-Aviv University, April 2003, Tel-Aviv

 

32.     Raanani P., Ben-Bassat I., Gan S., Trakhtenbrot L., Mark Z., Itskovich S.,  Amariglio N., Brok-Simoni F., Hardan I., Kneler A., Shimoni A., Nagler A.

The kinetics of molecular response in cml patients treated with imatinib: a comparison between the fish, multiplex and real-time quantitative RT-PCR techniques

The European Haematology Association – EHA 8, June 2003, Lyon, France

 

33.     Raanani P., Ben-Bassat I., Itskovich S., Gan S., Morgulis Y., Kneller A., Brok-Simoni F., Rechavi G., Amariglio N., Nagler A.

Hasford score correlates with the dynamics of imatinib induced reduction of BCR-ABL transcripts in chronic phase CML.
 American Society of Hematology, 45th  annual meeting, December 2003, San   Diego, U.S.A.

 

34.     Hardan I., Shimoni A., Avigdor A., Kneller A., Berkowiicz M., Raanani P., Yeshurum M., Stemmer SM., Shem-Tov N., Ben-Bassat I, Nagler A.
Salvage therapy with autologous stem cell support prior to allogeneic stem cell transplantation in patients with relapsing/secondary acute leukemia and CML blast crisis. American Society of Hematology, 45th  annual meeting, December 2003, San   Diego, U.S.A.

 

35.     Raanani P., Ben-Bassat I., Trachtenbrrot L., Avigdor A., Brok-Simoni F.,
Amariglio N., Nagler A.

Philadelphia positive T lymphoblastic leukemia – acute leukemia or cml blast crisis?

The Israeli Society of Hematology and Blood Transfusion,  April 2004, Dead Sea, Israel

 

36.     Hardan I. Kneller A., Shimoni A., Berkowicz M., Avigdor A., Yeshurun M., Raanani P., Davidowich Y., Shemtov N., Ben-Bassat I., Nagler A.
Salvage of multiple myeloma patients relapse after an autologous stem cell transplantation, in the era of thalidomide and reduced-intensity allogeneic stem cell transplantation. 30th annual meeting of the European group of blood and bone marrow transplanation, March 2004, Barcelona, Spain

 

37.     Hardan I., Shimoni A., Avigdor A., Kneller A., Berkowicz M., Raanani P., Stemmer SM., Shemtov N., Yeshurun M., Ben-Bassat I., Nagler A.
 Autologous stem cell support of induction therapy prior to allogeneic transplantation to improve treatment delivery in patients with relapsing or secondary acute leukemia and CML blast crisis. 30th annual meeting of the European group of blood and bone marrow transplanation, March 2004, Barcelona, Spain

 

 

38.     Hardan I., Kneller A., Shimoni A., Berkowicz M., Avigdor A., Yeshurun M., Raanani P., Davidowich I., Shemtov,N., Ben Bassat I., Nagler A.

Prolongation of overall survival of multiple myeloma patients by the combination therapy of thalidomide and reduced-intensity conditioning allogeneic stem cell transplantation at progression after autologous bone marrow transplantation.

31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, March 2005, Prague, Czech Republic

 

39.     Hardan L., Meirow D., Shimoni A., Levron J., Shemtov,N., Fridman E., Zalel Y., Kneller A., Raanani P., Berkowicz M., Ben-Bassat I., Schiff E., Nagler A., Dor J. Spontaneous pregnancy and fertility preservation program in women undergoing high dose chemotherapy for hematological malignancies.

47th Annual Meeting of the American-Society-of-Hematology, December,  2005 Atlanta GA, USA

 

40.     Ram R., Gafter-Gvili A., Yeshurun M., Paul M., Raanani P., Shpilberg O.

The efficacy of prophylaxis regimens for acute graft-versus-host disease in patients undergoing bone marrow and peripheral blood stem cell transplantation – systematic review and meta-analysis

34th Annual Meeting of the European Group for Blood and Marrow         Transplantation  March 2008, Florence, Italy

 

41.     Gurion R., Gafter-Gvili A., Paul M.,  Vidal L., Ben-Bassat I., Yeshurun M., Shpilberg O., Raanani P.

Should haematopoietic growth factors be included in the immunosuppressive    treatment for severe aplastic anaemia – a systematic review and meta-analysis
34th Annual Meeting of the European Group for Blood and Marrow   Transplantation  March 2008, Florence, Italy

 

42.  Mor R., Uziel O., Shpilberg O., Lahav J., Raanani P., Rabizadeh E., Zimra Y., Lahav M., Granot G.

The effect of imatinib mesylate on the signal transduction cascade regulating telomerase activity in k562 cells and in k562 cells resistant to imatinib mesylate.

13th Congress of the European-Hematology-Association, June, 2008 Copenhagen, Denmark

 

43.  Gurion R., Vidal L., Gafter-Gvili A., Belnik Y., Yeshurun M., Raanani P.,
Shpilberg O.

The role of hypomethylating agents in the treatment of patients with myelodysplastic syndrome - systematic review and meta-analysis.

14th Congress of the European Hematology Association, June 2009 Berlin, Germany

 

44.         Ram R., Gafter-Gvili A., Vidal L., Paul M., Ben-Bassat I., Shpilberg O.,                Raanani P.

Management of Adult Patients with Acute Lymphoblastic Leukemia in First Complete Remission: Systematic Review and Meta-Analysis.                                      51st  Annual Meeting of the American-Society-of-Hematology, December, 2009, New Orleans, USA

45.         Gurion R, Belnik-Plitman Y, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Shpilberg O, Raanani P.                                                                                                   Myeloid Colony- Stimulating Factors Do Not Increase the Risk of Mortality or Disease Activity Measures in Patients with Acute Myeloid Leukemia: Systematic Review and Meta-Analysis .                                                                          51st  Annual Meeting of the American-Society-of-Hematology, December,  2009, New Orleans, USA

 

{C}46.  Ovcharenko A, Granot G, Shpilberg O, Raanani P.                                                         Molecular Mechanisms Involved in the Development of Extramedullary Disease Following the Administration of All-Trans Retinoic Acid to Patients with Acute Promyelocytic Leukemia.                                                                                                                                       51st  Annual Meeting of the American-Society-of-Hematology, December,  2009, New Orleans, USA

{C}47.  Gafter-Gvili A, Bernstine H, Vidal L,Paul M, Ram R, Raanani P, Yeshurun Y, Shpilberg O, Groshar D.                                                                                                                                  The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography and CT (PET-CT) for the Diagnosis of Infections in Hemato-Oncological Patients with Persistent Neutropenia and Fever                                                                                                                                       51st  Annual Meeting of the American-Society-of-Hematology, December,  2009, New Orleans, USA

{C}48.  Cohen Y, Cohen-Berger T, Eshel L, Stern D, Bairey O, Raanani P, Bernstine H, Shpilberg O, Groshar D.                                                                                                                                        Pulmonary Infiltrates in NHL Patients Receiving Rituximab Combined with Chemotherapy: 18Fluorodeoxyglucose Positron Emission Tomography and CT (PET-CT) Analysis and Clinical Correlates                                                                                                                        51st  Annual Meeting of the American-Society-of-Hematology, December,  2009, New Orleans, USA

 

49.  Shapira S., Granot G,. Mor-Tzuntz R., Raanani P., Uziel O., Lahav M., Shpilberg O.

The effect of nilotinib and dasatinib on telomerase activity and regulation in k562 cells

15th Congress of the European Hematology Association, June 2010 Barcelona, Spain

 

 

50. Gafter-Gvili A., Bernstine H., Vidal L., Paul M., Ram R., Raanani P.,               Yeshurun Y., Shpilberg O., Groshar D.  

The role of 18f-fluorodeoxyglucose positron emission                                tomography and CT (PET-CT) for the diagnosis of infections                                          in hemato-oncological patients with persistent neutropenia and fever.

XXXIII World Congress of the International Society of Hematology 2010, Jerusalem, Israel

 

51.  Itchaki G., Gafter-Gvili A., Lahav M., Raanani P., Vidal L., Paul M., Shpilberg O.

Anthracycline-containing regimens for treatment of follicular lymphoma in adults: systematic review and meta-analysis.

52nd Annual Meeting of the American Society of Hematology  2010, Orlando, USA   

 

52.  Gurion R.,  Gafter-Gvili A., Vidal L., Paul M.,  Ben-Bassat,I., Yeshurun M., Shpilberg O., Raanani P.                                                                                   Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy: systematic review and meta-analysis-2010 update

52nd Annual Meeting of the American Society of Hematology  2010, Orlando, USA   

  

53.  Ram R., Paul M., Gafter-Gvili A., Heshkovitz K., Israeli M., Peck A., Raanani P., Shpilberg O., Yeshurun M.                                                                                            Early post-transplantation febrile episodes are associated with increased risk for acute graft-versus-host disease                                                                                        BMT Tandem Meetings, February 2011, Hawaii, USA

 

54.   Vidal L.,  Gafter-Gvili A.,  Gurion R., Dreyling M., Raanani P., Shpilberg O.

Bendamustine for patients with indolent lymphoma - a systematic review and meta-analysis of randomized controlled trials                                                                   11th International Conference on Malignant Lymphoma 15-18 June 2011, Lugano, Switzerland 

 

55.  Gurion R., Gafter-Gvili A., Vidal L., Leader A., Ram R., Sacham-  Abulafia A., Ben Bassat I., Shpliberg O., Raanani P.

The new tyrosine kinase inhibitors for first-line treatment in patients   with chronic myelogenous leukemia-systematic review and meta-analysis. 

16th Congress of the European Hematology Association, June 2011, London, UK

 

56.  Gafter-Gvili A., Leader A., Gurion R., Vidal L., Ram R., Shacham-Avulafia A., Ben-Bassat I., Lishner M., Shpilberg O., Raanani P.

The efficacy and safety of higher doses of imatinib for the treatment of  newly diagnosed previously untreated chronic myeloid leukemia patients in chronic phase –systematic review and meta-analysis

16th Congress of the European Hematology Association, June 2011, London, UK

 

57.  Ovcharenko A., Granot G., Shpilberg O., Raanani P.

Enhanced adhesion & migration and induction of pyk2 complex fomation in NB4 and k562 cells following ATRA and imatinib treatment

16th Congress of the European Hematology Association, June 2011, London, UK

                             

58.  Vidal L, Gurion R, Gafter-Gvili A, Raanani P, Bairy O, Robak T, Shpilberg O

Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - systematic review and meta-analysis.

17th Congress of the European Hematology Association, June 2012, Amsterdam, the Netherlands

 

59.  Muchtar E., Vidal L, Gafter-Gvili A, Ram R., Shpilberg O., Raanani P

The role of maintenance therapy in acute promyelocytic leukemia:

      a systematic review and meta-analysis

17th Congress of the European Hematology Association, June 2012, Amsterdam, the Netherlands

 

60.  Gafter-Gvili A, Paul M, Bernstine H, Vidal L, Ram R, Raanani P, Yeshurun M,

Tadmor B, Shpilberg O, Groshar D

The role of PET-CT for the diagnosis of infections in patients with hematological malignancies and persistent febrile neutropenia

17th Congress of the European Hematology Association, June 2012, Amsterdam, the Netherlands

 

61.  Gafter-Gvili A., Gurion R., Raanani P., Shpilberg O., Vidal L.                     Bendamustine is not associated with an increase in infections – systematic review and meta-analysis of randomized controlled trials.

19th Congress of the European Hematology Association, June 2014, Milan, Italy

 

62.  Hershkovitz Rokah O., Granot G., Ovcharenko A., Modai S., Pasmanik-Chor M., Toren A., Shomron N., Raanani P., Shpilberg O.                                      : miRNA-30E targets BCR-ABL1 and sensitizes K562 cells to imatinib treatment.

19th Congress of the European Hematology Association, June 2014, Milan, Italy

 

63.  Dahan-Shriki D., Gafter-Gvili A.,Vidal L., Raanani P., Shpilberg O., Gurion R.

The role of high dose chemotherapy followed by autologous stem cell transplantation as first line treatment in patients with aggressive non-hodgkin lymphoma: a systematic review and meta-analysis

19th Congress of the European Hematology Association, June 2014, Milan, Italy

 

64.  Gafter-Gvili A.,  Ribakovsky E.,  Mizrahi N.,  Avigdor A.,  Aviv A., Vidal L.,  Ram R.,  Nagler A., Raanani P., Gurion R.

Infections associated with bendamustine - a retrospective multicenter study

56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA 

 

65.  Griesshammer M., Vannucchi A.M.,  le Coutre P.,  Tavares R.S., Al-Ali H.K.,   Raanani P., Gupta, V., Foltz LM. ,Giraldo P., Bouard C., Ronco J.P., Ghosh J., Martino B.                                                                                                           Safety and Efficacy of ruxolitinib in patients with low platelets enrolled in a phase 3b expanded-access study in myelofibrosis (MF)

56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA 

 

66.  Gupta, V., Tavares R.S., Griesshammer M., Foltz LM. , Raanani P., Giraldo P., Al-Ali H.K., Martino B., Tannir  B., Ronco J.P., Ghosh J., Vannucchi A.M.                                                                                     Safety and safety and efficacy of ruxolitinib retreatment after treatment interruption in patients enrolled in an open-label, multicenter, expanded-access study in myelofibrosis

56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA

 

67.  Martino B., le Coutre P.,  Griesshammer M., Illmer T., Schlag R., Waller C.F., Liberati A.M., Schafhausen P., Tavares R.S., Vannucchi A.M., Giraldo P.,  Foltz LM., Raanani P., Gupta, V., Tannir  B., Ronco J.P., Ghosh J., Al-Ali H.K.                                                                                                                     Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm, expanded-access study in patients with myelofibrosis (mf): an 1144-patient update

56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA

 

68.  Gurion R., Vidal L., Leader A., Raanani P., Gafter-Gvili A.                                The role of the newer tyrosine kinase inhibitors as first line treatment in chronic phase chronic myeloid leukemia - an updated meta-analysis                                       56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA

 

69.  Shargian-Alon L.,  Pazgal I., Raanani P.,  Rachmilewitz E.,  Stark P.     Thalassemia major and intermedia in older patients - a single center experience                                                                                                                       56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA

 

70.  Tzadok S., Gurevich A., Inbal A., Bar-Natan M., Wolach O., Raanani P            Continuous platelet transfusion increases platelet increment in refractory hemato-oncological patients - a single center experience                                       56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA

 

71.  Vidal L., Gafter-Gvili  A., Dreyling M., Ghielmini M., Unterhalt M., Raanani P., Shpilberg O., Ram R., Gurion R.                                                                                                Rituximab maintenance (MR) for patients with mantle cell lymphoma (MCL) - a systematic review and meta-analysis of randomized controlled trials (RCTs)  56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA

 

72. Shepshelovich D., Klein A., Oniashvili N., Yeshaya J., Aviram A., Parnes D., Rabizadeh E., Raanani P.                                                                                                   Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. 10th European Cytogenetics Conference 2015, Strasburg, France

 

73. Shapira S., Raanani P.,  Lubin I.,  Nagler A.,  Arber N.,  Granot G.

      Selective death of leukemic stem cells induced by deferasirox

     20th Congress of European-Hematology-Association 2015, Vienna, Austria

 

74. Giraldo P.  Palandri F.,  Palumbo GA.,  Zaritskey A.,  Calistri E.,  Skotnicki A.,  Devos T.,  Saavedra D.,  Griesshammer M.,  Al-Ali, HK., Tavares R.,  Vannucchi, AM., Gupta V.,  Raanani P.,  Tannir B.,  Ghosh J., Ronco JP., Foltz L.

Safety and efficacy of Ruxolitinib (Rux) in patients with intermediate-1-risk myelofibrosis (MF) from an open-label, multicenter, single-arm expanded-access study.

20th Congress of European-Hematology-Association, 2015, Vienna, Austria

 

75. Leader A.,  Benyamini N.,  De Geest S.,  Dreyer J.,  Calvarysky B.,  ; Gechler S., Amitai A.,  Yarchovsky-Dolberg O.,  Sharf G.,  Tousset E.,  Caspi O.,  Ellis M., Levi I.,  Gvili, AG., Raanani P.

  Assessing risk factors of electronically measured medication non-adherence in    CML patients: an observational longitudinal design-a subanalysis of the TAKE-IT study.

20th Congress of European-Hematology-Association 2015, Vienna, Austria

 

76.  Gover-Proaktor A., Pasvolsky O., Raanani P., Nagler A., Shapira S., Lubin I., Granot G., Leader A.

 Pathogenesis of ponatinib associated vascular disease in chronic myeloid leukemia: an in vitro study.

57th Annual Meeting of the American-Society-of-Hematology 2015 Orlando, USA

77.  Leader A.,  Benyamini N.,  De Geest S.,  Dreyer J.,  Calvarysky B., Gechler S., Amitai A., Jarchowsky-Dolberg O., Sharf G., Tousset E., Caspi O., Ellis, M.,  Levi I., Gafter-Gvili A., Raanani P.

The effect of adherence-encouraging interventions on adherence to tyrosine kinase inhibitor treatment in chronic myeloid leukemia (TAKE-IT): a pre-post intervention pilot study

57th Annual Meeting of the American-Society-of-Hematology 2015, Orlando, USA

78.  Leader A.,  Zelikson-Saporta R.,  Rozovski U.,  Pereg D.,  Raanani P., Spectre G.,  Lishner M., Hermoni D.

Clopidogrel treatment is associated with a decrease in cancer incidence.

57th Annual Meeting of the American-Society-of-Hematology 2015, Orlando, USA

79.  Muchtar, E., Zelig A.,  Robenshtok E.,  Shochat T.,  Oniashvili N., Amitai I., Raanani P., Magen H.

Bone mineral density utilization in patients with newly diagnosed multiple myeloma: a single center experience.

57th Annual Meeting of the American-Society-of-Hematology 2015, Orlando, USA

80.  Muchtar E.,  Magen H.,  Itchaki G.,  Cohen A.,  Rosenfeld R., Shochat T.,  Kornowski R.,  Iakobishvili Z.,  Raanani P.

Uninvolved immunoglobulins predicting hematological response in newly diagnosed al amyloidosis.

57th Annual Meeting of the American-Society-of-Hematology 2015, Orlando, USA

81.  Muchtar E.,  Gatt M.,  Rouvio O.,  Ganzei C.,  Chubar E.,  Suriu C., Tadmor T.,  Shevetz O., Lavi N.,  Shochat T., Cohen YC., Avivi I.,  Raanani P., Magen, H.

Efficacy and safety of salvage therapy using carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.

57th Annual Meeting of the American-Society-of-Hematology 2015, Orlando, USA

82.  Tavares R.,  Palumbo GA.,  Le Coutre P.,  Palanciri F.,  ; Al-Ali HK., Martino B.,  Liberati AM.,  Arich JC., Breccia M.,  Brittain D.,  Foltz L.,  Griesshammer M.,  Raanani P.,  Gupta V.,  Giraldo P.,  Chosh J.,  Tannir B.,  Ronco JP., Vannucchi AM.

  Safety and efficacy of ruxolitinib in an 1869-patient cohort of jump: an open label, multicenter, single-arm, expanded-access study in patients with myelofibrosis.

57th Annual Meeting of the American-Society-of-Hematology 2015, Orlando, USA

83.  Vidal L., Shargian L.  Shpilberg O.,  Ram R.,  Raanani P., ; Gurion R., Gafter, A.

Bendamustine for patients with indolent lymphoma an updated meta-analysis of randomized controlled trials (RCT)

57th Annual Meeting of the American-Society-of-Hematology 2015, Orlando, USA

84.  Mittelman M.,  Filanovsky K., Ofran Y.,  Raanani P.,  Braester A.,  Goldshmidt N., ; Kirgner I.,  Herishanu Y.,  Perry C.,  Oster, HS.

High response rate for azacitidine-lenalidomide (vi-len) combination in higher-risk myelodysplastic syndromes (mds) - vilen-01 protocol update.

13th International Symposium on Myelodysplastic Syndromes (MDS), Washington, DC, USA

85.  Pasvolsky O., Rozovski U., Navon M., Pek A., Dreyer J., Klebovsky T., Vaxman I., Shacham A., Shargian L., Raanani P., Yeshurun M.

Differences in attitude towards hematopoietic stem cell transplantation (hsct) between physicians and nurses.

21st Congress of the European-Hematology-Association, June 2016, Copenhagen, Denmark

86.  Abulafia A.S., Raanani P.,. Lavie D., Volchek Y., Ram R., Hellmann I., Shargian L., Gourevietch A., Chubar E., Ratzon R. Rozovski U.

A nationwide observational study of the israeli experience with ponatinib outside clinical trials in chronic myeloid leukemia

21st Congress of the European-Hematology-Association, June 2016, Copenhagen, Denmark

87.  Ratzon R., Tzadok S., Raanani P., Gurion R.

Twenty years' experience of treatment of adolescents and young adults with non-hodgkin lymphoma - a single center experience

21st Congress of the European-Hematology-Association, June 2016, Copenhagen, Denmark

88.  Vaxman I., Rosovski U., Moshe M., Shargian L., Pasvolsky O., Yahav D

Bashara J., Lahav M., Gurion R., Magen H., Vidal L., Itzhaki G., Peck A.,  Sela MN., Raanani P.,  Yeshurun M.

Antibacterial prophylaxis reduces the risk of bacteremia in patients with multiple myeloma and lymphoma undergoing high-dose chemotherapy and autologous stem cell transplantation.

21st Congress of the European-Hematology-Association, June 2016, Copenhagen, Denmark

89.  Vidal L., Lando, S. Vaxman, I.  Raanani, P., Gurion R. Gafter-Gvili A.

Reduced rchop for elderly patients with dlbcl

21st Congress of the European-Hematology-Association, June 2016, Copenhagen, Denmark

90.  Passamonti F., Zaritskey A., Giraldo P., Liberati AM., Niederwieser D., Palandri F., Raanani P., Griesshammer M., Vannucchi AM., Al-Ali HK., Gupta V., Martino B., Foltz L., Ronco JP., Ghosh J.,  Bouard C., Tavares R.

Safety and efficacy of ruxolitinib in patients with dipss intermediate-1-risk myelofibrosis (mf) from jump: an open label, multicenter, single-arm, expanded-access study

21st Congress of the European-Hematology-Association, June 2016, Copenhagen, Denmark

91.  Shapira S., Raanani P., Nagler A., Lubin I., Arber N., Granot G.

Selective Death of Leukemia Initiating Cells Induced By Deferasirox

58th Annual Meeting of the American-Society-of-Hematology 2016, San Diego, USA

92.  Vidal L., Gafter-Gvili A., Dreyling MH., Unterhalt M., Raanani P., Ghielmini M., Gurion, R.

Maintenance Therapy for Patients with Mantle Cell Lymphoma (MCL) - a Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)

58th Annual Meeting of the American-Society-of-Hematology 2016, San Diego, USA

93.  Vaxman, I., Schlesinger, A., Goldberg, N.,  Lahav, M., Gafter, A., Lando, S., Raanani P., Vidal L.

Muscle Mass in Elderly Patients with DLBCL Treated with RCHOP

58th Annual Meeting of the American-Society-of-Hematology 2016, San Diego, USA

94.  Gurion R., Bernsteine H., Michelson C., Domachevsky L., Raanani P., Vidal L., Gafter-Gvili A.

FDG PET/CT As a Diagnostic and Prognostic Tool for the Evaluation of Patients with Peripheral T-Cell Lymphoma

58th Annual Meeting of the American-Society-of-Hematology 2016, San Diego, USA

95.  Foltz L., Palumbo GA., Martino B., Palandri F., Al-Ali HK., Liberati AM., Le Coutre PD., Vannucchi AM.,  Garcia-Hernandez C., Tavares R., Griesshammer M., Gupta V.,  Raanani P., Giraldo P.,  Bouard C.,  Ronco JP.,  Khanna S.,  Zaritskey A.

Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with

Myelofibrosis (N=2233)

58th Annual Meeting of the American-Society-of-Hematology 2016, San Diego, USA

 

 

 

 

 

 

 

 

 

 

 

D.3. ABSTRACTS

  1. Lavee J., Rath S., Tranquang H., Raanani P., Ruder A., Modan M., Neufeld H.N., Goor D.A.

Is Complete Revascularization in the Conventional Method Really Complete?

Israel Journal of Medical Sciences Vol 21, pp 400, 1985

 

  1. Shamir R., Kenet G., Raanani P., Zajicek G., Arber N.

Increased Turnover of Intrahepatic Bile-Ducts Induced by Bromobenzene.

Gastroenterology Vol 104, pp A990, 1993

 

 

  1. Weissenberg R., Lahav M., Raanani P., Madgar I.

Prevention of procarbazine - induced sterility by clomiphene isomers and tamoxifen: A rat model.

International Journal of Andrology Vol 20, pp 74, 1997

 

  1. Dazzi F., Raanani P., Van Rhee F., Olavarria E., Murphy K., Philpott N., Apperley J., Cross N., Goldman J.

Responses to donor lymphocyte infusion (DLI) in CML patients in relapse after BMT may be partial and transient: Further evidence for a dose-response effect.

Blood Vol 90, pp 518A, 1997

 

  1. Dazzi F., Raanani P., van Rhee F., Szydlo R., Olavarria E., Kaeda,J., Apperley J.F., Cross N.C.P., Goldman J.M.

Donor lymphocyte infusion (DLI) for relapse of CML after allo-BMT: Comparison of two regimens.

Bone Marrow Transplantation Vol 21, pp S70, 1998

 

 

  1. Shpilberg O., Livnat T., Chetrit A., Zegelman H., Raanani P., Ben-Bassat I., Ramot B.

Polymorphisms within phase I and phase II carcinogen metabolizing genes are not associated with increased risk for hematological malignancies.

Blood Vol 94, pp 4015, 1999

  1. Raanani P.; Levi I.; Shpilberg O.; Holzman F.; Grotto I.; Simoni F.; Avigdor,A.; Berkowicz,M.; Hardan,I.; Kneller,A.; Ben-Bassat,I.

Engraftment associated hypophosphatemia - The role of cytokine release and steep leukocyte rise post stem cell transplantation.

Blood Vol 94, pp 1477, 1999

 

  1. Lahav M., Raanani P., Luboshitz J., Szyper-Kravitz M., Weissenberg,R., Shaklai M.

High dose clomiphene prevents sterility in young males with Hodgkin's disease treated with MOPP/ABV.

Blood Vol 94, pp 2359, 1999

 

  1. Hardan I., Kneller A., Avigdor A., Raz H., Berkowicz M., Sareli R., Shimoni A., Levi I., Raanani P., Ben-Bassat I.

Rescue of multiple myeloma patients with disease progression after autologous PBSC transplantation.

Bone Marrow Transplantation Vol 27, pp S2521, 2001

 

  1. Raanani P., Levi I., Holzman F., Grotto I., Brok-Simoni F., Avigdor A., Davidson J., Shpilberg O.  Ben-Bassat I.

Engraftment associated hypophosphatemia - the role of cytokine release and steep leukocyte rise post stem cell transplantation.

Bone Marrow Transplantation Vol 27, pp 776, 2001

 

  1. Levy-Nissenbaum O., Sagi-Assif O., Kapon D., Hantisteanu S., Raanani P., Avigdor A., Ben-Bassat I., Witz I.P.

High expression of the dual-specificity phosphatase PYST2 in leukocytes derived from AML patients

Blood Vol 98, pp 2440, 2001

 

 

  1. Levy-Nissenbaum O., Sagi-Assif O., Hantisteanu S., Raanani P., Avigdor A., Ben-Bassat I., Witz I.

PYST2, a MAPK dual specificity phosphatase is regulated by microenvironmental factors.

Proceedings of the 2nd International Conference on Tumor Microenvironment: Progression, Therapy and Prevention. Baden, Austria. Isaac P. Witz, Ed., Monduzzi Editore, S.p.A., Bologna, Italy, pp. 11-17, 2002

 

13.  Hantisteanu S., Levy-Nissenbaum O., Sagi-Assif O., Raanani P., Avigdor A., Ben-Bassat I., Witz I. 

Adherence up regulates expression of PYST2-L in Myeloid Leukemia cells.

Proceedings of the 2nd International Conference on Tumor Microenvironment: Progression, Therapy and Prevention. Baden, Austria. Isaac P. Witz, Ed., Monduzzi Editore, S.p.A., Bologna, Italy, pp. 95-100,2002

 

14.  Gural A., Shtalrid M., Raanani P., Ben Neriah S., Goldschmidt N., Paltiel O., Ben-Yehuda D.

Inv(16) is not associated with favorable prognosis in Israeli AML patients: A multi-center retrospective analysis.

Annales de Genetique Vol 46, pp 121-122, 2003

 

  1. Raanani P., Ben-Bassat I., Itskovich S., Gan S., Morgulis Y., Kneller A., Brok-Simoni F., Rechavi G., Amariglio N., Nagler A.

Hasford score correlates with the dynamics of imatinib induced reduction of BCR-ABL transcripts in chronic phase CML.

Blood Vol 102, pp 4978, 2003

 

  1. Hardan I., Shimoni A., Avigdor A., Kneller A., Berkowiicz M., Raanani P., Yeshurum M., Stemmer S.M., Shem-Tov N., Ben-Bassat I., Nagler A

Salvage therapy with autologous stem cell support prior to allogeneic stem cell transplantation in patients with relapsing/secondary acute leukemia and CML blast crisis.

Blood Vol 102, pp 2732, 2003

 

  1. Hardan I., Shimoni A., Avigdor A., Kneller A., Berkowicz M., Raanani P., Stemmer S.M., Shemtov N., Yeshurun M., Ben-Bassat I., Nagler A.

Autologous stem cell support of induction therapy prior to allogeneic transplantation to improve treatment delivery in patients with relapsing or secondary acute leukemia and CML blast crisis.

Bone Marrow Transplantation Vol 33, pp S235-S236, 2004

 

  1. Hardan I., Kneller A., Shimoni A., Berkowicz,M., Avigdor A., Yeshurun,M., Raanani P., Davidowich Y., Shemtov N., Ben Bassat I., Nagler A.

Salvage of multiple myeloma patients relapse after an autologous stem cell transplantation, in the era of thalidomide and reduced-intensity allogeneic stem cell transplantation

Bone Marrow Transplantation Vol 33, pp S156- S157, 2004

 

  1. Avigdor A., Bulvik S., Shemtov N., Levi I., Berkowicz M., Ben-Yehuda D., Blickstein D., Goldschmidt N., Gural A., Kornberg A., Libster D., Merkel,D., Naparstek E., Raanani P., Roth B., Volchek Y., Nagler A., Ben-Bassat I., Polliack A.

A pilot study of combined escalated BEACOPP-ABVD therapy for advanced Hodgkin's lymphoma patients with high IPS score: The Israel Cooperative Lymphoma Group

Blood Vol 104, pp 4576, 2004

 

 

  1. Hardan I., Kneller A., Shimoni A., Berkowicz M., Avigdor A., Yeshurun M., Raanani P., Davidowich I., Shemtov,N.; Ben Bassat,I.; Nagler,A.

Prolongation of overall survival of multiple myeloma patients by the combination therapy of thalidomide and reduced-intensity conditioning allogeneic stem cell transplantation at progression after autologous bone marrow transplantation.

Bone Marrow Transplantation Vol 35, pp S48-S49, 2005

 

  1. Hardan L., Meirow D., Shimoni A., Levron J., Shemtov,N., Fridman E., Zalel Y., Kneller A., Raanani P., Berkowicz M., Ben-Bassat I., Schiff E., Nagler A., Dor J. Spontaneous pregnancy and fertility preservation program in women undergoing high dose chemotherapy for hematological malignancies.

Blood Vol 106, pp 324A-325A, 2005

 

  1. Mor R., Uziel O., Shpilberg O., Lahav J., Raanani P., Rabizadeh E., Lahav M., Granot G.

The effect of imatinib mesylate on the signal transduction cascade leading to down regulation of telomerase activity in K562 cells.

Blood Vol 108, pp 4787, 2006

 

  1. Raanani P., Gafter-Gvili A., Paul M., Ben-Bassat I., Leibovici L., Shpilberg O.

Immunoglobulin prophylaxis in patients undergoing hematopoietic stem cell transplantation - Systematic review and meta-analysis.

Blood Vol 110, pp 4962, 2007

 

             24.     Mor R., Uziel O., Shpilberg O., Lahav J., Raanani P., Rabizadeh E., Zimra Y., Lahav M., Granot G.

The effect of imatinib mesylate on the signal transduction cascade regulating telomerase activity in k562 cells and in k562 cells resistant to imatinib mesylate.

Haematologica-the Hematology Journal Vol 93, pp 108, 2008

 

             25.     Gurion R., Vidal, L., Gafter-Gvili A.,  Belnik Y.,  Yeshurun M.,  Raanani P., Shpilberg O.

Hypomethylating agents in myelodysplastic syndrome-systematic review and meta-analysis.

Haematologica-the Hematology Journal  Vol 94,   pp 104, Meeting Abstract: 0261, 2009

 

             26.     Cohen YC.,  Cohen-Berger T., Eshel L.,  Stern D.,  Bairey O.,  Raanani P.,  Bernstine H.,  Shpilberg O., Groshar D.

Pulmonary infiltrates in nhl patients receiving rituximab combined with chemotherapy: 18f-fluorodeoxyglucose positron emission tomography and CT (PET-CT) analysis and clinical correlates

Blood  Vol 114, pp 1445, 2009  

 

        27.     Gafrer-Gvili A. , Bernstine H., Vidal L., Paul M., Ram R., Raanani P., Yeshurun M., Shpilberg O., Groshar D.

The role of 18f-fluorodeoxyglucose positron emission tomography and CT (PET-CT) for the diagnosis of infections in hemato-oncological patients with persistent neutropenia and fever.

Blood  Vol 114, pp 1213-1214, 2009

 

28. Gurion R.,  Belnik-Plitman Y.,  Gafter-Gvili A., Paul M., Vidal L., Ben-Bassat I., Shpilberg O., Raanani P.

Myeloid colony-stimulating factors do not increase the risk of mortality or disease activity measures in patients with acute myeloid leukemia: Systematic review and meta-analysis.

Blood  Vol 114,  pp 807-808, 2009

 

        29.          Ovcharenko A.,  Granot G.,  Shpilberg O.,  Raanani P.  

Molecular mechanisms involved in the development of extramedullary disease following the administration of all-trans retinoic acid to patients with acute promyelocytic leukemia.

Blood  Vol 114, pp 638,   2009 

 

        30.           Ram R.,  Gafter-Gvili A., Vidal L., Paul M., Ben-Bassat I., Shpilberg O.,  Raanani P.

       Management of adult patients with acute lymphoblastic leukemia in firstcomplete remission: systematic review and meta-analysis

       Blood  Vol 114, pp 26,  2009

 

31.  Shapira S., Granot G., Mor-Tzuntz R., Raanani P., Uziel O., Lahav M., Shpilberg O.

The effect of nilotinib and dasatinib on telomerase activity and regulation in k562 cells.

Haematologica-the Hematology Journal,  Vol  95, pp 34, 2010

 

32.   Itchaki G., Gafter-Gvili A., Lahav M., Raanani P., Vidal L., Paul M.,                          Shpilberf O.             

Anthracycline-containing regimens for treatment of follicular lymphoma in adults: systematic review and meta-analysis.

Blood  Vol 116,   pp 1163,  2010

 

33.   Gurion, R., Gafter-Gvili A., Vidal L., Paul M.,  Ben-Bassat I., Yeshurun M.,                                                                                                                                                          Shpilberg O., Raanani P.

Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy: Systematic review and meta-analysis-2010 Update

Blood  Vol 116,   pp 502,  2010

 

34.   Ram R.,  Paul M., Gafter-Gvili A., Hershkovitz K., Israeli M., Peck A.,     Raanani P., Shpilberg O., Yeshurun, M.

Early post-transplantation febrile episodes are associated with increased risk for acute graft-versus-host disease.

Biology of Blood and Marrow Transplantation  Vol 17 Supplement: 2,   pp S346-S347    Meeting Abstract: 539, 2011

 

35.      Vidal L., Gafter-Gvili A., Gurion, R., Dreyling, M., Raanani, P., Shpilberg O.

Bendamustine for patients with indolent lymphoma - a systematic review and meta-analysis of randomized controlled trials (RCT)

Annals of Oncology  Vol  22   Supplement: 4   pp 185,  2011

 

36.  Ram R., Wolach O., Vidal L., Gafter-Gvili A., Shpilberg O., Raanani P.    Adolescents and young adults with acute lymphoblastic leukemia have better outcomes when treated with pediatric-inspired regimens - systematic review and meta-analysis of comparative trials

Blood  Vol 118   pp 1112,  2011

 

37.  Ram R.,  Magen-Nativ H.,  Hershkovitzi C., Vidal L., Peck A.,  Raanani P.,  Shpilberg O., Yeshurun M.

Impact of induction intensity in multiple myeloma patients on autologous haematopoietic cell transplantation morbidity - a single-centre experience

Bone marrow transplantation  Vol 47   Supplement: 1   pp S214-S214, 2012

 

38.  Gurion R.,  Gafter-Gvili A.,  Ram R., Vidal L., Raanani P.,  Shpilberg O.

The role of anti-CD33 for the treatment of acute myeloid leukemia - systematic review and meta-analysis 

Blood Vol 120 Issue 21Abstract 1521, 2012

 

39.  Wolach O.,  Rabizadeh E., Lederfein D., Binkovski N., Raanani P.,  Shpilberg O., Inbal A.                                                                                                                                  Increased activity of prothrombinase fgl-2 in peripheral blood mononuclear cells of patients with b-cell lymphoma

      Blood Vol 120 Issue 21 Abstract 2665, 2012

 

40.  Ovcharenko A.,  Granot G., Park J., Shpilberg O., Raanani P.                           Enhanced adhesion, migration and Pyk2 expression in K562 cells following imatinib treatment                                                                                                            Blood Vol 120 Issue 21 Abstract 4426, 2012

 

41.  Mittelman M., Filanovsky K., Rosenbaum H., Raanani P., Braester A,. Goldschmidt N., Hellman I., Kirgner I., Perri C., Oster H.S.                              

Azacitidine and lenalidomide combination in higher-risk myelodysplastic syndromes-preliminary results of the Vilen-01 protocol

Blood Vol 122 Issue 1 Abstract 1576, 2013

 

42.  Vidal L., Gurion R., Ram R., Shpilberg O., Raanani P., Gafter-Gvili A. CHOP/CHOP-Like-14 Vs. CHOP/CHOP-Like-21 for Patients with aggressive lymphoma - a systematic review and meta-Analysis of randomized controlled trials

Blood Vol 122 Issue 1 Abstract 1798, 2013

 

43.  Gafter-Gvili A., Gurion R., Raanani P., Shpilberg O., Vidal L.                 Bendamustine is not associated with an increase in infections - systematic review and meta-analysis of randomized controlled trials

Blood Vol 122 Issue 21 Abstract 5125, 2013

 

44.  Yeshurun M.,   Shpilberg O.,   Herscovici K.,  Shargian L.,  Dreyer J., Peck A.,  Israeli M., Levy-Assaraf M.,  Gruenewald T.,  Mechoulam R.,  Raanani, P., Ram R.

Cannabidiol for the prevention of graft-versus-host-disease after allogeneic stem cell transplantation: Results of a Phase I/II Study

Biology of blood and marrow transplantation Vol 21 Supplement: 1  pp S353-S354, 2015

 

45.  Abulafia, AS., Raanani P., Lavie  D., Volchek Y., Ram R., Hellmann I.,  Shargian L.,  Gourevietch A.,  Chubar E.,  Ratzon R.,  Rozovski U.

A nationwide observational study of the israeli experience with ponatinib outside clinical trials in chronic myeloid leukemia.

Blood Vol 126 Issue 23, Dec 2015

 

46.  Itchaki G., Wolach O ., Bar-Natan M., Yeshurun M., Ram R., Herscovici C., Douer D ., Tallman M., Shpilberg O., Raanani P.

Very High Dose Cytarabine as Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia in the Setting of Intensified Anthracycline Induction and Post Stem-Cell Transplantation.

Clinical Lymphoma Myeloma & Leukemia Vol 15, pp  S184-S184, June 2015

 

47.  Al-Ali HK., Tavares R., Palumbo GA., Palandri F., Martino B., Liberati AM.,  Ullrich JG., Breccia M., Brittain D., Foltz L., Griesshammer M.,  Raanani P., Gupta V., Giraldo P., Ghosh J., Tannir B.,  Ronco JP., Vannucchi AM., Le Coutre P.

Safety and efficacy of Ruxolitinib in expanded-access JUMP study: an update from a cohort of 1869 patients

Oncology Research And Treatment Vol 39, pp 233-233 (Supplement 3), Oct 2016

 

 

 

 

 

 

 

 

 

 

 

 

E.  ITEMS IN ENCYCLOPEDIAS

{C}1.    Raanani P.

Aplastic anemia

The Israeli Encyclopeida for Medicine

 

{C}2.        Raanani P.

Acute lymphoblastic leukemia

The Israeli Encyclopeida for Medicine

 

 

F.     BOOKS EDITED  
{C}1.    Raanani  P.,  Hochhaus A. -  Editors

           Special issue : Minimal residual disease in hematologic malignancies  

             Acta Haematologica Vol. 112, No. 1-2, 2004

 

 

2.    Raanani P., Skoetz N. – Editors

      Speical Issue: The role of systematic reviews and meta-analyses in the management of hemato-oncological disorders

           Acta Haematologica  Vol 125, No. 1-2, 2011

 

3. Raanani P., Tallman M. - Editors

   Special Issue: Adolescents and young adults with hematological disorders

   challenges and perspectives

   Acta Haematologica Vol 132, No. 3-4, 2014

 

 

{C}G.    OTHER PUBLICATIONS

1.       Shpilberg O., Raanani P., Ben-Bassat I., Ramot B.                                                  Recurrent bilateral parotitis in acute myeloid leukemia (letter to the editor)          Acta Haematologica, Vol. 86 pp. 56, 1991                                                                (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

2.       Raanani P., Bercowicz M., Harden I., Ben-Bassat I.                                            Severe hypophosphataemia in autograft recipients during accelerated leucocyte recovery. (letter to the editor)                                                                                                             British Journal of Haematology, Vol. 91 pp. 1031-1032, 1995                                    (journal IF =  4.490; journal 5-Year IF = 3.733; journal rank = 12 of 63)

 

3.       Raanani P, Hochhaus A. Minimal Residual Disease in Hematological Malignancies  (Editorial.)

         Acta Haematologica, Vol. 112 pp 5-7, 2004

        (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

4.      Ben-Bassat I, Raanani P.

         Bracha Ramot (1927-2006).

Blood Cells, Molecules and  Diseases Vol 39, pp 135-139, 2007                             (journal IF =  2.555; journal 5-Year IF = 2.560; journal rank = 30 of 63)

 

5.      Ram R, Raanani P.

     Rituximab - a double-edged sword: can one treatment for thrombocytopenia also
     induce it?

Leukemia and  Lymphoma Vol. 49, pp 2035-2036, 2008                                      (journal IF = 1.512; journal 5-Year IF = 1.461; journal rank = 41 of 63)

 

6.      Raanani P, Gafter-Gvili1 A., Paul M., Ben-Bassat I., Leibovici L., Shpilberg O. Reply to "Prophylactic intravenous immunoglobulin does not have a role in hematopoietic stem cell transplant: Is the evidence clear?" Nishitha Reddy, et. al.

Journal of Clinical Oncology Vol. 27, pp 2297-2298, 2009

(journal IF =  15.484; journal 5-Year IF = 13.753; journal rank = 5 of 132)

 

7.      Ram R, Raanani P.

The role of myeloid colony stimulating factors in the treatment of acute    lymphoblastic leukemia – more questions than answers?

      Leukemia and  Lymphoma  Vol 5, pp 1737-1739, 2009

(journal IF = 1.939; journal 5-Year IF = 1.680; journal rank = 43 of 62)

 

8.      Gurion R., Vidal L., Gafter-Gvili A., Belnik Y., Yeshuru M., Raanani P.,
Shpilberg O.

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - systematic review and meta-analysis (Reply to Kumar et al. and to Herbst et al.)

Haematologica Vol 95, pp. 343-344, 2010

 (journal IF =  5.978; journal 5-Year IF = 5.513; journal rank = 9 of 62)

 

{C}9.      {C}Raanani P., Skoetz N. 
The role of systematic reviews and meta-analyses in the management of hemato-oncological disorders. Introduction.
Acta Haematologica Vol. 125, pp 5-7, 2011

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank   = 62 of 70; Quartile in Category – Q4; no. of citations: 1)

 

10.  Raanani P.                                                                                                    Editorial: Taming of the shrew - overcoming extramedullary blast crisis in the era of    the new tyrosine kinase inhibitors.

       Acta Haematologica Vol. 125, pp 5-7, 2011

 (journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank   = 62 of 70; Quartile in Category – Q4; no. of citations: 2)

 

 

11.  Experts in Chronic Myeloid Leukemia.

Collaborators: Abboud C, Berman E, Cohen A, Cortes J, DeAngelo D, Deininger M, Devine S, Druker B, Fathi A, Jabbour E, Jagasia M, Kantarjian H, Khoury J,

Laneuville P, Larson R, Lipton J, Moore JO, Mughal T, O'Brien S, Pinilla-Ibarz J, Quintas-Cardama A, Radich J, Reddy V, Schiffer C, Shah N, Shami P, Silver RT, Snyder D, Stone R, Talpaz M, Tefferi A, Van Etten RA, Wetzler M, Abruzzese E, Apperley J, Breccia M, Byrne J, Cervantes F, Chelysheva E, Clark R, de Lavallade H, Dyagil I, Gambacorti-Passerini C, Goldman J, Haznedaroglu I, Hjorth-Hansen H, Holyoake T, Huntly B, le Coutre P, Lomaia E, Mahon FX, Marin-Costa D, Martinelli G, Mayer J, Milojkovic D, Olavarria E, Porkka K, Richter J, Rousselot P, Saglio G, Saydam G, Stentoft J, Turkina A, Vigneri P, Zaritskey A, Aguayo A, Ayala M, Bendit I, Bengio RM, Best C, Bullorsky E, Cervera E, DeSouza C, Fanilla E, Gomez-Almaguer D, Hamerschlak N, Lopez J, Magarinos A, Meillon L, Milone J, Moiraghi B, Pasquini R, Pavlovsky C, Ruiz-Arguelles GJ, Spector N, Arthur C, Browett P, Grigg A, Hu J, Huang XJ, Hughes T, Jiang Q, Jootar S, Kim DW, Malhotra H, Malhotra P, Matsumura I, Melo J, Ohnishi K, Ohno R, Saikia T, Schwarer AP, Takahashi N, Tam C, Tauchi T, Usuki K, Wang J, Abdel-Rahman F, Aljurf MD, Bazarbachi A, Ben Yehuda D, Chaudhri N, Durosinmi M, Kamel H, Louw V, Matti BF, Nagler A, Raanani P, Salem Z.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the

unsustainable prices of cancer drugs: from the perspective of a large group of

CML experts.

Blood Vol 121, pp 4439-4442, 2013

(journal IF =  11.841; journal 5-Year IF = 10.233; journal rank = 2 of 70; Quartile in Category – Q4; no. of citations: 104)

 

12.  Raanani P., Tallman MS.

The challenges and perspectives in treating adolescent and young adult patients with hematological malignancies. Introduction.

Acta Haematologica Vol 132, pp 263, 2014

 (journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank   = 62 of 70; Quartile in Category – Q4; no. of citations: 0)

13.  Raanani P.

The Importance of Being Cured: A Chronic Myeloid Leukemia Perspective.                        Acta Haematologica Vol 135, pp 131-132, 2016
     (journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank   = 62 of 70; Quartile in Category – Q4; no. of citations: 0)

 

14.  Amitai I., Leader A., Raanani P.

Adherence to tyrosine kinase inhibitors in chronic myeloid leukemia: the challenge that lies ahead

      Acta Haematologica Vol 136, pp 43 - 44, 2016

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal        rank= 62 of 70; Quartile in Category – Q4; no. of citations: 0)

 

 

 

 

{C}H.    MEMBER OF EDITORIAL BOARD / REVIEWER                   (International Journals)

 

1. Editorial Board:

1. Cochrane Haematological Malignancies Group (CHMG) –The Cochrane Collaboration (since 2006)

2. ACTA HAEMATOLOGICA (since 2012)

3. The Israel Medical Association Journal (IMAJ) (since 2014)

4. Cardio-Oncology (since 2015)

 

 

2. Reviewer:

1. ACTA HAEMATOLOGICA (since 1999)

2. British Journal of Haematology (since 2003)

3. Leukemia (since 2004)

4. European Journal of Haematology (since 2007)

5. Leukemia and Lymphoma (since 2008)

6. Haematlogica (since 2009)

7. Blood (since 2011)

8. Journal of Cancer (since 2012)

9. Leukemia Research (since 2013)

 

 

 

 

 

 

 

               

 

CURRICULUM VITAE

 

 

Name:              Pia        Raanani   Clinical Associate Professor                5655050-2   

                        (first)      (last)         (academic Degree)                             I.D.    no.

Faculty/Dept: Sackler School of Medicine, Tel-Aviv University

Place of work: Rabin Medical Center, Beilinson Hospital, Israel

Hospital/Dept: Head, Division of Hematology, Rabin Medical Center, Beilinson Hospital

Phone No.:03-9377906

Home address: 11, Efter  st., Tel-Aviv, 69362  

Mobile phone no.: 050-4065447                                   

Phone no.: 03-6995525

E-mail: praanani@012.net.il

Date & Place of birth: 11.6.1960          Israel

                                 (date)             (country)

Zahal (Israeli) Military Service: 26.10.1978 - 25.10.1980

Marital status: divorced                     No. of children:    -

 

 

A. EDUCATION

 

Period of Study (dates)

 

____________

Name of University (city, country)

__________

Subject

 

 

_____________

Degree or professional

License

_____________

Date Awarded

 

 

_____________

1980-1986

Hebrew University Jerusalem

Medicine

B.Sc

 

 

M.D.

1984

(cum laude)       

 

1989

 

Title of Master's Thesis: None

Name of Supervisors: None

 

Title of Doctoral Dissertation: Does complete revascularization by conventional method truly provide the best possible results?

 

Name of Supervisors: Professor Daniel A. Goor; Dr. Jacob Lavee

 

Date of receiving specialization certificate:

September 1992 - Internal Medicine

March 1995     - Hematology

 

 

B. FURTHER STUDIES

 

Period of study (dates)

 

 

 

 

Name of university (including city and country if not in Israel)

 

Subject

 

 

 

 

 

Degree or professional license

 

 

 

Date awarded

 

 

 

 

 

1.1988-5.1990

Tel-Aviv University

Postgraduate Medical School-Faculty of Medicine

      

5.1990

 

 

 

 

6.1995

Royal Postgraduate Medical School,  London, U.K.

 

Advances in Hematology

 

 

 

 

 

 

6.1997

Royal Postgraduate Medical School, London, U.K.

Advances in Hematology

 

 

 

 

C. ACADEMIC & PROFESSIONAL ACTIVITIES & ACHIEVEMENTS

    C1. ACADEMIC EXPERIENCE

 

Period (dates)

 

 

Name of institution (city, country)

Department

 

 

 

Rank/function

 

 

 

1.1991-7.1991

 

 

 

 

Beilinson Medical Center, Petah-Tikva, Israel

Laboratory of Hemostasis

Head: Prof. Judith Lahav

Basic sciences

 

 

 

 

8.1996-8.1997

 

 

 

 

 

Hammersmith Hospital-Royal Postgraduate Medical School

Hematology-Leukaemia Research Unit

Head: Prof. John Goldman

Reaserch  in Minimal Residual Disease in leukemia

Suprevisor: Dr. N.C.P Cross-Head of MRD laboratory

2006 ®

The Cochrane Collaboration

Cochrane Haematological Malignancies Group (CHMG)

 

Editor

2007-2010

Tel-Aviv University

Senate

Representative of Senior Lecturers in the Senate

2007-2010

Tel-Aviv University

Sackler School of Medicine

Representative of Senior Lecturers in the Faculty Council

2008-2014

Tel-Aviv University

Sackler School of Medicine

Member in the Research Funds Committee

 

2009 -2014

 

"Harefuah" - journal of the Israel Medical Association

Editorial Board

Editor

 

 

 

5.2010 ®

Tel-Aviv University

Sackler School of Medicine   

Clinical Associate Professor in Hematology

 

 

9.2010 -9.2014

 

Tel-Aviv University

Sackler School of Medicine   

Chairman of Hematology Department

 

 

1.2011®

 

Tel-Aviv University

Sackler School of Medicine

Member in the Scientific Committee of the Cancer Biology Research Center

 

 

12.2011®

Tel-Aviv University

The Djerassi Oncology Center

Member in the Scientific Committee of

 

 

 

 

5.2012 ®    American Society of Hematology                      Invited abstract reviewer                                                    

                                                                                                for 54th ASH meeting

 

7.2012 ®    Acta Haematologica       Editorial Board           Editor

 

2013–2016   Tel-Aviv University       Senate                         Deputee Representative                                                                                              of Associate Professors                                                                                                     in the Senate

 

2013 – 2016    Rabin Medical Center   Institutional review board (IRB)      Member

 

2014 ®           IMAJ –Israel Medical

                        Association Journal        Editorial Board                                Editor

 

5.2014®

Tel-Aviv University

 

  The Varda and Boaz Dotan                 Member in

   Research Center in                             Scientific

  Hemato-oncology                               Committee

 

9.2014 ®        Tel-Aviv University    Sackler School of Medicine                                                                                                                Research Funds Committee              Chairman

 

2.2015 ®        Cardio-oncology           Editorial Board                                 Editor

 

2015 ®           Tel-Aviv University      Department of Human                      Adjunct

                                                                         Genetics and Biochemistry                Professor

2015 ®           MD Anderson             Society of Hematologic Oncology                                                                             (SOHO)                                                         Ambassador

2017                            Harvard                     Buisness School Course                     Strategy for

                                                                                                                                 Health Care

                                                                                                                     Delivery

 

 

 

 

C2. PROFESSIONAL  EXPERIENCE

 

Period (dates)

 

 

 

Name of Institution (city, country)

 

 

   Department

 

 

 

Rank/Function

 

 

 

8.1988-8.1992

 

 

 

 

Beilinson Medical Center, Petah-Tikva, Israel

Internal Medicine

Resident

 

 

 

9.1992-3.1995

 

 

 

 

Sheba Medical Center, Tel-Hashomer, Israel

Hematology

Resident

 

 

 

4.1996-3.2002

 

 

 

 

Sheba Medical Center, Tel-Hashomer, Israel;

Rabin Medical Center, Campus Beilinson, Israel

Hematology

Senior Hematologist

 

 

 

 

 

 

 

3.2002 – 11.2004

Sheba Medical Center, Tel-Hashomer, Israel

 

Hematology

Head, Leukemia Service

11.2004 – 1.2007

Rabin Medical Center, Campus Beilinson, Israel

Hematology

Head, Leukemia Unit

 

2.2005 – 2.2008

 

 

 

1.2007®

Israeli Society of   Hematology and Blood Transfusions

 

Davidoff Cancer Center, Rabin Medical Center

Hematology

 

 

 

Hematology

Secretary

 

 

 

Establishment & Head of the Hemato-oncology Hospitalization  Unit

 

10.2011-11.2011

Memorial Sloan Kettering Cancer Center

Leukemia Service-Department of Medicine

Chief: Prof. Tallman

Visiting Professor

 

 

 

 

 

10.2013®               Rabin Medical Center    Hematology          Head of the Division                                           

 

C3. ACTIVE PARTICIPATION IN SCIENTIFIC MEETINGS

 

Year

Subject  (Role)

Place

3.1990

The Israeli Society of Internal Medicine, Ramat-Gan.

Life threatening hypophosphatemia in a patient with Philadelphia chromosome positive CML in acute blastic crisis.

P. Raanani, M. Lahav, M. Prococimer, E. Theodor  (Speaker)

 

Israel

11.1993

The Israeli Society of Hematology, Tel-Aviv.

Salvage combination chemotherapy for acute leukemia using high dose Ara-C and mitoxantrone. Experience of the Sheba Medical Center.

P. Raanani., O. Shpilberg, M. Bercowicz, O. Sofer, I. Hardan, A. Chetrit, I. (Speaker)

 

Israel

3.1996

The Israeli Society of Hematology, Natanya.

Salvage combination chemotherapy for acute leukemia using high dose Ara-C and mitoxantrone. Experience of the Sheba Medical Center: 1991-1995.

P. Raanani., O. Shpilberg, M. Bercowicz, O. Sofer, I. Hardan, A. Avigdor, A. Chetrit, I. Ben-Bassat (Speaker)

 

Israel

9.1997

The Israeli Society of Hematology and Blood Transfusion,            Dead Sea

Competitive PCR-The method and clinical applications.

P. Raanani,  N.Cross, J.Goldman - Institute of Hematology,            Sheba Medical Center, Tel-Hashomer, Hammersmith Hospital,

London    (Speaker)                                                                                    

 

Israel

10.1999

The Israeli Society of Hematology and Blood Transfusion,         Dead Sea

Engraftment associated hypophosphatemia - the role of cytokine release and steep leukocyte rise post stem cell transplantation.

P. Raanani, I. Levi, O. Shpilberg, F. Holzman, I. Grotto, F. Brok-Simoni, A. Avigdor, M. Berkowicz, I. Hardan, A. Kneller and I. Ben-Bassat. (Speaker)

 

 

2.2001

Annual meeting of the Cancer  Biology Research Center , Eilat

The role of cytokines and leukocyte rise in the development of hypophosphatemia after PBSCT.

P. Raanani, I. Levi, F. Holzman, I. Grotto,                      F. Brok-Simoni, A. Avigdor, J. Davidson, O. Shpilberg, and   I. Ben-Bassat. (Speaker)

 

Israel

1.2003

The Israeli Society of Hematology and Blood Transfusion,          Tel-Aviv

A high rate of BCR-ABL negativity by FISH & multiplex RT-pcr  but not by real-time RT-PCR can be achieved in cml patients treated with imatinib. 

P. Raanani, I. Ben-Bassat, S. Gan, L. Trakhtenbrot, Z. Mark, S. Itskovich,  N. Amariglio, F. Brok-Simoni, I. Hardan, A. Kneler, A. Shimoni, A. Nagler (Speaker)

 

Israel

4.2003

Annual meeting of the Cancer  Biology Research Center , Kfar Blum

Monoclonal antibodies in the treatment of hematological malignancies.

P. Raanani and I. Ben-Bassat (Speaker)

 

Israel

1.2004

The Israeli Society of Hematology and Blood Transfusion,          Tel-Aviv

Hasford score may predict for the dynamics of imatinib induced reduction of bcr-abl transcripts in chronic phase cml – should an old score be used for a new drug?

P. Raanani, I. Ben-Bassat, S. Itskovich,  S. Gan, Y.Morgulis, O. Ashur-Fabian, A. Kneller, I. Hardan, F. Brok-Simoni, A.Simon, G. Rechavi, N. Amariglio, A. Nagler (Speaker)

 

Israel

4.2004

The Israeli Society of Hematology and Blood Transfusion,          Dead sea

Philadelphia positive T lymphoblastic leukemia – acute leukemia or cml blast crisis?

P. Raanani, I. Ben-Bassat, L. Trachtenbrrot, A. Avigdor, F.Brok-Simoni, N. Amariglio, A. Nagler (Speaker)

 

Israel

4.2004

Annual meeting of the Cancer  Biology Research Center , Kfar Blum

Detection of minimal residual disease in myeloid leukemias – methods and their clinical significance.

P. Raanani, I. Ben-Bassat, A. Nagler (Speaker)

 

Israel

11.2007

The Israeli Society of Hematology and Blood Transfusion,          Avenue Convenetion and Event Center

Immunoglobulin prophylaxis in patients undergoing hematopoietic stem cell transplantation – systematic review and meta-analysis.

P. Raanani,  A. Gafter-Gvili, M. Paul, I. Ben-Bassat, L. Leibovici, O. Shpilberg (Speaker)

 

Israel

4.2008

Annual Meeting of the European Group for Blood and Marrow Transplantation - EBMT 2008

Immunoglobulin prophylaxis in patients undergoing hematopoietic stem cell transplantation: systematic review and meta-analysis.
P. Raanani, A. Gafter-Gvili, M. Paul, I. Ben-Bassat, L. Leibovici, O. Shpilberg (Speaker)

 

Italy

   11.2009        The Israeli Society of Hematology and Blood Transfusion        Israel Management of adult patients with ALL                                                                      in first  complete remission: systematic review and meta-analysis.

R. Ram, A. Gafter-Gvili, L. Vidal, M. Paul, I. Ben-Bassat,                                    O. Shpilberg, P. Raanani   (Speaker) 

    5.2011         A Joint Meeting of the CBRC and the Department of Hematology  Israel Tel-Aviv University: Should personalized medicine be the standard of care in Hematology in the third millenium? Biological and clinical aspects   (Member of steering committee)

    5.2011         A Joint Meeting of the CBRC and the Department of Hematology  Israel Tel-Aviv University: Cure in CML in the 3rd millenium – a target or a dream?   (Speaker)      

9.2011     Meeting in celebration of 30 years since the establishment of the   Israel

Cancer Biology Research Center (CBRC)

(Member of steering committee)

                                                     

7.2011   10th Anniversary of the Cochrane Haematological Malignancies  Germany

               Group                                                                                            

               Systematic reviews in hematological malignancies

               Pia Raanani (Speaker) 

 

6.2012    CBRC – Hematology Department Joint Discussion Forum:           Israel

         Drug Development in Cancer, June 21 2012

         (Member of steering committee)

 

11.2012  Tel-Aviv University–Mayo Clinic Cancer Centre Alliance              Israel

    Symposium

         (Member of steering committee)

 

11.2012  Tel-Aviv University–Mayo Clinic Cancer Centre Alliance              Israel

    Symposium

    The role of Systematic Reviews and Meta-analyses in Hematological                     Malignancies

    Pia Raanani (Speaker) 

 

12.2012      54th Annual Meeting of the American Society of Hematology       USA

                    Health Services and Outcome Research (Moderator)

 

6.2013         2013 Biennial Retreat of  theCancer Biology Research Center     Israel

                    (Member of steering committee)

 

6.2014        Cancer Prevention and Intervention 2014 Conference                   Israel

                   (Member of steering committee)

 

6.2014        Cancer Prevention and Intervention 2014 Conference                   Israel

                   Can leukema be cured in 2014?

                   P. Raanani (Speaker) 

 

2.2015        IMCO – International Meeting on CardioOncology:                      Israel

Towards a Comprehensive Cardiac – Cancer Care

(Member of steering committee)

 

2.2015        IMCO – International Meeting on CardioOncology:                      Israel

Towards a Comprehensive Cardiac – Cancer Care

                   Can leukema be cured in 2014?

                   P. Raanani  (Speaker) 

 

 

 

C4. MEMBERSHIP IN PROFESSIONAL SOCITIES

 

Year

Society

Country

1987®

Israeli Society of Medicine

Israel

1989®

Israeli Society of Internal Medicine

 

Israel

1993®

2.2004 – 2.2007

Israeli Society of Hematology

Secretary of the Israeli Society of Hematology and Blood Transfusions

Israel

1999 – 2003

5.2012 ®                  

American Society of Hematology

Invited Abstract Reviewer of the American Society of Hematology

 

USA

 

 

2007 ®

European  Hematology Association 

Europe

 

2009 ®

American Society of Hematology

USA

 

 

USA

2015®                                    Society of Hematologic Oncology (SOHO)   USA

 

 

D1. DOCTORAL STUDENTS SUPERVISED BY CANDIDATE

 

Years

Name of student

Subject

Academic Institute

Ph.D/M.D

In collaboration with

2008 - 2012

Adelina Ovcharenko

Molecular mechanisms involved in the occurrence of extramedullary disease following targeted therapies for hematological malignancies

Felsenstein Medical Research Center

Ph.D

Prof. Nadir Arber, Dr. Galit Granot, Prof. Ofer Shpilberg

From 2014

Adi Zelig

The influence of bone mineral density at diagnosis on other manifestations of bone disease and on patients' survival in multiple myeloma -A historical cohort study

Institute of Hematology, Rabin Medical Center

M.D

Dr. Eli Muchtar

From 2014 (2012 – 2014 suprevised by Prof. Ofer Shpilberg)

Saar Shapira

Sensitivity of CML stem cells to tyrosine kinase inhibitors

Felsenstein Medical Research Center

Ph.D

Prof. Nadir Arber, Dr. Galit Granot

From 2014 (2013 – 2014 suprevised by Prof. Ofer Shpilberg)

Ala Aladin Samara

Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma

Felsenstein Medical Research Center

Ph.D

Dr. Smadar Avigad, Dr. Galit Granot

From 2015

Gili Kroitoro

Early Identification of Myelodysplatic Syndrome among Patients with Unexplained Anemia Based on Laboratory Indices from the Years Predating the Diagnosis

Institute of Hematology, Rabin Medical Center   

M.D

Dr. Erel Joffe

 

 

 

 

D2. MEMEBERSHIP IN COLLOQUIUM OF M.D. STUDENTS

1.Member, colloquium committee for  M.D. thesis of the student Gil Shlomovitz (supervisor Prof. Yohai Birenbaum): “In vitro ultrasound augmented pharmacological thrombolysis – what is the correct timing of the ultrasound irradiation?” , Tel-Aviv University

2. Member,  colloquium committee for M.D thesis of the student Orit Mimon (Supervisor Prof. Michael Lishner): “Replication pattern in polycythemia vera and essential thrombocytosis, comparison between patients treated with hydroxyurea and untreated patients”, Tel-Aviv University

3. Head, colloquium committee for M.D. thesis of the student Eliahu Rakach

(Supervisors Prof. Raphael Katan and Dr. Ofer Marimsky): "Imatinib mesylate- a breakthrough in the treatment of GIST: long term follow-up”, Tel-Aviv University

4.      Member,  colloquium committee for M.D thesis of the student Uri Inbal (Supervisors Prof. Hillele Halkin and Dr. Daniel Kurnik and Dr. Ronen Loebstein): “The effect of low dose vitamin K supplementation on warfarin anticoagulation among vitamin K deficient patients”, Tel-Aviv University

5.      Member,  colloquium committee for M.D thesis of the student Joseph Landman (Supervisors Dr. Maya Koren-Michowitz and Dr. Yoram Cohen and Prof. Arnon Nagler): “The relation between JAK2-V617F mutation load in polycythemia vera patients and the clinical chracteristics of their disease” , Tel-Aviv University

6.      Member,  colloquium committee for M.D thesis of the student Ido Matia from the Technion (Supervisors Dr. Ayelet Barak and Dr. Rachel Bar-Shalom): “The value of FDG-PET/CT during complete remission in identifying relapse of pediatric lymphoma” , Technion, Haifa

7.      Head, colloquium committee for M.D thesis of the student Zvi Sirotkin (Supervisors Prof. Sara Apter and Dr. Abraham Avigdor):"Primary mediastinal large B-cell lymphoma: the impact of adding rituximab on the outcome of patients treated with VACOP-B or CHOP, clinical and imaging prognostic factors", Tel-Aviv University

8.      Member,  colloquium committee for M.D thesis of the student Einat Mader (Supervisors Dr. Giora Shubinsky and Dr. Itai Levi): “Diagnosis and Characterization of Myelodysplsatic Syndrome by Flow Cytometry Immunophenotyping”, Ben-Gurion University of the Negev

{C}9.      {C}Member, colloquium committee for  M.D. thesis of the student Amit Ben-Hayman (supervisors Dr. Amit Gil-Ad and Dr. Michael Taler): “In vitro effect of sertaline as an antiproliferative and chemosensitizing agent in T-cell lymphoma/leukemia(Jurkat) cell” , Tel-Aviv University

10.  Head, colloquium committee for M.D thesis of the student Shani Bergman Frank: " Lymphocytes Reconstitution Following Hematopoietic Stem Cell Transplantation - Clinical Implications", Tel-Aviv University

{C}11.  {C}Head, colloquium committee for  M.D. thesis of the student Shani Saborai Litvak (supervisors Prof. Moshe Mittelman and Dr. Ophira Ben-Tal): “Myelodysplatic syndrome – have the clinical characteristics changed over the years?” , Tel-Aviv University

{C}12.  {C}Member, colloquium committee for  M.D. thesis of the student Michael Frumer (supervisor: Prof. Eldad Dan): “Evaluation the follow-up by PET/CT of Hodgkin’s lymphoma patients, who are in remission after first-line of therapy, compared with the follow-up by clinical examination” , Technion, Haifa

13.  Member, colloquuium committee for M.D thesis of the student Yoav Binenbaum (supervisors Dr. Izhar Hardan and Prof. Gideon Rechavi): “Discontinuation of anti-leukemic treatment followoing combination therapy with imatinib and alpha interferon in chronic phase CML: Molecular mechanisms that characterize the responding patients”, Tel-Aviv University

14.  Head, colloquium committee for  M.D. thesis of the student Aviv Aharon (Supervised by Prof. Moshe Mittelman): “Thrombocytopenia causes and bleeding– A retrospective analysis” ”, Tel-Aviv University

15.  Member, colloquuium committee for M.D thesis of the student Gigozinsky Michal (supervisors Dr. Ronit El-Hasid, Prof. Btia Stark and Prof. Shai Izraeli): “Characteristics and outcomes of treatment of childhood ALL in Israel”, Tel-Aviv University

 

 

E. M.A/M.Sc Students

Years

Name of student

Subject

Academic Institute

In collaboration with

2008 - 2011

Saar Shapira

The effect of nilotinib on the signal transduction cascade leading to down  regulation of telomerase activity in K562 cells sensitive and resistant to imatinib

Felsenstein Medical Research Center

Prof. Ofer Shpilberg, Dr. Dr. Galit Granot

 

                                                                                                                                                         

 

E. GRANTS &AWARDS

     

Year

 

 

 

Name of Institution (city, country)

 

 

Award

1984

 

 

 

The Hebrew University, Faculty of Medicine, Jerusalem

List of excellent students

1985

 

 

 

The Hebrew University, Faculty of Medicine, Jerusalem

Scholarship for excellency

1986

 

 

 

The Hebrew University, Faculty of Medicine, Jerusalem

List of excellent students

1991

 

 

 

Beilinson Medical Center, Petah-Tikva

$1200.-  to fund research in the Laboratory of Hemostasis

1995

 

 

 

 

 

The Israel Cancer Association

$700 .- to fund participation in the course "Advances in Haematology" at the Hammersmith Hospital, U.K.

 

 

1996

 

 

 

 

The Israel Cancer Association

10,000 NIS.- Grant to fund a continuing education in the field of hemato-oncology and bone marrow transplantation at the Hammersmith Hospital, London, U.K

1996

 

 

 

 

 

 

 

 

The British Council, Tel-Aviv

A one year scholarship of 1,250 GBP.- per month.

The British Council and the Barclay Family Cancer Research Foundation-Scholarship for Oncological Research- to undertake a research in the field of CML and bone marrow transplantation at the Hammersmith Hospital, London, U.K

1998

Tel-Aviv University

$3,000 grant.

The Zoss & Fanny Safoon grant for research on the subject of : “Quantitative RT-PCR for quantifucation of bcr-abl transcripts in chronic myeloid leukemia (CML)”

 

 

1999

Israel Cancer Association

35,000 NIS grant for research on:

Cytokine mediated Engraftment syndrome and hypophosphatemia in patients undergoing high dose chemotherapy with peripheral blood stem cell support for hematological malignancies

1999

Israel Cancer Association

6,500 NIS grant

For participation in ASH 1999 where a poster on the subject: "Cytokine mediated Engraftment syndrome and hypophosphatemia in patients undergoing high dose chemotherapy with peripheral blood stem cell support for hematological malignancies" was presented

 

2000

Israel Cancer Association

23,000 NIS grant

The role of cytokines and the "cytokine release syndrome" in the development of adverse effects during treatment with anti CD20 (rituximab) in general and in the development of the "1St Dose reaction" in particular

 

2001

Tel-Aviv University

Excellent Lecturer in Hematology for the year 2000

 

2002

Israel Cancer Association

2,800 NIS grant

for training  in quantitative Real-Time RT-PCR for follow-up of CML patients in the laboratory of minimal residual disease in Hammersmith Hospital, Lomdon

2004

Tel-Aviv University

Excellent Lecturer in Hematology for the 3 years 2001-2003

 

 

2008

The Barclay Family Cancer Research Foundation

30,000.00 GBP grant to be allocated for research studies under the direction of Dr. Pia Raanani. Dedicated mainly for the research on: "Molecular mechanisms involved in the occurrence of extramedullary disease following targeted therapies for hematological malignancies". Dr. Pia Raanani   - Principal Investigator

 

2009

Beilinson Medical Center, Petah-Tikva (Research Authority)

30,000 NIS grant for research on: "The role of colony stimulating factors administered for prevention and treatment of infectious complications in patients with acute  myelogenous leukemia-a meta –analysis". (Research conducted by Dr. Pia Raanani- Principal Investigator, grant donated to young investigator - Dr. Ronit Gurion)

 

 

 

2010             Tel-Aviv University                   32,000 NIS grant for research on: "The

                     (Research Authority)                 effect of nilotinib and dasatinib on

                                                                        telomerase activity in BCR-ABL                                                                                                                   positive K562 cells" (The Meirbaum/

the Safoon grants) – Principal    Investigator

 

2010            Tel-Aviv University                    $ 5,000 grant for Ph.D student Adelina

(The Cancer Biology                   Ovcharenko-Mermelshtein for the research, entitled: “Molecular mechanisms involved in the occurrence of extramedullary disease following targeted therapies for hematological malignancies“- Research conducted by Prof. Pia Raanani- Principal Investigator

 Research Center)

2010     Tel-Aviv University               18,325 NIS grant for research on: “Molecular mechanisms involved in the occurrence of extramedullary disease following targeted therapies for hematological malignancies”

                                                            (Van Bits, Cancer Research  Center)- Principal Investigator

 

2013    Tel-Aviv University                37,000 NIS grant for research on: “Molecular

(Research Authority)              mechanisms invovled in the occurrence of extramedullary disease following targeted 

therapies for hematological malignancies” (The Fenster Foundation  Grant for Leukemia Research) - Principal Investigator

 

2012 Kupat Holim Clalit                    50,000 NIS grant for Research on: "The effect     of active adherence encouraging intervention on adherence to TKI treatment in CML- a multi center study (TAKE-IT)"- Principal Investigator

 

2013  Israel Cancer Association       45,000 NIS grant for Research on: "Regulatory                

mechanisms involved in Pyk2 expression following novel agents' treatment for hematological malignancies"- Principal Investigator

 

2013 Israeli Society of Hematology   30,000 NIS grant for Research on: "The effect     of active adherence encouraging intervention on adherence to TKI treatment in CML- a multi center study (TAKE-IT)"- Principal Investigator

 

2014 Dotan Center for Research        350,000 NIS grant/year for 2 years on: “Targeting mantle cell lymphoma with nanomedicines” (Prof. Dan Peer – principal-investigator; Prof. Pia Raanani – co-investigator)

In Hemato-oncology

2015 Pfizer Pharmaceuticals Israel    63,000$ for  Investigator-Initiated Research (“IIR”) grant for 2 years (2016 – 2017) a non-human Research study entitled “Pathogenesis of Tyrosine Kinase Inhibitors (TKIs) Associated Vascular Disease in Chronic Myeloid Leukemia (CML): An in vitro Model”- Principal Investigator

 

2015 ARIAD Pharmaceuticals Inc.   50,000$ for  Investigator-Initiated Research (“IIR”) grant for Research study entitled “Subclinical markers of tyrosine kinase inhibitor associated vascular disease in chronic myeloid leukemia: An exploratory multicenter cohort study” - Principal Investigator

 

 

LIST  OF  SCIENTIFIC  PUBLICATIONS

 

 

A. BOOKS & MONOGRAPHS

1.      Dr. Pia Raanani & Prof. Isaac Ben-Bassat

      Anemia - It Is in Our Blood

      Prolog Publishers, 2004 (112 pages)

 

 

B.1. ORIGINAL ARTICLES

Published

 

  1. Lavee J., Rath S., Hoa T.Q., Raanani P.,  Ruder A., Modan., Neufeld H.N., Goor D.A.                                                                                                                      Does complete revascularization by the conventional method truly provide the best  possible results? Analysis of results and comparison with revascularization of infarct  prone segments (systemic segmental myocardial revascularization):The Sheba Study.                                                                                                                 Journal of Thoracic and Cardiovascular Surgery, Vol. 92, pp. 279-290, 1986 (journal IF =  3.354; journal 5-Year IF = 3.505; journal rank = 16 of 75)

 

  1. Lahav M., Regev A., Raanani P., Theodor E.                                              Intermittent administration of furosemide vs. continuous infusion preceded by a   loading dose for congestive heart failure.                                                                 Chest, Vol. 102, pp. 725-731, 1992

      (journal IF =  4.143 ; journal 5-Year IF = 4.311 ; journal rank = 6 of 34)

 

 

3.      Arber N., Zajicek G., Shamir R., Kenet G., Raanani P., Nordenberg J., Sidi Y. Bromobenzene accelerates hepatocyte streaming in rats.                         Gastroenterology, Vol. 103, pp. 1273-1276, 1992

(journal IF =  11.673; journal 5-Year IF = 12.424; journal rank = 1 of 50)

 

4.      Singer R., Levinsky H., Sagiv M., Raanani P., Weissenberg R., Lahav M. Spermatogenesis and sialic acid content and sialytransferase activity in testis, epididimisand prostate of gossypol treated male rats.                                             Advances in Contraceptive Delivery Systems, Vol. 7, pp. 201-209, 1992

(journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

5.      Singer R., Weissenberg R.,Lahav M., Sagiv M.,  Raanani P., Kyser S,  Cohen A, Levinsky H.                                                                                                        Sialic acid and sialytransferase activity in testis, epididymis and prostate of rats: developmental stages.                                                                                 Advances in Contraceptive Delivery Systems, Vol. 8, pp. 247-252, 1992

(journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

6.      Varon D., Handsher R., Dardik R., Gitel S., Raanani P., Heim M., Martinowitz U. Response of hemophilic patients to poliovirus vaccination:correlation with HIV serology and with immunological parameters.                                                            

      Journal of Medical Virology, Vol. 40, pp. 91-95, 1993

(journal IF =  2.831; journal 5-Year IF = 2.739; journal rank = 14 of 25)

 

7.      Singer R.,  Levinsky H., Kyzer S., Cohen A., Sagiv M., Raanani P., Lurie B., Lahav M.

Effect of procarbazine/clomiphene citrate on sialyltransferase activity in testis/epididymis of rats.

Advances in Contraceptive Delivery Systems, Vol 9, pp 107-111, 1993

(journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

8.      Raanani P., Shpilberg O., Berezin M., Ben-Bassat I.                                            Acute leukemia relapse presenting as central diabetes insipidus.                             Cancer, Vol. 73, pp. 2312-2316, 1994

(journal IF =  4.632; journal 5-Year IF = 4.865; journal rank = 28 of 132)

 

9.      Weissenberg R., Lahav M., Raanani P., Singer R., Regev A., Sagiv M., Giler S., Theodor E.                                                                                                             Clomiphene citrate reduces procarbazine-induced sterility in a rat model.                   British Journal of Cancer, Vol. 71, pp. 48-51, 1995

            (journal IF =  4.635; journal 5-Year IF = 4.322; journal rank = 27 of 132)

 

10.  Shpilberg O., Haddad N., Sofer O., Raanani P., Berkowicz M., Chetrit A.,       Carter A., Ramot B., Tatarski I., Ben-Bassat I.                                                          Postremission therapy with two different dose regimens of cytarabine in adults with acute myelogenous leukemia.                                                              Leukemia-Research, Vol. 19, pp. 893-897, 1995

            (journal IF =  2.561; journal 5-Year IF = 2.278; journal rank = 67 of 132)

 

11.  Bessler H., Singer R., Raanani P., Levinsky H., Lahav M., Cohen A.M.                              Interferon alpha-2b modulates beta-galactoside alpha-2,6-sialyltransferase gene expression in rat testes.                                                                                            Biology of Reproduction, Vol. 53, pp. 1474-1477, 1995

            (journal IF =  3.670; journal 5-Year IF = 3.766; journal rank = 2 of 25)

 

12.  Singer R., Cohen A., Levinsky H., Raanani P., Luria B.B., Weissenberg R.,   Lahav M.                                                                                                                               Effect of interferon alpha IIb on the activity of sialyltransferase in testis homogenates of adult rats.                                                                                                                 Archives of Andrology, Vol. 35, pp. 1-3, 1995

            (journal IF =  0.808; journal 5-Year IF = 0.777; journal rank = 2 of 5)

 

13.  Berkowicz M., Toren A., Rosner E., Biniaminov M., Rosenthal E., Gipsh N., Berman S., Hardan I., Mandel M., Amariglio N., Mark Z., Sofer O., Raanani P., Kenet G., Neuman Y., Sharon N., Brok-Simoni, F., Rubnov V., Ben-Bassat I, Rechavi G.

Translocation (2;14)(p13;q32) in CD10+CD13+ acute lymphatic leukemia.                                                                                                                     Cancer Genetics and Cytogenetics, Vol. 83, pp. 140-143, 1995

      (journal IF =  1.559; journal 5-Year IF = 1.581; journal rank = 99 of 132)

 

14.  Raanani P.,  Rosner E., Bercowicz M., Ben-Bassat I.                                 t(12;20)(q13;p11.2)- a new translocation involving the 12q13 breakpoint in acute nonlymphoblastic leukemia.                                                                                      Cancer Genetics and Cytogenetics, Vol. 89, pp. 118-119, 1996

            (journal IF =  1.559; journal 5-Year IF = 1.581; journal rank = 99 of 132)

 

15.  Raanani P., Bercowicz M., Rosner E., Rosenthal E., Berman S., Rechavi G.,   Ben- Bassat I.                                                                                                           Translocation t(3;17)(q23;q21)  - a new translocation in acute lymphoblastic       leukaemia.                                                                                                                      British Journal of Haematology, Vol. 95, pp. 131-134, 1996

            (journal IF =  4.490; journal 5-Year IF = 3.733; journal rank = 12 of 63)

 

16.  Oren R.,  Zajicek G., Maaravi Y., Kenet G., Karmely F., Hubert A.,
 Raanani P.,  Arber N.   

Methimazole slows hepatocyte streaming in rats.                                                                 Digestive Diseases and Sciences, Vol. 42, pp. 1433-1437, 1997

(journal IF =  1.319; journal 5-Year IF = 1.582; journal rank = 41 of 50)

 

17.  Raanani P.,  Dazzi F.,  Sohal J.,  Szydlo R.M., van Rhee F., Reiter A., Lin F., Goldman J.M. and  Cross N.C.P.  

The rate and Kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation.                                                                                                             British Journal of Haematology, Vol. 99, pp. 945-950, 1997

(journal IF =  4.490; journal 5-Year IF = 3.733; journal rank = 12 of 63)

 

18.  Dreiher J, Shpilberg O, Raanani P, Chetrit A, Ben-Bassat I.

The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.                                                      Leukemia  Research Vol. 22, pp 997-1002,  1998 (Written by mistake as Raamami)

             (journal IF =  2.561; journal 5-Year IF = 2.278; journal rank = 67 of 132)

 

19.  Reiter A., Marley S.B., Hochhaus H., Sohal .J, Raanani P, Hehlmann R., Gordon M.Y., Goldman J.M., Cross N.C.P.                                                                                  

       BCR-ABL positive primitive progenitors in chronic   myelogenous leukemia patients in complete cytogenetic remission after treatment with interferon-a.

       British Journal of Hematology. Vol. 102 pp. 1271-1278, 1998

      (journal IF =  4.490; journal 5-Year IF = 3.733; journal rank = 12 of 63)

 

20.  Raanani P., Shpilberg O., Bercowicz M., Sofer O., Hardan I., Chetrit A., 
 Ben-Bassat I.                                                                                                                 Salvage therapy of relapsed and primary resistant acute leukemia with high dose mitoxantrone and cytarabine.                                                                          leukemia Research , Vol 23 pp 695-700, 1999                                                    (journal IF =  2.561; journal 5-Year IF = 2.278; journal rank = 67 of 132)

 

21.  Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M, Ben-Bassat I.

Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug.                                                                                                                             British Journal of Hematology Vol 108 pp 391-393, 2000                                                    (journal IF =  4.490; journal 5-Year IF = 3.733; journal rank = 12 of 63)

 

22.  Goldstein G, Shpilberg O, Raanani P, Chetrit A, Ben-Bassat I

Acute lymphoblastic leukemia in adults treated with German multicenter study group protocols.

Harefuah  Vol 139 pp 255-9, 328, 327, 2000                                                                     (journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

  1. Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I

High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease.

Harefuah  Vol 139 pp 174-9, 248, 247, 2000                                                          (journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

  1. Raanani P, Segal E, Levi I, Bercowicz M, Berkenstat H, Avigdor A, Perel A,   Ben-Bassat I.

Diffuse alveolar hemorrhage in acute promyelocytic lLeukemia patients treated with Atra - a manifestation of the basic disease or the treatment.

      Leukemia & Lymphoma  Vol 37 pp 605-610, 2000 

     (journal IF =  1.512; journal 5-Year IF = 1.461; journal rank = 41 of 63)

 

  1. Raanani P, Levi I, Holzman F, Grotto I, Brok-Simoni F, Avigdor A, Davidson J, Shpilberg O, Ben-Bassat I.

      Engraftment-associated hypophosphatemia--the role of cytokine release and steep leukocyte rise post stem cell transplantation.

Bone Marrow Transplantation  Vol. 27, pp :311-317, 2001                                          (journal IF =  3.000; journal 5-Year IF = 2.542; journal rank = 25 of 63)

 

  1. Avigdor A., Raanani P., Levi I., Hardan I., Ben-Bassat I.

Extramedullary progression despite a good response in bone marrow in patients treated with thalidomide for multiple myeloma.

Leukemia & Lymphoma Vol 42, pp 683-687, 2001                                                                      (journal IF =  1.512; journal 5-Year IF = 1.461; journal rank = 41 of 63)

 

{C}27.  {C}Levy-Nissenbaum O., Sagi-Assif O., Raanani P., Avigdor A., Ben-Bassat I., Witz I.P.

      Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukaemia.

 Cancer Letters  Vol. 199, pp185-192, 2003                                                       (journal IF =  3.398; journal 5-Year IF = 3.193; journal rank = 49 of 132)

 

{C}28.  {C}Levy-Nissenbaum O. , Sagi-Assif  O. , Kapon D. , Hantisteanu S. , Burg T., Raanani  P., Avigdor A. , Ben-Bassat I. ,  Witz I.P. 

Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in     myeloid leukemia and other malignant cells.

Oncogene Vol.  22, pp. 7649–7660, 2003                                                             (journal IF =  6.440; journal 5-Year IF = 6.371; journal rank = 14 of 132)

 

{C}29.  {C}Shimoni A., Hardan I., Avigdor A., Yeshurun M., Raanani P., Ben-Bassat I., Nagler A.

       Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma.

British Journal of Haematology  Vol.  122 , pp 457 – 464, 2003                                (journal IF =  4.490; journal 5-Year IF = 3.733; journal rank = 12 of 63)

 

  1. Levy-Nissenbaum O., Sagi-Assif O., Raanani P., Avigdor A., Ben-Bassat I., Witz I.P.

     cDNA microarray analysis reveals an overexpression of the dual-specificity    

     MAPK phosphatase PYST2 in acute leukemia.

     Methods in Enzymology Vol. 366, pp 103-113,  2003

    (journal IF =  2.122; journal 5-Year IF = 1.886; journal rank = 31 of 60)

 

{C}31.  {C}Raanani P.,  Ben-Bassat I., Gan S., Trakhtenbrot L., Mark Z. , Ashur-Fabian S. , Itskovich S. , Brok-Simoni F., Rechavi G., Amariglio N., Nagler A.. Assessment of the response to imatinib in chronic myeloid leukemia patients – comparison between the FISH, multiplex and real-time RT-PCR methods.

 European Journal of Haematology Vol. 73, pp 243 – 250, 2004                  (journal IF =  2.163; journal 5-Year IF = 2.056; journal rank = 34 of 63)

 

  1. Raanani P .,Trakhtenbrot L., Rechavi G., Rosenthal E., Avigdor A., Brok-   

Simoni F., Leiba M.,  Amariglio N., Nagler A., Ben-Bassat I.

Philadelphia chromosome positive T- lymphoblastic leukemia: acute leukemia or  chronic  myelogenous leukemia blastic crisis.

      Acta Haematologica Vol. 113, pp 181-189, 2005

    (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

{C}33.  {C}Raanani P., Shasha Y., Peri C., Metser U., Naparstek E., Apter S., Nagler A., Polliack A., Ben-Bassat I., Even-Sapir E.

Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?

     Annals of Oncology Vol. 17, pp 117-122, 2006                                               (journal IF =  4.875; journal 5-Year IF = 4.805; journal rank = 23 of 132)

 

{C}34.  {C}Apter S., Shemesh J., Raanani P., Portnoy O., Thaler M., Zissin R., Ezra D., Rozenman J., Pfeffer R., Hertz M.

 Cardiovascular calcifications after radiation therapy for Hodgkin lymphoma: computed tomography detection and clinical correlation.
Coronary artery disease  Vol 17, pp 145-151, 2006                                            (journal IF =  1.556; journal 5-Year IF = 1.596; journal rank = 33 of 54)

 

{C}35.  {C}Tecuceanu N., Dardik R., Rabizadeh E., Raanani P., Inbal A.

A family with hereditary thrombocythaemia and normal genes for thrombopoietin and c-Mpl.

British Journal of Haematology Vol 135, pp 348-351, 2006                             (journal IF =  4.490; journal 5-Year IF = 3.733; journal rank = 12 of 63)

 

{C}36.  {C}Ashur-Fabian O., Adamsky K., Trakhtenbrot L., Cohen Y., Raanani P, Hardan I., Nagler A., Rechavi G., Amariglio N.

Apaf1 in chronic myelogenous leukemia (CML) progression: reduced Apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis.
 Cell Cycle Vol 6, pp 589-594,  2007                                                                  (journal IF =  3.314; journal 5-Year IF = not applicable; journal rank = 31 of 156)

 

{C}37.  {C}Ram R., Gafter-Gvili A., Okon E., Pazgal I., Shpilberg O., Raanani P.

Gelatinous transformation of bone marrow in chronic myeloid leukemia    during treatment with imatinib mesylate: a disease or a drug effect?

    Acta Haematologica Vol 119, pp 104-107, 2008                                                      (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

{C}38.  {C}Mashiah A., Wolach O., Sandbank J., Uziel O., Raanani P., Lahav M.

Lymphoma and leukemia cells possess fractal dimensions that correlate with their biological features.

Acta Haematologica Vol 119, pp 142-150, 2008                                               (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

{C}39.  {C}Raanani P., Gafter-Gvili A., Paul M., Ben-Bassat I., Leibovici L., Shpilberg O.

Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation.
      Cochrane Database of Systematic Reviews Vol 4,  Art. No.: CD006501, 2008                                                                                                         (journal IF =  4.654; journal 5-Year IF = not applicable; journal rank = 27 of 100)

 
{C}40.  {C}Ram R., Gafter-Gvili A., Yeshurun M., Paul M., Raanani P., Shpilberg O.
       Prophylaxis regimens for GVHD: systematic review and meta-analysis.
       Bone Marrow Transplantation Vol 43, pp 643-653, 2009 
      (journal IF =  3.000; journal 5-Year IF = 2.542; journal rank = 25 of 63)
 
{C}41.  {C}Raanani P., Gafter-Gvili A., Paul M., Ben-Bassat I., Leibovici L., Shpilberg O.

       Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: Systematic review and meta-analysis.

       Journal of Clinical Oncology Vol 27, pp 770-781, 2009                              (journal IF =  15.484; journal 5-Year IF = 13.753; journal rank = 5 of 132)

 

{C}42.  {C}Gafter-Gvili A., Ram R., Gurion R., Paul M., Yeshurun M., Raanani P.,   Shpilberg O.

ATG plus cyclosporine reduces all-cause mortality in patients with Severe aplastic Anemia – Systematic Review and Meta-Analysis.

Acta Haematologica  Vol 120, pp 237-243, 2009                                           (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

{C}43.     Ram R., Bonstein L., Gafter-Gvili A,. Ben-Bassat I., Shpilberg O., Raanani P.

Rituximab-associated acute thrombocytopenia: An under-diagnosed phenomenon.

American Journal of Hematology  Vol 84, pp 247-250, 2009                              (journal IF =  1.949; journal 5-Year IF = 1.914; journal rank = 36 of 63)

 

 

    44.     Raanani P., Gafter-Gvili A., Paul M., Ben-Bassat I., Leibovici L., Shpilberg O.

Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma - systematic review and meta-analysis.
Leukemia & Lymphoma  Vol 50, pp 764-772, 2009

(journal IF = 1.512; journal 5-Year IF = 1.461; journal rank = 41 of 63)

 

    45.     Ram R., Gafter-Gvili A., Raanani P., Yeshurun M., Shpilberg O., Dreyer J., Peck A., Leibovici L., Paul M.

Surveillance of infectious complications in hemato - oncological patients.

Israel Medical Association Journal  Vol 11, pp 133-137, 2009

(journal IF =  0.577; journal 5-Year IF = 0.583; journal rank = 42 of 100)

 

    46.     Gurion R., Gafter-Gvili A., Paul M., Vidal L., Ben-Bassat I,. Yeshurun M,. Shpilberg O., Raanani P.

Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy systematic review and meta analysis.

 Haematologica  Vol 94, pp 712-719, 2009                                                    (journal IF =  5.516; journal 5-Year IF = 4.758; journal rank = 9 of 63)

 

47.     Magen-Nativ H., Ram R., Yeshurun M., Gafter-Gvili A., Raanani P., Shpilberg O.

Total therapy based treatment for multiple myeloma - a single center experience.

     Annals of Hematology Vol 89, pp 53-59, 2010 

   (journal IF =  2.342; journal 5-Year IF = 1.914; journal rank = 31 of 63)

 

48.  Gurion R., Vidal L., Gafter-Gvili A., Belnik Y., Yeshurun M., Raanani P.,
Shpilberg O.

The role of hypomethylating agents in the treatment of patients with myelodysplastic syndrome - systematic review and meta-analysis.

        Haematologica Vol 95, pp 303-310, 2010

   (journal IF =  5.978; journal 5-Year IF = 5.513; journal rank = 9 of 62)

 

 

49.  Mor R., Uziel O., Shpilberg O., Lahav J., Raanani P., Bakhanashvili M., Rabizadeh  E., Zimra Y., Lahav M., Granot G.

The effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL positive) cells sensitive and resistant to imatinib.

        Experimental Hematology Vol 38, pp 27-37, 2010

   (journal IF =  3.203; journal 5-Year IF = 3.490; journal rank = 24 of 62)

 

 

50.  Ram R., Gafter-Gvili A., Vidal L., Paul M., Ben-Bassat I., Shpilberg O., Raanani P.

Management of adult patients with acute lymphoblastic leukemia in first    complete remission: systematic review and meta-analysis.

        Cancer  Vol 116, pp 3447 – 3457, 2010 

   (journal IF =  5.238; journal 5-Year IF = 5.517; journal rank = 23 of 143)

 

51.  Gafter-Gvili A., Leader A., Gurion R., Vidal L., Ram R., Shacham-Abulafia A., Ben-Bassat I., Lishner M., Shpilberg O., Raanani P.

High-dose imatinib for newly diagnosed chronic phase chronic myeloid     leukemia patients-systematic review and meta-analysis.

        American Journal of Hematology Vol 86, pp 657 – 662, 2011

 (journal IF =5; journal 5-Year IF = 4.041; HEMATOLOGY journal rank  = 13 of 70; Quartile in Category – Q1; no. of citations: 15)

 

52.  Gurion R., Belnik-Plitman Y., Gafter-Gvili A., Paul M., Vidal L., Ben-Bassat I., Shpilberg O., Raanani P.

Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia.

Cochrane Database of Systematic Reviews Vol 9,  Art. No.: CD008238, 2011

(journal IF =  6.035; journal 5-Year IF = 6.539; MEDICINE, GENERAL & INTERNAL   journal rank = 13 of 154; Quartile in Category – Q1; no. of citations: 2)

 

 

53.  Pfreundschuh M., Kuhnt E., Trümper L., Osterborg A., Trneny M., Shepherd L., Gill D.S., Walewski J., Pettengell R., Jaeger U., Zinzani P.L., Shpilberg O., Kvaloy S., de Nully Brown P., Stahel R., Milpied N, López-Guillermo A., Poeschel V., Grass S., Loeffler M., Murawski N.; MabThera International Trial (MInT) Group.

Collaborators: Jäger G., Jäger U, Ruckser R., Thaler J., Bell R., Cannell P., Cartwright K.D, Enno A., Fay K., Filshie R., Gibson J., Gill D., Green M., Grigg A., Hertzberg M.S., Horvath N., Irving I., Kanourakis G., Leahy M., Lowenthal R.M., Ma D., Norman E., Prosser W., Schwarer A., Smith C.L., Tileay C.R., Underhill C., Wolf M., Alves  de Souza Scheliga A., Belch A., Bence-Bruckler I., Burnell M., Cantin G., Charpentier D., Crump M., Desjardins P., Findlay B., Gapski J., Howson-Jan K., Imrie K., Matthews J.H., Pressnail B., Sheperd L., Stevens R., Stewart D., Tompkins K., Voralia M., White D., Bolomská I., Jankovská M., Kubáckova K., Matuska M, Papajík T., Pytlík R., Siffnerová H., Trneny M., Vásová I., Vozobulová V, Zák P., Boesen A.M., de Nully Brown P., Hansen M., Plesner T., Lehtinen T., Pyrhönen S., Teerenhovi L., Colombat P., Maisonneuve H., Milpied N., Andreesen R., Aulitzky W., Berdel W., Bodenstein H., Brugger W., Clemens M., deWit M., Döhner H., Dörken B., Eimermacher H., Franke A., Frickhofen N., Haas R., Herold M., Hiddemann W., Ho A., Höffken K., Hoelzer D., Huber C., Kneba M., Mergenthaler H.G., Metzner B., Mantovani L, Nerl C, Peest D, Pfreundschuh M, Pielken HJ, Reiser M, Schlimok G, Schmitz N, Trümper L, Steinhauer HB, Uppenkamp M, Verbeek W, Berrebi A, Cohen A, Kornberg A, Raanani P, Rachmilevitz E, Shpilberg O, Yehuda B, Yukla M, Amadori S, Falini B, Fanin R, Foa R, Gobbi M, Mazza P, Zaccaria A, Zinzani PL, Ekanger R, Johnsen H, Kvaløy S, Maisenhølder M, Östenstad B, Telhaug R, Dmoszyńska A, Hellmann A, Hołowiecki J, Jedrzejczak W, Robak T, Sułek K, Utracka-Hutka B, Walewski J, Caballero Barrigón D, Conde García E, Díaz Mediavilla J, Guillermo AL, Adriansson M, Andreassen L, Cavallin-Ståhl E, Erlanson M, Fredén S, Hagberg H, Hedenus M, Johansson JE, Kimby E, Lauri B, Lindblom A, Österborg A, Rådlund A, Rylander H, Betticher D, Ghielmini M, Hitz F, Mingrone W, Pless M, Stahel R, Widmer LA, Cunningham D, Dyer JS, Evely R, Hancock B, Hatton C, Haynes A, Hoskin P, Johnson P, Lister A, Marcus R, Milligan DW, Morris TC, Pettengell R, Pettitt A, Poynton C, Tighe J, Wimperis J.

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Lancet Oncology  Vol 12, pp 1013-1022, 2011

(journal IF =  26.509; journal 5-Year IF = 28.181; ONCOLOGY journal rank = 3 of 213; Quartile in Category – Q1;  no. of citations:187)

 

54.  Ram R., Wolach O., Vidal L., Gafter-Gvili A., Shpilberg O., Raanani P.

Adolescents and young adults with acute lymphoblastic leukemia have a better

outcome when treated with pediatric-inspired regimens: systematic review and

meta-analysis.

American Journal of  Hematology Vol 87, pp 472 – 478, 2012

(journal IF =  5; journal 5-Year IF = 4.041; HEMATOLOGY journal rank =   13 of 70; Quartile in Category – Q1;   no. of citations: 30)

 

55.  Shapira S., Granot G, Mor-Tzuntz R., Raanani P., Uziel O., Lahav M., Shpilberg O.

Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells.

Cancer Letters Vol. 323, pp 223 – 231, 2012

(journal IF =  5.992; journal 5-Year IF = 5.174; ONCOLOGY journal rank = 23 of 213; Quartile in Category – Q1; no. of citations: 3)

 

56.  Gurion R., Belnik-Plitman Y., Gafter-Gvili A., Paul M., Vidal L., Ben-Bassat I., Shpilberg O., Raanani P.

Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia - update of

Cochrane Database of Systematic Reviews Vol 9,  Art. No.: CD008238, 2011

Cochrane Database of Systematic Reviews Vol 6,  Art. No.: CD008238, 2012

(journal IF =  6.035; journal 5-Year IF = 6.539; MEDICINE, GENERAL & INTERNAL   journal rank = 13 of 154; Quartile in Category – Q1; no. of citations: 3)

 

 

57.  Ram R., Farbman L., Leibovici L., Raanani P., Yeshurun M., Vidal L., Gafter-Gvili A., Peck A., Shpilberg O., Paul M.

  Characteristics of initial compared with subsequent bacterial infections among

  hospitalised haemato-oncological patients.

  International Journal of Antimicrobial Agents Vol. 40, pp 123 – 126, 2012

(journal IF =  4.097; journal 5-Year IF = 4.349; INFECTIOUS DISEASES   journal rank = 16 of 83; Quartile in Category – Q1; no. of citations: 9)

 

{C}58.  {C}Gurion R., Gafter-Gvili A., Vidal L., Leader A., Ram R., Shacham-Abulafia A., Paul M., Ben-Bassat I., Shpilberg O., Raanani P.

Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come?

  Systematic review and meta-analysis.

  Haematologica Vol 98, pp 95-102, 2013

  (journal IF =  6.671; journal 5-Year IF = 5.877; HEMATOLOGY journal rank  = 4 of 70; Quartile in Category – Q1;  no. of citations: 13)

 

59.  Vidal L., Gafter-Gvili A., Gurion R., Raanani P., Dreyling M., Shpilberg O. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.

  Cochrane Database of Systematic Reviews Vol 9,  Art. No.: CD009045, 2012

 (journal IF =  6.035; journal 5-Year IF = 6.539; MEDICINE, GENERAL & INTERNAL   journal rank = 13 of 154; Quartile in Category – Q1; no. of citations: 0)

 

 

60.  Ram R., Magen-Nativ H., Vidal L., Herscovici C., Peck A,. Raanani P., Shpilberg O., Yeshurun M.

Toxicity of autologous hematopoietic cell transplantation in patients with

multiple myeloma - comparison between two different induction regimens.

Clinical Transplantation Vol. 26, E549-54, 2012

(journal IF =  1.844; journal 5-Year IF = 1.761; SURGERY journal rank = 77 of 199; Quartile in Category – Q2; no. of citations: 0)

 

61.  Muchtar E., Vidal L., Ram R., Gafter-Gvili A., Shpilberg O., Raanani P.

The role of maintenance therapy in acute promyelocytic leukemia in first   complete remission. Systematic review and meta-analysis.

  Cochrane Database of Systematic Reviews Vol 3,  Art. No.: CD009594, 2013

(journal IF =  6.035; journal 5-Year IF = 6.539; MEDICINE, GENERAL & INTERNAL   journal rank = 13 of 154; Quartile in Category – Q1; no. of citations: 0)

 

{C}62.  Ovcharenko A., Granot G., Shpilberg O.,  Raanani P.

Retinoic acid induces adhesion and migration in NB4 cells through Pyk2 signaling.

Leukemia Research Vol. 37 , pp 956 – 962, 2013

(journal IF =  2.606; journal 5-Year IF = 2.507; HEMATOLOGY journal rank = 38 of 70; Quartile in Category – Q3; no. of citations: 3)

 

63.  Itchaki G., Gafter-Gvili A., Lahav M., Vidal L., Raanani P, Shpilberg O., Paul M.

Anthracycline-containing regimens for treatment of follicular lymphoma in    adults.

Cochrane Database Systematic Reviews Vol 7, Art. No.: CD008909, 2013

(journal IF =  6.035; journal 5-Year IF = 6.539; MEDICINE, GENERAL & INTERNAL   journal rank = 13 of 154; Quartile in Category – Q1; no. of citations: 2)

 

64.  Gafter-Gvili A., Paul M., Bernstine H., Vidal L., Ram R., Raanani P., Yeshurun M., Tadmor B., Leibovici L., Shpilberg O., Groshar D.                                                                                      The Role  of 18F-FDG PET/CT for the diagnosis of infections in patients with   hematological malignancies and  persistent febrile neutropenia

 Leukemia Research Vol 37, pp 1057 – 1062, 2013

(journal IF =  2.606; journal 5-Year IF = 2.507; HEMATOLOGY journal rank = 38 of 70; Quartile in Category – Q3; no. of citations: 4)

 

65.  Ovcharenko A., Granot G., Shpilberg O.,  Raanani P.

Enhanced adhesion/migration and induction of Pyk2 expression K562 cells     following imatinib exposure

   Leukemia Research Vol 37, pp 1729 – 1736, 2013

(journal IF =  2.606; journal 5-Year IF = 2.507; HEMATOLOGY journal rank     = 38 of 70; Quartile in Category – Q3; no. of citations: 4)

 

66.  Paul M., Ram R. ,Kugler E., Farbman L., Peck A., Leibovici L., Lahav M., Yeshurun M., Shiplberg O., Herscovici C, Wolach O., Itchaki G., Bar-Nathan M., Vidal L., Gafter-Gvili A., Raanani P.

Subcutaneous vs. intravenous G-CSF for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial.

   American Journal of Hematology  Vol 89, pp 243 – 248, 2014

(journal IF =  5; journal 5-Year IF = 4.041; HEMATOLOGY journal rank  =     13 of 70; Quartile in Category – Q1; no. of citations: 3)

 

67.  Muchtar E., Raanani P., Yeshurun M., Shpliberg O. , Magen-Nativ H.

Myeloma in scar – an under reported phenomenon or an emerging entity in the novel agents' era? Single center series report.

Acta Haematologica Vol 132, pp 39 - 44,  2014

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 2)

 

68.  Muchtar E., Ram R., Raanani P., Yeshurun M., Oniashvili N., Shpilberg O., Magen H.

First line and salvage therapy with total therapy 3-based treatment for multiple

myeloma-An extended single center experience.

Leukemia Research  Vol 38, pp 1401-1406, 2014

(journal IF =  2.606; journal 5-Year IF = 2.507; HEMATOLOGY journal rank        = 38 of 70; Quartile in Category – Q3; no. of citations: 0)

 

69.  Shepshelovich D., Edel Y., Goldvaser H., Dujovny T., Wolach O., Raanani P. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study.

British Journal of Clinical Pharmacology  Vol 79, pp 685 - 691, 2014

(journal IF =  3.83; journal 5-Year IF = 3.878; PHARMACOLOGY & PHARMACY journal rank = 48 of 253; Quartile in Category – Q1; no. of citations: 0)

 

70.  Hershkovitz-Rokah O., Modai S., Pasmanik-Chor M., Toren A., Shomron N., Raanani P., Shpilberg O., Granot G.

MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.

Cancer Letters Vol 356, pp 597 – 605, 2015

  (journal IF =  5.992; journal 5-Year IF = 5.174; ONCOLOGY journal rank =   23 of 213; Quartile in Category – Q1; no. of  citations: 10)

 

71.  Kugler E., Levi A., Goldberg E., Zaig E., Raanani P., Paul M.

The association of central venous catheter placement timing with infection rates in patients with acute leukemia.

Leukemia Research  Vol 38, pp 1401-1406, 2014

  (journal IF =  2.606; journal 5-Year IF = 2.507; HEMATOLOGY journal rank        = 38 of 70; Quartile in Category – Q3; no. of citations: 2)

 

72.  Wolach O., Itchaki G., Bar-Natan M., Yeshurun M., Ram R., Herscovici C.,    Shpilberg O., Douer D., Tallman M., Raanani P.

High dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia – is more better or more of the same?

Hematological Oncology Vol 34, pp 28 - 35, 2016                                                                            (journal IF =  3.494; journal 5-Year IF = 2.533; HEMATOLOGY journal rank = 24 of 70; Quartile in Category – Q2; no. of citations: 0)

 

73.  Hershkovitz-Rokah O., Modai S., Pasmanik-Chor M., Toren A., Shomron N.,    Raanani P., Shpilberg O, Granot G.

Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.

Cancer Letters Vol 360, pp 245 – 256, 2015

(journal IF =  5.992; journal 5-Year IF = 5.174; ONCOLOGY journal rank =   23 of 213; Quartile in Category – Q1; no. of  citations: 5)

 

 

74.  Hazan-Halevy I., Rosenblum D., Weinstein  S., Bairey O. , Raanani P., Peer D.               Cell-specific uptake of mantle cell lymphoma- derived exosomes by B-lymphocytes in a cholesterol dependent pathway.

  Cancer Letters Vol 364, pp 59 – 69, 2015

 (journal IF =  5.992; journal 5-Year IF = 5.174; ONCOLOGY journal rank =    23 of 213; Quartile in Category – Q1; no. of  citations: 4)

 

 

75.  Gafter-Gvili A., Ribakovsky E., Mizrahi N., Avigdor A.,  Aviv A., Vidal L., Ram R., Perry C., Avivi I., Kedmi M., Nagler A., Raanani P., Gurion R.

Infections associated with bendamustine - retrospective multicenter study.  Leukemia and Lymphoma Vol 57, pp 63 – 69 ,2016

(journal IF =  3.093; journal 5-Year IF = 2.704; HEMATOLOGY journal rank = 28 of 70; Quartile in Category – Q2; no. of  citations: 0)

 

 

76.  Vidal L., Shpilberg O., Gurion R., Monsef I., Raanani P., Ram R., Gafter -Gvili A.                                                                                                                                      CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma – a meta-analysis of randomized controlled trials.

Acta Oncologica Vol 55, pp 77 – 84, 2016

(journal IF =  3.73; journal 5-Year IF = 3.417; ONCOLOGY journal rank = 66 of 213; Quartile in Category – Q2; no. of  citations: 0)

 

{C}77.  {C}Yeshurun M., Shpilberg O., Herscovici C., Shargian L., Dreyer J., Peck A., Israeli M., Levy-Assaraf M., Gruenewald  T., Mechoulam R., Raanani P., Ram R.                                                                                                                        Cannabidiol for the prevention of graft-versus-host-disease after allogeneic hematopoietic cell transplantation: results of a phase II study

Biology of Blood and Marrow Transplantation Vol 21, pp 1770 - 1775, 2015

 (journal IF =  3.98; journal 5-Year IF = 3.992; TRANSPLANTATION journal rank = 4 of 25; Quartile in Category – Q1; no. of  citations: 0)

 

{C}78.  {C}Shahal-Zimra Y., Rotem Z., Chezar J., Oniashvili N., Leader A., Raanani P., Rabizadeh E.

Adult pre B-cell acute lymphoblastic leukemia with unusually large proportion of bone marrow CD45 bright/high SSc blasts.

Cytometry, part B (Clinical Cytometry) 2015 Sep 28. [Epub ahead of

print]

(journal IF =  2.822; journal 5-Year IF =2.323  ; MEDICAL LABORATORY TECHNOLOGY journal rank =    6 of 30; Quartile in Category – Q1; no. of  citations: 0)

 

79.  Shacham-Abulafia A., Itchaki G., Yeshurun M., Paul M., Peck A., Leader A., Shpilberg O., Ram R., Raanani P.

High intensity induction chemotherapy is feasible for elderly patients with          acute myeloid leukemia.

      Acta Haematologica  Vol 135, pp 55-64, 2016

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 0)

 

80.  Muchtar E. Gatt M., Rouvio O., Ganzel C., Lavi N., Shochat T.,Cohen Y., Avivi I., Raanani P., Magen H.

Efficacy and safety of salvage therapy using Carfilzomib for relapsed or  refractory multiple myeloma patients: a multicentre retrospective observational study.

       British Journal of  Haematology  Vol 172, pp 89-96, 2016

   (journal IF =  5.401; journal 5-Year IF = 5.151; HEMATOLOGY journal rank    = 10 of 70; Quartile in Category – Q1; no. of  citations: 1)

 

81.  Muchtar E.,  Magen H.,  Itchaki G.,  Cohen A.,  Rosenfeld R,  Shochat T.,  Kornowski R.,  Iakobishvili Z.,  Raanani P.                                                         Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis.                                                                                          Leukemia Research  Vol 41, pp 56 – 61, 2016

(journal IF =  2.606; journal 5-Year IF = 2.507; HEMATOLOGY journal rank        = 38 of 70; Quartile in Category – Q3; no. of citations: 0)

 

 

82.  Weinstein S., Toker I.A., Emmanuel R., Ramishetti S., Hazan-Halevy I., Rosenblum D., Goldsmith M., Abraham A., Benjamini O., Bairey O., Raanani P., Nagler A., Lieberman J., Peer D.                                                                         Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.                                                                                                         Proceedings of the  National Academy of Sciences  U S A (PNAS) Vol 113, pp E16-22, 2016

(journal IF =  9.423; journal 5-Year IF = 10.285; MULTIDISCIPLINARY   SCIENCES  journal rank    = 4 of 63; Quartile in Category – Q1; no. of  citations: 1)

 

83.  Vidal L., Gurion R., Ram R., Raanani P., Bairey O., Robak T., Gafter-Gvili A., Shpilberg O.

  Chlorambucil for the treatment of patients with chronic lymphocytic leukemia

  (CLL) - a systematic review and meta-analysis of randomized trials.                                                                                             

  Leukemia and Lymphoma. 2016 Mar 16:1-11. [Epub ahead of print]

(journal IF =  3.093; journal 5-Year IF = 2.704; HEMATOLOGY journal rank = 28 of 70; Quartile in Category – Q2; no. of  citations: not availabel yet)

 

84.  Al-Ali HK., Griesshammer M., le Coutre P., Waller CF., Liberati AM., Schafhausen P, Tavares R., Giraldo P., Foltz L., Raanani P., Gupta V., Tannir B., Perez Ronco J., Ghosh J., Martino B., Vannucchi AM.

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.                                                                    Haematologica 2016 May 31. [Epub ahead of print]

(journal IF =  6.671; journal 5-Year IF = 5.877; HEMATOLOGY journal rank  = 4 of 70; Quartile in Category – Q1;  no. of citations: not availabel yet)

 

 

85. Muchtar E.,  Zelig  A., Robenshtok E., Shochat T., Oniashvili  N., Amitai I., Raanani P., Magen H.

Bone Mineral Density Utilization in Patients with Newly Diagnosed Multiple Myeloma: a Single Center Experience.

Hematological Oncology 2016 June 21[Epub ahead of print]

 (journal IF =  3.494; journal 5-Year IF = 2.533; HEMATOLOGY journal rank = 24 of 70; Quartile in Category – Q2; no. of citations: not available yet)

 

86.  Mittelman M., Filanovsky K., Ofran Y., Rosenbaum H., Raanani P., Braester A.,  Goldschmidt N., Kirgner I., Herishanu Y., Perri C., Ellis M., Oster HS.; Israel Myelodysplastic Syndrome Working Group (MDS-WG).

Azacitidine-lenalidomide (ViLen) combination yields a high response rate in

higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.     

Annals of Hematology Vol 95, pp 1811 – 1818, 2016.

(journal IF =  3.022; journal 5-Year IF = 2.751; HEMATOLOGY journal rank        = 31 of 70; Quartile in Category – Q2; no. of citations: 0)

 

87.  Gurion R., Raanani P., Vidal L., Leader A.,  Gafter-Gvili A.                                First line treatment with the newer tyrosine kinase inhibitors in chronic myeloid leukemia is associated with a deep and durable molecular response – systematic review and meta-analysis

Acta Oncologica Vol 55, pp1077-1083, 2016

(journal IF =  3.73; journal 5-Year IF = 3.417; ONCOLOGY journal rank = 66 of 213; Quartile in Category – Q2; no. of  citations: 0)

 

 

88.  Gover-Proaktor A., Granot G., Shapira S.,  Raz O.,  Pasvolsky O., Nagler A.,  Lev D.L.,  Inbal A.,  Lubin I.,  Raanani P.,  Leader A.

Ponatinib reduces viability, migration, and functionality of human endothelial

cells.

Leukemia and Lymphoma Vol 58, pp 1455 – 1467, 2016

(journal IF =  3.093; journal 5-Year IF = 2.704; HEMATOLOGY journal rank = 28 of 70; Quartile in Category – Q2; no. of  citations: 0)

 

 

  1. Grisariu S., Vaxman I., Gatt M., Elias S., Avni B., Arad A., Pasvolsky O., Raanani P., Paltiel O.

Enteroviral infection in patients treated with rituximab for non- Hodgkin lymphoma: a case series and review of the literature.

Hematological Oncology 2016 Oct 13

(journal IF =  3.494; journal 5-Year IF = 2.533; HEMATOLOGY journal rank = 24 of 70; Quartile in Category – Q2; no. of citations: not available yet)

 

  1. Gafter-Gvili A., Gurion R., Raanani P.,  Shpilberg O., Vidal L.

Bendamustine-associated infections-systematic review and meta-analysis of

randomized controlled trials.

Hematological Oncology 2016 Oct 13

(journal IF =  3.494; journal 5-Year IF = 2.533; HEMATOLOGY journal rank = 24 of 70; Quartile in Category – Q2; no. of citations: 0)

 

91.  Leader A.,  Zelikson-Saporta R., Pereg D.,  Spectre G.,  Rozovski U., Raanani P., Hermoni D., Lishner M.

The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence.

(journal IF =  5.61; journal 5-Year IF = 5.263; MEDICINE, GENERAL & INTERNAL journal rank = 14 of 155; Quartile in Category – Q1; no. of citations: not available yet)

 

 

     Accepted

92.  Gurevich A., Tzadok S., Rosenberg A., Inbal A., Bar-Natan M., Wolach O., Raanani P.

Extended small dose platelet transfusions in multi-transfused hemato-oncological patients:   a single center experience.

Accepted to: Acta Haematologica

  

 

 

 

 

 

 

B.2. CASE REPORTS

 

Published

1.       Raanani P., Levi Y., Varon D., Gitel S., Martinowitz U.                                   Congenital afibrinogenemia with bleeding, bone cysts and antibodies to fibrinogen. Harefuah Vol. 121, pp. 291-293, 1991                                                                          (journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

2.       Raanani P., Lahav M., Prokocimer M., Poles L., Theodor E.                                   Life threatening hypophosphataemia in a patient with Philadelphia chromosome positive chronic myelogenous leukaemia in acute blastic crisis.                                    Postgraduate Medical Journal Vol. 68, pp. 283-286, 1992                                         (journal IF =  1.218; journal 5-Year IF = 1.232; journal rank = 56 of 100)

 

3.       Raanani P., Kunicevki M., Sidi Y.                                                                          Fever and lymphadenopathy in a 33 year old patient with discoid lupus erythematosus. Clinico-pathological conference.                                                                                Harefuah Vol. 124, pp. 854-660, 1993                                                                 (journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

4.       Bar-Dayan Y., Raanani P.,  Levy Y., Aharon A., Likumovich P., Skurnik Y.              Acute renal failure and fatal respiratory failure in leukemic hyperleukocytosis                                     (clinical conference).                                                                                             Harefuah Vol. 132, pp. 63-67, 1997                                                                            (journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

5.       Raanani P., Thaler M., Keller N., Ben-Bassat I.                                                             Skin lesions in a patient with hairy cell leukaemia.                                                    Postgraduate Medical Journal Vol. 73, pp. 375-377, 1997                                        (journal IF =  1.218; journal 5-Year IF = 1.232; journal rank = 56 of 100)

 

6.       Kreiss Y., Schwartz E., Kaminski N., Raanani P., Schiby G.., Zvas Z., Sidi Y.

 Unique pulmonary presentation of intravascular large cell lymphoma.                   

 Respiratory Medicine Vol. 92, pp. 1087-1089, 1998                                                (journal IF =  2.235; journal 5-Year IF = 2.146; journal rank = 28 of 75)

 

7.       Rachmani R., Avigdor A., Youkla M., Raanani P., Zilber M., Ravid M.,
Ben-Bassat I.

Thrombotic thrombocytopenic purpura complicating chronic myelogenous      leukemia. A report of two successfully treated patients.

Acta Haematologica Vol. 100, pp. 204-206, 1998                                                            (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

8.       Levi I., Raanani P., Shalmon B., Schiby-Brilliant R., Ben-Bassat I.                               Acute neutrophilic dermatosis induced by all-trans-retinoic acid treatment for acute promyelocytic leukaemia.

Leukemia & Lymphoma  Vol. 34, pp. 401-404, 1999                                                 (journal IF = 1.512; journal 5-Year IF = 1.461; journal rank = 41 of 63)

 

9.       Sharabi Y., Raanani P., Shenkar A, Thaler M., Grossman E.

Plasma cell dyscrasia with polyneuropathy - POEMS syndrome presenting with

vasculitic skin lesions and responding to combination chemotherapy

Leukemia & lymphoma  Vol. 40, pp. 209-213, 2000                                                      (journal IF = 1.512; journal 5-Year IF = 1.461; journal rank = 41 of 63)

 

10.     Gayer G., Zandman-Goddard G., Raanani P., Hertz M., Apter S.

Widespread abdominal venous thrombosis in paroxysmal nocturnal    hemoglobinuria diagnosed on CT.

Abdominal Imaging Vol. 26,  pp. 414-419, 2001                                                          (journal IF = 1.213; journal 5-Year IF = 1.258; journal rank = 60 of 87)

 

11.     Raanani P., Goldman J.M., Ben-Bassat I.

Depigmentation in a chronic myeloid leukemia patient treated with STI-571

Journal of Clinical Oncology Vol 20, pp. 869 – 870, 2002                                          (journal IF =  15.484; journal 5-Year IF = 13.753; journal rank = 5 of 132)

 

12.     Levi I.,  Dinour D.,  Ben-Bassat I.,   Raanani P.

Acute myeloid leukemia associated with nephrotic syndrome.

Leukemia & Lymphoma Vol 4 , pp.  1133-1136, 2002                                              (journal IF = 1.512; journal 5-Year IF = 1.461; journal rank = 41 of 63)

 

13.     Gurion R., Groshar D., Schindel A., Shpilberg O., Raanani P.

18F-fluorodeoxyglucose-avid mammary mass in a patient with insulin-dependent diabetes mellitus and Hodgkin's lymphoma: relapse or pitfall?

The Israel Medical Association Journal Vol 8, pp 838-839, 2006                              (journal IF =  0.577; journal 5-Year IF = 0.583; journal rank = 42 of 100)

 

14.     Sapoznikov B., Morgenstern S., Raanani P., Aviram A., Rabizadeh E., Prokocimer M., Niv Y.

Follicular lymphoma with extensive gastrointestinal tract involvement: follow-  up by capsule endoscopy.
Digestive Diseases and Sciences  Vol 52, pp 1031 – 1035,  2007                              (journal IF =  1.319; journal 5-Year IF = 1.582; journal rank = 41 of 50)

 

15.     Gafter-Gvili A., Ram R., Gafter U., Shpilberg O., Raanani P.

Renal failure associated with tyrosine kinase inhibitors – case report and review of the literature.

Leukemia Research Vol 34, pp. 123-127, 2010

(journal IF =  2.390; journal 5-Year IF = 2.160; journal rank = 34 of 62)

 

 

16.     Wolach O, Yeshurun M, Amariglio N, Shpilberg O, Raanani P.

Acute promyelocytic leukemia with a smoldering course associated with

therapy-related myelodysplastic syndrome.

Acta Haematologica Vol 126, pp 152 – 156,  2011

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 1)

 

17.     Muchtar E, Paul M, Horowitz A, Shpilberg O, Raanani P.

Persistent carbapenem-resistant Klebsiella pneumoniae bacteremia in a patient

with acute lymphoblastic leukemia.

Israel Medical Association Journal : IMAJ Vol 14, pp 195 – 197, 2012

(journal IF =  0.879; journal 5-Year IF = 1.014; MEDICINE, GENERAL & INTERNAL journal rank = 98 of 151; Quartile in Category – Q3;  no. of citations: 1)

 

18.     Shacham – Abulafia A., Nagar R., Ram E., Levavi H., Vidal L., Shpilberg O., Raanani P.

     Burkitt Lymphoma of the Ovary: Case Report and Literature Review

    Acta Haematologica Vol 129, pp 169 – 174,  2013

 

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 0)

 

19.     Shepshelovich D., Shpilberg O., Lahav M., Itchaki G., Raanani P., Cohen A.

Hodgkin Lymphoma and Hypothermia: Case Report and Review of the Literature.

Acta Haematologica Vol 131, pp 227 – 230, 2014

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 1)

 

20.     Shepshelovich D., Oniashvili N., Parnes D., Klein A., Muchtar E., Yeshaya J., Aviram A., Rabizadeh E., Raanani P.                                                                              Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.

    Cancer Genetics  Vol 208, pp 575-579, 2015

(journal IF =  2.333; journal 5-Year IF = 2.805; ONCOLOGY  journal rank = 135 of 213; Quartile in Category – Q3; no. of citations: 0)

 

21.     Wasserstrum Y., Raanani,P., Kornowski R., Iakobishvili Z.

 Concomitant treatment with ibrutinib and amiodarone causing reversible heart failure syndrome.

Israel Medical Association Journal  Vol 18, pp 433- 434, 2016

(journal IF =  0.879; journal 5-Year IF = 1.014; GENERAL & INTERNAL MEDICINE  journal rank = 99 of 105; Quartile in Category – Q3; no. of citations: 0)

 

 

 

 

B.3. REVIEW ARTICLES

Published

 

1.       Raanani P., Martinowitz U.                                                                                             Chronic fatigue syndrome - review.                                                                         Harefuah, Vol. 127, pp. 467-471, 1994                                                                         (journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

2.       Raanani P., Shpilberg O., Ben-Bassat I.                             

2-chlorodeoxyadenosine(2-CdA) therapy in hairy cell leukemia - review.         Harefuah, Vol. 126, pp. 673-676, 1994                                                                         (journal IF =  not applicable; journal 5-Year IF = not applicable; journal rank = not applicable)

 

3.       Raanani P., Ben-Bassat I.

Immune-mediated Complications during interferon therapy in hematological patients.

Acta Haematologica, Vol. 107, pp. 133-144 ,2002                                                      (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

4.       Raanani P.,  Ben-Bassat I..

Detection of Minimal Residual Disease in Acute Myelogenous Leukemia.

Acta Haematologica  Vol. 112, pp 40-54, 2004                                                 (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

 

{C}5.       Raanani P., Shpilberg O., Ben-Bassat I.

Extramedullary disease and targeted therapies for hematological   malignancies - is the association real?
Annals of Oncology  Vol. 18, pp 7-12, 2007                                                              (journal IF =  4.875; journal 5-Year IF = 4.805; journal rank = 23 of 132)

 

6.       Shpilberg O, Ben-Bassat I, Raanani P.

Targeted and tailored therapy in hemato-oncology: vision for the 21st century.

The Israel Medical Association Journal Vol. 8, pp 843-844, 2006                            (journal IF =  0.577; journal 5-Year IF = 0.583; journal rank = 42 of 100)

 

7.       Ben-Bassat I, Raanani P, Gale RP.

Graft-versus-leukemia in chronic lymphocytic leukemia.
Bone Marrow Transplantation Vol 39, pp441-446,  2007                                          (journal IF =  3.000; journal 5-Year IF = 2.542; journal rank = 25 of 63)

 

{C}8.       Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P.

The late adverse events of rituximab therapy – rare but there!

     Leukemia & Lymphoma Vol 50, pp 1083-1095, 2009
  (journal IF = 1.512; journal 5-Year IF = 1.461; journal rank = 41
     of 63)
 
 
{C}9.       {C}Ram R, Gafter-Gvili A, Shpilberg O, Raanani P. 
                          Allogeneic hematopoietic cell  transplantation for adult patients with acute    leukemia: the role of meta-analyses. 
     Acta Haematologica Vol. 125, pp 39-46, 2011

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 1)

 

{C}10.     {C}Gafter-Gvili A, Ram R, Raanani P, Shpilberg O. 
                          Management of aplastic anemia: the role of systematic reviews and meta-analyses. 
     Acta Haematologica Vol. 125, pp 47-54, 2011

 (journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 3)

 

 
{C}11.     {C}Gurion R, Shacham-Abulafia A, Shpilberg O, Raanani P. 
The use of myeloid colony-stimulating factors in hematologic malignancies:          the  role of systematic reviews and meta-analyses. 
     Acta Haematologica Vol. 125, pp 68-79, 2011

 (journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank = 62 of 70; Quartile in Category – Q4; no. of citations: 3)

 

12.     Raanani P, Granot G, Ben-Bassat I

Is cure of chronic myeloid leukemia in the third millennium a down to earth target (ed) or a castle in the air?

Cancer Letters Vol. 352, pp 21 – 27, 2014

(journal IF =  5.992; journal 5-Year IF = 5.174; ONCOLOGY journal rank =    23 of 213; Quartile in Category – Q1; no. of  citations: 1)

 

13.     Leader A., Raanani P.

Adherence-related issues in adolescents and young adults with hematological disorders.

  Acta Haematologica Vol. 132, pp 348 - 362, 2014

   (journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank   = 62 of 70; Quartile in Category – Q4; no. of citations: 0)

 

14.    Pasvolsky O., Leader A., Iakobishvili Z., Wasserstrum Y., Kornowski R., Raanani P.

 Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid

  Leukemia

 Cardio-Oncology Vol  1: 5, 2015 DOI 10.1186/s40959-015-0008-5

(No IF yet)

 

15.       Wasserstrum Y., Kornowski R., Raanani P., Leader A., Pasvolsky O., Iakobishvili Z.,

Hypertension in cancer patients treated  with anti-angiogenic based regimens Cardio-Oncology Vol  1: 6, 2015 DOI 10.1186/s40959-015-0009-4

(No IF yet)

 

16.  Asheknazy S., Dreyer J., Raanani P., Leader A.

Adherence to oral treatment in hemato-oncology

Harefuah, Vol. 156, pp. 254-258, 2017

 

C.      CHAPTERS IN BOOKS

      Published

 

1.      Ram R., Vidal L., Gurion R., Raanani P., Shpilberg O.: Evidence-based guided interventions in acute leukemia. In: Antica M (Ed): Acute leukemia - the scientist's perspective and challenge. InTech, 2011, pp 349 -370

 

2.      Raanani P., Gurion R., Gafter-Gvili A., Ben-Bassat I.,  Shpilberg O.: The role          of hematopoietic growth factors in aplastic anemia: an evidence-based perspective. In: Molineux G, Foote MA, Arvedson T (Eds): Twenty years of G-CSF. Springer Basel, 2012, pp 195 - 210

 

    

3.      Saar N., Raanani P., Rozovski U.: Prognostic and Predictive Indicators in Treatment Naïve Patients with Chronic Lymphocytic Leukemia:
Is It Prime Time to Stratify Patients According to IGHV Mutation Status?                     In: Chronic Lymphocytic Leukemia: Diagnosis, Treatment Options and Prognosis" - Nova Science Publishers 2016

 

 

D.1.  INVITED PAPERS IN SCIENTIFIC MEETINGS

Raanani P

Systematic reviews in haematological malignancies

Evidence-based Reviews in Haemato-Oncology: 10th Anniversary of the Cochrane Haematological Malignancies Group, Cologne, 2011.

D.2. PAPERS PRESENTED AT SCIENTIFIC MEETINGS AND PUBLISHED    AS PROCEEDINGS

 

1.      Martinowitz U., Verroust F., Raanani P., Varon D., Lemay D., Heim M.  

TENS enhanced joint recovery in hemophiliacs with hemarthrosis.                           Tenth congress of the International Society of Hematology, September 1989, Jerusalem, Israel.

 

2.      Raanani, P., Lahav M., Prococimer M., Theodor E.                                                  Life threatening hypophosphatemia in a patient with Philadelphia chromosome positive CML in acute blastic crisis.                                                                                           The Israeli Society of Internal Medicine, March 1990, Ramat-Gan, Israel.

 

3.      Martinowitz U., Verroust F., Raanani P., Varon D., Lemay D., Heim M. 

 

TENS enhanced joint recovery in hemophiliacs with hemarthrosis.                              XIX International Congress of the World Federation of Hemophilia                         International Congress of World Federation of Hemophilia, August 1990, Washington D.C., U.S.A.

 

4.      Lahav M., Raanani P., Weissenberg R., Regev A., Sagiv M., Singer R.                         Prevention of procarbazine induced sterility by clomiphene - a rat model.

American Society of Hematology, 33rd annual meeting, December 1991, Denver, Colorado, U.S.A.

 

5.      Lahav M., Raanani P., Weissenberg R., Regev A., Sagiv M., Singer R.                  Time dependence for the protective effect of clomiphene from procarbazine induced sterility.                                                                                                                 American Society of Hematology, 34th annual meeting, December 1992, Anaheim, California, U.S.A.

 

6.    Singer R., Lahav M., Sagiv M., Raanani P., Lurie B., Cohen A., Magazanik A., Levinski H.                                                                                                              Sialic acid content and sialyltransferase activity in rats and epididmis of male rats.

     The 27th National Congress of the Israel Society of Clinical   Biochemistry, January 1993, Tel-Aviv, Israel

 

7.       Levinsky H., Singer R., Cohen A., Lurie B., Weissenberg R., Sagiv M., Raanani P., Regev A., Lahav M.                                                                                                          The effect of clomiphene citrate and procarbazine on sialytransferase activity in testis and epididmis of the adult rat.                                                                                  Annual meeting of the Israel Society of Fertility, April 1993, Tel-Aviv, Israel

 

8.       Shamir R., Kenet G., Raanani P., Zajicek G, Arber N.                                               Increased turnover of intra-hepatic bile ducts induced by bromobenzene.                    American Gastroenterology Association, American Association for the Study of Liver Diseases, May 1993. Boston, Massachusettes, U.S.A.

 

9.       Raanani P., Shpilberg O., Bercowicz M., Sofer O., Hardan I., Chetrit A.,
Ben-Bassat I.                                                                                                        

Salvage combination chemotherapy for acute leukemia using high dose Ara-C and mitoxantrone. Experience of the Sheba Medical Center.                                       

The Israeli Society of Hematology, November 1993 , Tel-Aviv, Israel

 

10.     Hardan I., Sofer O., Shpilberg O., Ra'anani P., Ben-Bassat I.

Safety of stringent prophylactic platelet transfusion (PT) policy for lymphoma patients treated by high dose chemotherapy (HDC) and autologous stem cell support (ASCS(

20th Annual Meeting of the European Group for Bone Marrow Transplantation and the 10th Meeting of the Nurses Group, March 1994, Harrogate, England, UK

 

11.     Levinsky H., Singer R., Cohen A., Raanani P., Regev A., Kyzer S., Lahav M.         The effect of clomiphene citrate and cyclophosphamide activity in extract of kidney and liver of the rat.                                                                                                              The 29th National Congress of the Israel Society of Clinical Biochemistry, January 1995, Tel-Aviv, Israel

 

12.     Raanani P., Shpilberg O., Bercowicz M., Sofer O., Hardan I., Chetrit A., Avigdor A., Ben-Bassat I.                                                                                                      Salvage combination chemotherapy for acute leukemia using high dose Ara-C and mitoxantrone. Experience of the Sheba Medical Center: 1991-1995.                                       The Israeli Society of Hematology, March 1996, Natanya, Israel

 

13.     Weissenberg R., Lahav M., Raanani P., Madgar I.

Prevention of procarbazine - induced sterility by clomiphene isomers and  tamoxifen: A rat model

VIth International Congress of Andrology, May 1997, Salzburg, Austria

14.         Dazzi F., Raanani P., van Rhee F., Olavarria E., Szydlo R.M., Apperley J.,   Goldman, J.M., Cross N.C.P.                                                                                 RT-PCR for BCR-ABL transcripts in CML patients receiving DLI as treatment for relapse after BMT: differing patterns of molecular response.                                       EBMT-European Group for Blood and Bone Marrow Transplantation-23 Annual meeting, March 1997, Aix-les-bains, France

 

15.         Raanani P., Cross N., Goldman J.                                                              Competitive PCR-The method and clinical applications.                                                The Israeli Society of Hematology and Blood Transfusion, September 1997, Dead Sea Israel.

 

16.         Dazzi F., Raanani P., van Rhee F., Olavarria O., Murphy K.M., Philpott N.J., Apperley J.F., Cross N.C..P, Goldman J.M.                                                                                Responses to donor lymphocyte infusion in CML patients in relapse after BMT may be partial and transient: further evidence for a dose-response effect.                                                                                                                  American Society of Hematology, 39th annual meeting, December 1997, San Diego, California, U.S.A.

 

17.         Raanani P., Dazzi F., Sohal J., Szydlo R.M., van Rhee F., Reiter A., Lin F., Apperley J.F., Goldman J.M., Cross N.C.P.                                                                                       The incidence, kinetics and durability of response to donor leukocyte transfusions for CML patients who relapse after BMT.                                                                                  

American Society of Hematology, 39th annual meeting, December 1997, San Diego, California, U.S.A.

 

18.     Raanani P., Shpilberg O., Gilis S., Avigdor A., Hardan I., Berkowicz M., Sofer O., Lossos I., Chetrit A., Ben-Yehuda D., Ben-Bassat I.                                                        Salvage therapy of refractory acute leukemia with high-dose mitoxantrone and cytarabine.                                                                                                           American Society of Hematology, 39th annual meeting. December 1997, San Diego, California, U.S.A.

 

19.     Dazzi F., Raanani P., van Rhee F., Szydlo R. M., Olavarria E., Kaeda J., Apperley     J.F., Cross N.C.P., Goldman J.M.                                                                                         Donor lymphocyte infusion (DLI) for relapse of CML after allo-BMT: comparison of two regimens.                                                                                      EBMT-European Group for Blood and Bone Marrow Transplantation- 24th Annual Meeting, March 1998, Courmayeur, Italy

 

20.     Kaeda J.S., Dazzi .F., Baker P., Raanani .P, Knafer E., Apperley J.F.,
 Cross N.C.P., Goldman J.M.                                                                                                       Escalating doses of DLI identify a subset of CML patients in relapse after allografting in whom only a partial or transient response is achieved.   

EBMT-European Group for Blood and Bone Marrow Transplantation-

24th Annual Meeting, March 1998, Courmayeur, Italy

 

21.     Hardan I., Avigdor A., Attias D., Raz H.,  Berkowitcz M., Raanani .P, Sareli R.,  Levy I., Ben-Bassat I.                                                                                                       

High dose melphalan and etoposide (VP-16) with autologous stem cell support for newly diagnosed multiple myeloma (MM) patients- a phase II study.

EBMT-European Group for Blood and Bone Marrow Transplantation- 24th

Annual Meeting, March 1998, Courmayeur, Italy

 

22.     Raanani P., Levi I. , Shpilberg O., Holzman F. , Grotto I. , Simoni F. , Avigdor A., Berkowicz M.  , Hardan I., Ben-Bassat I..

Engraftment associated hypophosphatemia - the role of cytokine release and steep leukocyte Rise post stem cell transplantation.

American Society of Hematology, 41st  annual meeting, December 1999, New-Orleans, U.S.A.

 

23.     Raanani P., Levi I., Shpilberg O., Holzman F., Grotto I., Brok-Simoni F., Avigdor A., Berkowicz M., Hardan I., Kneller A.  and Ben-Bassat I..

Engraftment associated hypophosphatemia - the role of cytokine release and steep leukocyte rise post stem cell transplantation.

The Israeli Society of Hematology and Blood Transfusion, October 1999,  Dead Sea, Israel

 

24.     Raanani P., Levi I., Holzman F., Grotto I., Shpilberg O., Brok-Simoni F., Avigdor A., Berkowicz M., Hardan I., Kneller A., Ben-Bassat I.

The role of cytokines and leucocyte rise in the development of hypophosphataemia after pbsct.

26th Annual Meeting European Group for Blood and Marrow Transplantation and    16th Meeting of the Nurses Group, March 2000, Innsbruck, Austria

 

25.     Raanani P., Levi I., Holzman F., Grotto I., Brok-Simoni F., Avigdor A., Berkowicz M., Davidson J., Shpilberg O., Ben-Bassat I.

The role of cytokines and leukocyte rise in the development of hypophosphatemia after PBSCT.

Cancer Biology Research Center – annual meeting February 2001, Eilat

 

26.     Hardan I., Kneller A., Avigdor A., Raz H., Berkowicz M., Sareli R., Shimoni A.,    Levi I., Raanani P., Ben-Bassat I.
Rescue of multiple myeloma patients with disease progression after autologous PBSC transplantation.

27th Annual Meeting European Group for Blood and Marrow Transplantation and 17th Meeting of the Nurses Group, March 2001

 

 

27.     Levy-Nissenbaum O.,  Sagi-Assif O.,  Kapon D., Hantisteanu S.,  Raanani P.,

Avigdor A.,  Ben-Bassat I.,  Witz I.P.

High Expression of the Dual-Specificity Phosphatase PYST2 in Leukocytes Derived from AML Patients.

American Society of Hematology, 43rd  annual meeting, December 2001, Orlando, U.S.A.

 

28.     Shimoni A. , Hardan I., Avigdor A., Yeshurun M., Raanani P., Ben-Bassat I.,

Nagler A.

Post-transplant Rituximab reduces relapse risk after allogeneic and

autologous stem-cell transplantation (SCT) in high-risk aggressive lymphoma.

American Society of Hematology, 44th  annual meeting, December 2002, Philadelphia, U.S.A.

 

29.     Cohen A., Polliack A. ,Ben-Bassat I.,Avigdor A., Bennett M.,Berkowicz M., Attias D., Dann E., Hatskelzon L.,Levi I., Libster D.,Rahmani R,  Raanani P., Rowe JM, Shtalrid M., Yerushalmi R.,Yeshurun M.

Results of a Phase II study employing a combination of fludarabine, cyclophosphamide and Rituximab (FCR) as primary therapy for patients with advanced follicular lymphoma (FL): The Israel Cooperative Lymphoma Group.

American Society of Hematology, 44th  annual meeting, December 2002, Philadelphia, U.S.A.

 

30.     Raanani P., Ben-Bassat I., Gan S., Trakhtenbrot L., Mark Z., Itskovich S.,  Amariglio N., Brok-Simoni F., Hardan I., Kneler A., Shimoni A., Nagler A.

A  high rate of BCR-ABL negativity by FISH & multiplex RT-PCR  but not by real-time RT-PCR can be achieved in cml patients treated with imatinib.

The Israeli Society of Hematology and Blood Transfusion, January 2003, Tel-

Aviv

 

31.     Raanani P., Ben-Bassat I., Gan S., Trakhtenbrot L., Mark Z., Itskovich S.,  Amariglio N., Brok-Simoni F., Hardan I., Kneler A., Shimoni A., Nagler A.

A high rate of bcr-abL negativity by fish & multiplex rt-pcr  but not by real-time RT-PCR can be achieved in cml patients treated with imatinib 

Research conference Tel-Aviv University, April 2003, Tel-Aviv

 

32.     Raanani P., Ben-Bassat I., Gan S., Trakhtenbrot L., Mark Z., Itskovich S.,  Amariglio N., Brok-Simoni F., Hardan I., Kneler A., Shimoni A., Nagler A.

The kinetics of molecular response in cml patients treated with imatinib: a comparison between the fish, multiplex and real-time quantitative RT-PCR techniques

The European Haematology Association – EHA 8, June 2003, Lyon, France

 

33.     Raanani P., Ben-Bassat I., Itskovich S., Gan S., Morgulis Y., Kneller A., Brok-Simoni F., Rechavi G., Amariglio N., Nagler A.

Hasford score correlates with the dynamics of imatinib induced reduction of BCR-ABL transcripts in chronic phase CML.
 American Society of Hematology, 45th  annual meeting, December 2003, San   Diego, U.S.A.

 

34.     Hardan I., Shimoni A., Avigdor A., Kneller A., Berkowiicz M., Raanani P., Yeshurum M., Stemmer SM., Shem-Tov N., Ben-Bassat I, Nagler A.
Salvage therapy with autologous stem cell support prior to allogeneic stem cell transplantation in patients with relapsing/secondary acute leukemia and CML blast crisis. American Society of Hematology, 45th  annual meeting, December 2003, San   Diego, U.S.A.

 

35.     Raanani P., Ben-Bassat I., Trachtenbrrot L., Avigdor A., Brok-Simoni F.,
Amariglio N., Nagler A.

Philadelphia positive T lymphoblastic leukemia – acute leukemia or cml blast crisis?

The Israeli Society of Hematology and Blood Transfusion,  April 2004, Dead Sea, Israel

 

36.     Hardan I. Kneller A., Shimoni A., Berkowicz M., Avigdor A., Yeshurun M., Raanani P., Davidowich Y., Shemtov N., Ben-Bassat I., Nagler A.
Salvage of multiple myeloma patients relapse after an autologous stem cell transplantation, in the era of thalidomide and reduced-intensity allogeneic stem cell transplantation. 30th annual meeting of the European group of blood and bone marrow transplanation, March 2004, Barcelona, Spain

 

37.     Hardan I., Shimoni A., Avigdor A., Kneller A., Berkowicz M., Raanani P., Stemmer SM., Shemtov N., Yeshurun M., Ben-Bassat I., Nagler A.
 Autologous stem cell support of induction therapy prior to allogeneic transplantation to improve treatment delivery in patients with relapsing or secondary acute leukemia and CML blast crisis. 30th annual meeting of the European group of blood and bone marrow transplanation, March 2004, Barcelona, Spain

 

 

38.     Hardan I., Kneller A., Shimoni A., Berkowicz M., Avigdor A., Yeshurun M., Raanani P., Davidowich I., Shemtov,N., Ben Bassat I., Nagler A.

Prolongation of overall survival of multiple myeloma patients by the combination therapy of thalidomide and reduced-intensity conditioning allogeneic stem cell transplantation at progression after autologous bone marrow transplantation.

31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, March 2005, Prague, Czech Republic

 

39.     Hardan L., Meirow D., Shimoni A., Levron J., Shemtov,N., Fridman E., Zalel Y., Kneller A., Raanani P., Berkowicz M., Ben-Bassat I., Schiff E., Nagler A., Dor J. Spontaneous pregnancy and fertility preservation program in women undergoing high dose chemotherapy for hematological malignancies.

47th Annual Meeting of the American-Society-of-Hematology, December,  2005 Atlanta GA, USA

 

40.     Ram R., Gafter-Gvili A., Yeshurun M., Paul M., Raanani P., Shpilberg O.

The efficacy of prophylaxis regimens for acute graft-versus-host disease in patients undergoing bone marrow and peripheral blood stem cell transplantation – systematic review and meta-analysis

34th Annual Meeting of the European Group for Blood and Marrow         Transplantation  March 2008, Florence, Italy

 

41.     Gurion R., Gafter-Gvili A., Paul M.,  Vidal L., Ben-Bassat I., Yeshurun M., Shpilberg O., Raanani P.

Should haematopoietic growth factors be included in the immunosuppressive    treatment for severe aplastic anaemia – a systematic review and meta-analysis
34th Annual Meeting of the European Group for Blood and Marrow   Transplantation  March 2008, Florence, Italy

 

42.  Mor R., Uziel O., Shpilberg O., Lahav J., Raanani P., Rabizadeh E., Zimra Y., Lahav M., Granot G.

The effect of imatinib mesylate on the signal transduction cascade regulating telomerase activity in k562 cells and in k562 cells resistant to imatinib mesylate.

13th Congress of the European-Hematology-Association, June, 2008 Copenhagen, Denmark

 

43.  Gurion R., Vidal L., Gafter-Gvili A., Belnik Y., Yeshurun M., Raanani P.,
Shpilberg O.

The role of hypomethylating agents in the treatment of patients with myelodysplastic syndrome - systematic review and meta-analysis.

14th Congress of the European Hematology Association, June 2009 Berlin, Germany

 

44.         Ram R., Gafter-Gvili A., Vidal L., Paul M., Ben-Bassat I., Shpilberg O.,                Raanani P.

Management of Adult Patients with Acute Lymphoblastic Leukemia in First Complete Remission: Systematic Review and Meta-Analysis.                                      51st  Annual Meeting of the American-Society-of-Hematology, December, 2009, New Orleans, USA

45.         Gurion R, Belnik-Plitman Y, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Shpilberg O, Raanani P.                                                                                                   Myeloid Colony- Stimulating Factors Do Not Increase the Risk of Mortality or Disease Activity Measures in Patients with Acute Myeloid Leukemia: Systematic Review and Meta-Analysis .                                                                          51st  Annual Meeting of the American-Society-of-Hematology, December,  2009, New Orleans, USA

 

{C}46.  Ovcharenko A, Granot G, Shpilberg O, Raanani P.                                                         Molecular Mechanisms Involved in the Development of Extramedullary Disease Following the Administration of All-Trans Retinoic Acid to Patients with Acute Promyelocytic Leukemia.                                                                                                                                       51st  Annual Meeting of the American-Society-of-Hematology, December,  2009, New Orleans, USA

{C}47.  Gafter-Gvili A, Bernstine H, Vidal L,Paul M, Ram R, Raanani P, Yeshurun Y, Shpilberg O, Groshar D.                                                                                                                                  The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography and CT (PET-CT) for the Diagnosis of Infections in Hemato-Oncological Patients with Persistent Neutropenia and Fever                                                                                                                                       51st  Annual Meeting of the American-Society-of-Hematology, December,  2009, New Orleans, USA

{C}48.  Cohen Y, Cohen-Berger T, Eshel L, Stern D, Bairey O, Raanani P, Bernstine H, Shpilberg O, Groshar D.                                                                                                                                        Pulmonary Infiltrates in NHL Patients Receiving Rituximab Combined with Chemotherapy: 18Fluorodeoxyglucose Positron Emission Tomography and CT (PET-CT) Analysis and Clinical Correlates                                                                                                                        51st  Annual Meeting of the American-Society-of-Hematology, December,  2009, New Orleans, USA

 

49.  Shapira S., Granot G,. Mor-Tzuntz R., Raanani P., Uziel O., Lahav M., Shpilberg O.

The effect of nilotinib and dasatinib on telomerase activity and regulation in k562 cells

15th Congress of the European Hematology Association, June 2010 Barcelona, Spain

 

 

50. Gafter-Gvili A., Bernstine H., Vidal L., Paul M., Ram R., Raanani P.,               Yeshurun Y., Shpilberg O., Groshar D.  

The role of 18f-fluorodeoxyglucose positron emission                                tomography and CT (PET-CT) for the diagnosis of infections                                          in hemato-oncological patients with persistent neutropenia and fever.

XXXIII World Congress of the International Society of Hematology 2010, Jerusalem, Israel

 

51.  Itchaki G., Gafter-Gvili A., Lahav M., Raanani P., Vidal L., Paul M., Shpilberg O.

Anthracycline-containing regimens for treatment of follicular lymphoma in adults: systematic review and meta-analysis.

52nd Annual Meeting of the American Society of Hematology  2010, Orlando, USA   

 

52.  Gurion R.,  Gafter-Gvili A., Vidal L., Paul M.,  Ben-Bassat,I., Yeshurun M., Shpilberg O., Raanani P.                                                                                   Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy: systematic review and meta-analysis-2010 update

52nd Annual Meeting of the American Society of Hematology  2010, Orlando, USA   

  

53.  Ram R., Paul M., Gafter-Gvili A., Heshkovitz K., Israeli M., Peck A., Raanani P., Shpilberg O., Yeshurun M.                                                                                            Early post-transplantation febrile episodes are associated with increased risk for acute graft-versus-host disease                                                                                        BMT Tandem Meetings, February 2011, Hawaii, USA

 

54.   Vidal L.,  Gafter-Gvili A.,  Gurion R., Dreyling M., Raanani P., Shpilberg O.

Bendamustine for patients with indolent lymphoma - a systematic review and meta-analysis of randomized controlled trials                                                                   11th International Conference on Malignant Lymphoma 15-18 June 2011, Lugano, Switzerland 

 

55.  Gurion R., Gafter-Gvili A., Vidal L., Leader A., Ram R., Sacham-  Abulafia A., Ben Bassat I., Shpliberg O., Raanani P.

The new tyrosine kinase inhibitors for first-line treatment in patients   with chronic myelogenous leukemia-systematic review and meta-analysis. 

16th Congress of the European Hematology Association, June 2011, London, UK

 

56.  Gafter-Gvili A., Leader A., Gurion R., Vidal L., Ram R., Shacham-Avulafia A., Ben-Bassat I., Lishner M., Shpilberg O., Raanani P.

The efficacy and safety of higher doses of imatinib for the treatment of  newly diagnosed previously untreated chronic myeloid leukemia patients in chronic phase –systematic review and meta-analysis

16th Congress of the European Hematology Association, June 2011, London, UK

 

57.  Ovcharenko A., Granot G., Shpilberg O., Raanani P.

Enhanced adhesion & migration and induction of pyk2 complex fomation in NB4 and k562 cells following ATRA and imatinib treatment

16th Congress of the European Hematology Association, June 2011, London, UK

                             

58.  Vidal L, Gurion R, Gafter-Gvili A, Raanani P, Bairy O, Robak T, Shpilberg O

Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - systematic review and meta-analysis.

17th Congress of the European Hematology Association, June 2012, Amsterdam, the Netherlands

 

59.  Muchtar E., Vidal L, Gafter-Gvili A, Ram R., Shpilberg O., Raanani P

The role of maintenance therapy in acute promyelocytic leukemia:

      a systematic review and meta-analysis

17th Congress of the European Hematology Association, June 2012, Amsterdam, the Netherlands

 

60.  Gafter-Gvili A, Paul M, Bernstine H, Vidal L, Ram R, Raanani P, Yeshurun M,

Tadmor B, Shpilberg O, Groshar D

The role of PET-CT for the diagnosis of infections in patients with hematological malignancies and persistent febrile neutropenia

17th Congress of the European Hematology Association, June 2012, Amsterdam, the Netherlands

 

61.  Gafter-Gvili A., Gurion R., Raanani P., Shpilberg O., Vidal L.                     Bendamustine is not associated with an increase in infections – systematic review and meta-analysis of randomized controlled trials.

19th Congress of the European Hematology Association, June 2014, Milan, Italy

 

62.  Hershkovitz Rokah O., Granot G., Ovcharenko A., Modai S., Pasmanik-Chor M., Toren A., Shomron N., Raanani P., Shpilberg O.                                      : miRNA-30E targets BCR-ABL1 and sensitizes K562 cells to imatinib treatment.

19th Congress of the European Hematology Association, June 2014, Milan, Italy

 

63.  Dahan-Shriki D., Gafter-Gvili A.,Vidal L., Raanani P., Shpilberg O., Gurion R.

The role of high dose chemotherapy followed by autologous stem cell transplantation as first line treatment in patients with aggressive non-hodgkin lymphoma: a systematic review and meta-analysis

19th Congress of the European Hematology Association, June 2014, Milan, Italy

 

64.  Gafter-Gvili A.,  Ribakovsky E.,  Mizrahi N.,  Avigdor A.,  Aviv A., Vidal L.,  Ram R.,  Nagler A., Raanani P., Gurion R.

Infections associated with bendamustine - a retrospective multicenter study

56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA 

 

65.  Griesshammer M., Vannucchi A.M.,  le Coutre P.,  Tavares R.S., Al-Ali H.K.,   Raanani P., Gupta, V., Foltz LM. ,Giraldo P., Bouard C., Ronco J.P., Ghosh J., Martino B.                                                                                                           Safety and Efficacy of ruxolitinib in patients with low platelets enrolled in a phase 3b expanded-access study in myelofibrosis (MF)

56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA 

 

66.  Gupta, V., Tavares R.S., Griesshammer M., Foltz LM. , Raanani P., Giraldo P., Al-Ali H.K., Martino B., Tannir  B., Ronco J.P., Ghosh J., Vannucchi A.M.                                                                                     Safety and safety and efficacy of ruxolitinib retreatment after treatment interruption in patients enrolled in an open-label, multicenter, expanded-access study in myelofibrosis

56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA

 

67.  Martino B., le Coutre P.,  Griesshammer M., Illmer T., Schlag R., Waller C.F., Liberati A.M., Schafhausen P., Tavares R.S., Vannucchi A.M., Giraldo P.,  Foltz LM., Raanani P., Gupta, V., Tannir  B., Ronco J.P., Ghosh J., Al-Ali H.K.                                                                                                                     Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm, expanded-access study in patients with myelofibrosis (mf): an 1144-patient update

56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA

 

68.  Gurion R., Vidal L., Leader A., Raanani P., Gafter-Gvili A.                                The role of the newer tyrosine kinase inhibitors as first line treatment in chronic phase chronic myeloid leukemia - an updated meta-analysis                                       56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA

 

69.  Shargian-Alon L.,  Pazgal I., Raanani P.,  Rachmilewitz E.,  Stark P.     Thalassemia major and intermedia in older patients - a single center experience                                                                                                                       56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA

 

70.  Tzadok S., Gurevich A., Inbal A., Bar-Natan M., Wolach O., Raanani P            Continuous platelet transfusion increases platelet increment in refractory hemato-oncological patients - a single center experience                                       56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA

 

71.  Vidal L., Gafter-Gvili  A., Dreyling M., Ghielmini M., Unterhalt M., Raanani P., Shpilberg O., Ram R., Gurion R.                                                                                                Rituximab maintenance (MR) for patients with mantle cell lymphoma (MCL) - a systematic review and meta-analysis of randomized controlled trials (RCTs)  56th Annual Meeting of the American Society of Hematology  2014, San Francisco, USA

 

72. Shepshelovich D., Klein A., Oniashvili N., Yeshaya J., Aviram A., Parnes D., Rabizadeh E., Raanani P.                                                                                                   Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. 10th European Cytogenetics Conference 2015, Strasburg, France

 

73. Shapira S., Raanani P.,  Lubin I.,  Nagler A.,  Arber N.,  Granot G.

      Selective death of leukemic stem cells induced by deferasirox

     20th Congress of European-Hematology-Association 2015, Vienna, Austria

 

74. Giraldo P.  Palandri F.,  Palumbo GA.,  Zaritskey A.,  Calistri E.,  Skotnicki A.,  Devos T.,  Saavedra D.,  Griesshammer M.,  Al-Ali, HK., Tavares R.,  Vannucchi, AM., Gupta V.,  Raanani P.,  Tannir B.,  Ghosh J., Ronco JP., Foltz L.

Safety and efficacy of Ruxolitinib (Rux) in patients with intermediate-1-risk myelofibrosis (MF) from an open-label, multicenter, single-arm expanded-access study.

20th Congress of European-Hematology-Association, 2015, Vienna, Austria

 

75. Leader A.,  Benyamini N.,  De Geest S.,  Dreyer J.,  Calvarysky B.,  ; Gechler S., Amitai A.,  Yarchovsky-Dolberg O.,  Sharf G.,  Tousset E.,  Caspi O.,  Ellis M., Levi I.,  Gvili, AG., Raanani P.

  Assessing risk factors of electronically measured medication non-adherence in    CML patients: an observational longitudinal design-a subanalysis of the TAKE-IT study.

20th Congress of European-Hematology-Association 2015, Vienna, Austria

 

76.  Gover-Proaktor A., Pasvolsky O., Raanani P., Nagler A., Shapira S., Lubin I., Granot G., Leader A.

 Pathogenesis of ponatinib associated vascular disease in chronic myeloid leukemia: an in vitro study.

57th Annual Meeting of the American-Society-of-Hematology 2015 Orlando, USA

77.  Leader A.,  Benyamini N.,  De Geest S.,  Dreyer J.,  Calvarysky B., Gechler S., Amitai A., Jarchowsky-Dolberg O., Sharf G., Tousset E., Caspi O., Ellis, M.,  Levi I., Gafter-Gvili A., Raanani P.

The effect of adherence-encouraging interventions on adherence to tyrosine kinase inhibitor treatment in chronic myeloid leukemia (TAKE-IT): a pre-post intervention pilot study

57th Annual Meeting of the American-Society-of-Hematology 2015, Orlando, USA

78.  Leader A.,  Zelikson-Saporta R.,  Rozovski U.,  Pereg D.,  Raanani P., Spectre G.,  Lishner M., Hermoni D.

Clopidogrel treatment is associated with a decrease in cancer incidence.

57th Annual Meeting of the American-Society-of-Hematology 2015, Orlando, USA

79.  Muchtar, E., Zelig A.,  Robenshtok E.,  Shochat T.,  Oniashvili N., Amitai I., Raanani P., Magen H.

Bone mineral density utilization in patients with newly diagnosed multiple myeloma: a single center experience.

57th Annual Meeting of the American-Society-of-Hematology 2015, Orlando, USA

80.  Muchtar E.,  Magen H.,  Itchaki G.,  Cohen A.,  Rosenfeld R., Shochat T.,  Kornowski R.,  Iakobishvili Z.,  Raanani P.

Uninvolved immunoglobulins predicting hematological response in newly diagnosed al amyloidosis.

57th Annual Meeting of the American-Society-of-Hematology 2015, Orlando, USA

81.  Muchtar E.,  Gatt M.,  Rouvio O.,  Ganzei C.,  Chubar E.,  Suriu C., Tadmor T.,  Shevetz O., Lavi N.,  Shochat T., Cohen YC., Avivi I.,  Raanani P., Magen, H.

Efficacy and safety of salvage therapy using carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.

57th Annual Meeting of the American-Society-of-Hematology 2015, Orlando, USA

82.  Tavares R.,  Palumbo GA.,  Le Coutre P.,  Palanciri F.,  ; Al-Ali HK., Martino B.,  Liberati AM.,  Arich JC., Breccia M.,  Brittain D.,  Foltz L.,  Griesshammer M.,  Raanani P.,  Gupta V.,  Giraldo P.,  Chosh J.,  Tannir B.,  Ronco JP., Vannucchi AM.

  Safety and efficacy of ruxolitinib in an 1869-patient cohort of jump: an open label, multicenter, single-arm, expanded-access study in patients with myelofibrosis.

57th Annual Meeting of the American-Society-of-Hematology 2015, Orlando, USA

83.  Vidal L., Shargian L.  Shpilberg O.,  Ram R.,  Raanani P., ; Gurion R., Gafter, A.

Bendamustine for patients with indolent lymphoma an updated meta-analysis of randomized controlled trials (RCT)

57th Annual Meeting of the American-Society-of-Hematology 2015, Orlando, USA

84.  Mittelman M.,  Filanovsky K., Ofran Y.,  Raanani P.,  Braester A.,  Goldshmidt N., ; Kirgner I.,  Herishanu Y.,  Perry C.,  Oster, HS.

High response rate for azacitidine-lenalidomide (vi-len) combination in higher-risk myelodysplastic syndromes (mds) - vilen-01 protocol update.

13th International Symposium on Myelodysplastic Syndromes (MDS), Washington, DC, USA

85.  Pasvolsky O., Rozovski U., Navon M., Pek A., Dreyer J., Klebovsky T., Vaxman I., Shacham A., Shargian L., Raanani P., Yeshurun M.

Differences in attitude towards hematopoietic stem cell transplantation (hsct) between physicians and nurses.

21st Congress of the European-Hematology-Association, June 2016, Copenhagen, Denmark

86.  Abulafia A.S., Raanani P.,. Lavie D., Volchek Y., Ram R., Hellmann I., Shargian L., Gourevietch A., Chubar E., Ratzon R. Rozovski U.

A nationwide observational study of the israeli experience with ponatinib outside clinical trials in chronic myeloid leukemia

21st Congress of the European-Hematology-Association, June 2016, Copenhagen, Denmark

87.  Ratzon R., Tzadok S., Raanani P., Gurion R.

Twenty years' experience of treatment of adolescents and young adults with non-hodgkin lymphoma - a single center experience

21st Congress of the European-Hematology-Association, June 2016, Copenhagen, Denmark

88.  Vaxman I., Rosovski U., Moshe M., Shargian L., Pasvolsky O., Yahav D

Bashara J., Lahav M., Gurion R., Magen H., Vidal L., Itzhaki G., Peck A.,  Sela MN., Raanani P.,  Yeshurun M.

Antibacterial prophylaxis reduces the risk of bacteremia in patients with multiple myeloma and lymphoma undergoing high-dose chemotherapy and autologous stem cell transplantation.

21st Congress of the European-Hematology-Association, June 2016, Copenhagen, Denmark

89.  Vidal L., Lando, S. Vaxman, I.  Raanani, P., Gurion R. Gafter-Gvili A.

Reduced rchop for elderly patients with dlbcl

21st Congress of the European-Hematology-Association, June 2016, Copenhagen, Denmark

90.  Passamonti F., Zaritskey A., Giraldo P., Liberati AM., Niederwieser D., Palandri F., Raanani P., Griesshammer M., Vannucchi AM., Al-Ali HK., Gupta V., Martino B., Foltz L., Ronco JP., Ghosh J.,  Bouard C., Tavares R.

Safety and efficacy of ruxolitinib in patients with dipss intermediate-1-risk myelofibrosis (mf) from jump: an open label, multicenter, single-arm, expanded-access study

21st Congress of the European-Hematology-Association, June 2016, Copenhagen, Denmark

91.  Shapira S., Raanani P., Nagler A., Lubin I., Arber N., Granot G.

Selective Death of Leukemia Initiating Cells Induced By Deferasirox

58th Annual Meeting of the American-Society-of-Hematology 2016, San Diego, USA

92.  Vidal L., Gafter-Gvili A., Dreyling MH., Unterhalt M., Raanani P., Ghielmini M., Gurion, R.

Maintenance Therapy for Patients with Mantle Cell Lymphoma (MCL) - a Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)

58th Annual Meeting of the American-Society-of-Hematology 2016, San Diego, USA

93.  Vaxman, I., Schlesinger, A., Goldberg, N.,  Lahav, M., Gafter, A., Lando, S., Raanani P., Vidal L.

Muscle Mass in Elderly Patients with DLBCL Treated with RCHOP

58th Annual Meeting of the American-Society-of-Hematology 2016, San Diego, USA

94.  Gurion R., Bernsteine H., Michelson C., Domachevsky L., Raanani P., Vidal L., Gafter-Gvili A.

FDG PET/CT As a Diagnostic and Prognostic Tool for the Evaluation of Patients with Peripheral T-Cell Lymphoma

58th Annual Meeting of the American-Society-of-Hematology 2016, San Diego, USA

95.  Foltz L., Palumbo GA., Martino B., Palandri F., Al-Ali HK., Liberati AM., Le Coutre PD., Vannucchi AM.,  Garcia-Hernandez C., Tavares R., Griesshammer M., Gupta V.,  Raanani P., Giraldo P.,  Bouard C.,  Ronco JP.,  Khanna S.,  Zaritskey A.

Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with

Myelofibrosis (N=2233)

58th Annual Meeting of the American-Society-of-Hematology 2016, San Diego, USA

 

 

 

 

 

 

 

 

 

 

 

D.3. ABSTRACTS

  1. Lavee J., Rath S., Tranquang H., Raanani P., Ruder A., Modan M., Neufeld H.N., Goor D.A.

Is Complete Revascularization in the Conventional Method Really Complete?

Israel Journal of Medical Sciences Vol 21, pp 400, 1985

 

  1. Shamir R., Kenet G., Raanani P., Zajicek G., Arber N.

Increased Turnover of Intrahepatic Bile-Ducts Induced by Bromobenzene.

Gastroenterology Vol 104, pp A990, 1993

 

 

  1. Weissenberg R., Lahav M., Raanani P., Madgar I.

Prevention of procarbazine - induced sterility by clomiphene isomers and tamoxifen: A rat model.

International Journal of Andrology Vol 20, pp 74, 1997

 

  1. Dazzi F., Raanani P., Van Rhee F., Olavarria E., Murphy K., Philpott N., Apperley J., Cross N., Goldman J.

Responses to donor lymphocyte infusion (DLI) in CML patients in relapse after BMT may be partial and transient: Further evidence for a dose-response effect.

Blood Vol 90, pp 518A, 1997

 

  1. Dazzi F., Raanani P., van Rhee F., Szydlo R., Olavarria E., Kaeda,J., Apperley J.F., Cross N.C.P., Goldman J.M.

Donor lymphocyte infusion (DLI) for relapse of CML after allo-BMT: Comparison of two regimens.

Bone Marrow Transplantation Vol 21, pp S70, 1998

 

 

  1. Shpilberg O., Livnat T., Chetrit A., Zegelman H., Raanani P., Ben-Bassat I., Ramot B.

Polymorphisms within phase I and phase II carcinogen metabolizing genes are not associated with increased risk for hematological malignancies.

Blood Vol 94, pp 4015, 1999

  1. Raanani P.; Levi I.; Shpilberg O.; Holzman F.; Grotto I.; Simoni F.; Avigdor,A.; Berkowicz,M.; Hardan,I.; Kneller,A.; Ben-Bassat,I.

Engraftment associated hypophosphatemia - The role of cytokine release and steep leukocyte rise post stem cell transplantation.

Blood Vol 94, pp 1477, 1999

 

  1. Lahav M., Raanani P., Luboshitz J., Szyper-Kravitz M., Weissenberg,R., Shaklai M.

High dose clomiphene prevents sterility in young males with Hodgkin's disease treated with MOPP/ABV.

Blood Vol 94, pp 2359, 1999

 

  1. Hardan I., Kneller A., Avigdor A., Raz H., Berkowicz M., Sareli R., Shimoni A., Levi I., Raanani P., Ben-Bassat I.

Rescue of multiple myeloma patients with disease progression after autologous PBSC transplantation.

Bone Marrow Transplantation Vol 27, pp S2521, 2001

 

  1. Raanani P., Levi I., Holzman F., Grotto I., Brok-Simoni F., Avigdor A., Davidson J., Shpilberg O.  Ben-Bassat I.

Engraftment associated hypophosphatemia - the role of cytokine release and steep leukocyte rise post stem cell transplantation.

Bone Marrow Transplantation Vol 27, pp 776, 2001

 

  1. Levy-Nissenbaum O., Sagi-Assif O., Kapon D., Hantisteanu S., Raanani P., Avigdor A., Ben-Bassat I., Witz I.P.

High expression of the dual-specificity phosphatase PYST2 in leukocytes derived from AML patients

Blood Vol 98, pp 2440, 2001

 

 

  1. Levy-Nissenbaum O., Sagi-Assif O., Hantisteanu S., Raanani P., Avigdor A., Ben-Bassat I., Witz I.

PYST2, a MAPK dual specificity phosphatase is regulated by microenvironmental factors.

Proceedings of the 2nd International Conference on Tumor Microenvironment: Progression, Therapy and Prevention. Baden, Austria. Isaac P. Witz, Ed., Monduzzi Editore, S.p.A., Bologna, Italy, pp. 11-17, 2002

 

13.  Hantisteanu S., Levy-Nissenbaum O., Sagi-Assif O., Raanani P., Avigdor A., Ben-Bassat I., Witz I. 

Adherence up regulates expression of PYST2-L in Myeloid Leukemia cells.

Proceedings of the 2nd International Conference on Tumor Microenvironment: Progression, Therapy and Prevention. Baden, Austria. Isaac P. Witz, Ed., Monduzzi Editore, S.p.A., Bologna, Italy, pp. 95-100,2002

 

14.  Gural A., Shtalrid M., Raanani P., Ben Neriah S., Goldschmidt N., Paltiel O., Ben-Yehuda D.

Inv(16) is not associated with favorable prognosis in Israeli AML patients: A multi-center retrospective analysis.

Annales de Genetique Vol 46, pp 121-122, 2003

 

  1. Raanani P., Ben-Bassat I., Itskovich S., Gan S., Morgulis Y., Kneller A., Brok-Simoni F., Rechavi G., Amariglio N., Nagler A.

Hasford score correlates with the dynamics of imatinib induced reduction of BCR-ABL transcripts in chronic phase CML.

Blood Vol 102, pp 4978, 2003

 

  1. Hardan I., Shimoni A., Avigdor A., Kneller A., Berkowiicz M., Raanani P., Yeshurum M., Stemmer S.M., Shem-Tov N., Ben-Bassat I., Nagler A

Salvage therapy with autologous stem cell support prior to allogeneic stem cell transplantation in patients with relapsing/secondary acute leukemia and CML blast crisis.

Blood Vol 102, pp 2732, 2003

 

  1. Hardan I., Shimoni A., Avigdor A., Kneller A., Berkowicz M., Raanani P., Stemmer S.M., Shemtov N., Yeshurun M., Ben-Bassat I., Nagler A.

Autologous stem cell support of induction therapy prior to allogeneic transplantation to improve treatment delivery in patients with relapsing or secondary acute leukemia and CML blast crisis.

Bone Marrow Transplantation Vol 33, pp S235-S236, 2004

 

  1. Hardan I., Kneller A., Shimoni A., Berkowicz,M., Avigdor A., Yeshurun,M., Raanani P., Davidowich Y., Shemtov N., Ben Bassat I., Nagler A.

Salvage of multiple myeloma patients relapse after an autologous stem cell transplantation, in the era of thalidomide and reduced-intensity allogeneic stem cell transplantation

Bone Marrow Transplantation Vol 33, pp S156- S157, 2004

 

  1. Avigdor A., Bulvik S., Shemtov N., Levi I., Berkowicz M., Ben-Yehuda D., Blickstein D., Goldschmidt N., Gural A., Kornberg A., Libster D., Merkel,D., Naparstek E., Raanani P., Roth B., Volchek Y., Nagler A., Ben-Bassat I., Polliack A.

A pilot study of combined escalated BEACOPP-ABVD therapy for advanced Hodgkin's lymphoma patients with high IPS score: The Israel Cooperative Lymphoma Group

Blood Vol 104, pp 4576, 2004

 

 

  1. Hardan I., Kneller A., Shimoni A., Berkowicz M., Avigdor A., Yeshurun M., Raanani P., Davidowich I., Shemtov,N.; Ben Bassat,I.; Nagler,A.

Prolongation of overall survival of multiple myeloma patients by the combination therapy of thalidomide and reduced-intensity conditioning allogeneic stem cell transplantation at progression after autologous bone marrow transplantation.

Bone Marrow Transplantation Vol 35, pp S48-S49, 2005

 

  1. Hardan L., Meirow D., Shimoni A., Levron J., Shemtov,N., Fridman E., Zalel Y., Kneller A., Raanani P., Berkowicz M., Ben-Bassat I., Schiff E., Nagler A., Dor J. Spontaneous pregnancy and fertility preservation program in women undergoing high dose chemotherapy for hematological malignancies.

Blood Vol 106, pp 324A-325A, 2005

 

  1. Mor R., Uziel O., Shpilberg O., Lahav J., Raanani P., Rabizadeh E., Lahav M., Granot G.

The effect of imatinib mesylate on the signal transduction cascade leading to down regulation of telomerase activity in K562 cells.

Blood Vol 108, pp 4787, 2006

 

  1. Raanani P., Gafter-Gvili A., Paul M., Ben-Bassat I., Leibovici L., Shpilberg O.

Immunoglobulin prophylaxis in patients undergoing hematopoietic stem cell transplantation - Systematic review and meta-analysis.

Blood Vol 110, pp 4962, 2007

 

             24.     Mor R., Uziel O., Shpilberg O., Lahav J., Raanani P., Rabizadeh E., Zimra Y., Lahav M., Granot G.

The effect of imatinib mesylate on the signal transduction cascade regulating telomerase activity in k562 cells and in k562 cells resistant to imatinib mesylate.

Haematologica-the Hematology Journal Vol 93, pp 108, 2008

 

             25.     Gurion R., Vidal, L., Gafter-Gvili A.,  Belnik Y.,  Yeshurun M.,  Raanani P., Shpilberg O.

Hypomethylating agents in myelodysplastic syndrome-systematic review and meta-analysis.

Haematologica-the Hematology Journal  Vol 94,   pp 104, Meeting Abstract: 0261, 2009

 

             26.     Cohen YC.,  Cohen-Berger T., Eshel L.,  Stern D.,  Bairey O.,  Raanani P.,  Bernstine H.,  Shpilberg O., Groshar D.

Pulmonary infiltrates in nhl patients receiving rituximab combined with chemotherapy: 18f-fluorodeoxyglucose positron emission tomography and CT (PET-CT) analysis and clinical correlates

Blood  Vol 114, pp 1445, 2009  

 

        27.     Gafrer-Gvili A. , Bernstine H., Vidal L., Paul M., Ram R., Raanani P., Yeshurun M., Shpilberg O., Groshar D.

The role of 18f-fluorodeoxyglucose positron emission tomography and CT (PET-CT) for the diagnosis of infections in hemato-oncological patients with persistent neutropenia and fever.

Blood  Vol 114, pp 1213-1214, 2009

 

28. Gurion R.,  Belnik-Plitman Y.,  Gafter-Gvili A., Paul M., Vidal L., Ben-Bassat I., Shpilberg O., Raanani P.

Myeloid colony-stimulating factors do not increase the risk of mortality or disease activity measures in patients with acute myeloid leukemia: Systematic review and meta-analysis.

Blood  Vol 114,  pp 807-808, 2009

 

        29.          Ovcharenko A.,  Granot G.,  Shpilberg O.,  Raanani P.  

Molecular mechanisms involved in the development of extramedullary disease following the administration of all-trans retinoic acid to patients with acute promyelocytic leukemia.

Blood  Vol 114, pp 638,   2009 

 

        30.           Ram R.,  Gafter-Gvili A., Vidal L., Paul M., Ben-Bassat I., Shpilberg O.,  Raanani P.

       Management of adult patients with acute lymphoblastic leukemia in firstcomplete remission: systematic review and meta-analysis

       Blood  Vol 114, pp 26,  2009

 

31.  Shapira S., Granot G., Mor-Tzuntz R., Raanani P., Uziel O., Lahav M., Shpilberg O.

The effect of nilotinib and dasatinib on telomerase activity and regulation in k562 cells.

Haematologica-the Hematology Journal,  Vol  95, pp 34, 2010

 

32.   Itchaki G., Gafter-Gvili A., Lahav M., Raanani P., Vidal L., Paul M.,                          Shpilberf O.             

Anthracycline-containing regimens for treatment of follicular lymphoma in adults: systematic review and meta-analysis.

Blood  Vol 116,   pp 1163,  2010

 

33.   Gurion, R., Gafter-Gvili A., Vidal L., Paul M.,  Ben-Bassat I., Yeshurun M.,                                                                                                                                                          Shpilberg O., Raanani P.

Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy: Systematic review and meta-analysis-2010 Update

Blood  Vol 116,   pp 502,  2010

 

34.   Ram R.,  Paul M., Gafter-Gvili A., Hershkovitz K., Israeli M., Peck A.,     Raanani P., Shpilberg O., Yeshurun, M.

Early post-transplantation febrile episodes are associated with increased risk for acute graft-versus-host disease.

Biology of Blood and Marrow Transplantation  Vol 17 Supplement: 2,   pp S346-S347    Meeting Abstract: 539, 2011

 

35.      Vidal L., Gafter-Gvili A., Gurion, R., Dreyling, M., Raanani, P., Shpilberg O.

Bendamustine for patients with indolent lymphoma - a systematic review and meta-analysis of randomized controlled trials (RCT)

Annals of Oncology  Vol  22   Supplement: 4   pp 185,  2011

 

36.  Ram R., Wolach O., Vidal L., Gafter-Gvili A., Shpilberg O., Raanani P.    Adolescents and young adults with acute lymphoblastic leukemia have better outcomes when treated with pediatric-inspired regimens - systematic review and meta-analysis of comparative trials

Blood  Vol 118   pp 1112,  2011

 

37.  Ram R.,  Magen-Nativ H.,  Hershkovitzi C., Vidal L., Peck A.,  Raanani P.,  Shpilberg O., Yeshurun M.

Impact of induction intensity in multiple myeloma patients on autologous haematopoietic cell transplantation morbidity - a single-centre experience

Bone marrow transplantation  Vol 47   Supplement: 1   pp S214-S214, 2012

 

38.  Gurion R.,  Gafter-Gvili A.,  Ram R., Vidal L., Raanani P.,  Shpilberg O.

The role of anti-CD33 for the treatment of acute myeloid leukemia - systematic review and meta-analysis 

Blood Vol 120 Issue 21Abstract 1521, 2012

 

39.  Wolach O.,  Rabizadeh E., Lederfein D., Binkovski N., Raanani P.,  Shpilberg O., Inbal A.                                                                                                                                  Increased activity of prothrombinase fgl-2 in peripheral blood mononuclear cells of patients with b-cell lymphoma

      Blood Vol 120 Issue 21 Abstract 2665, 2012

 

40.  Ovcharenko A.,  Granot G., Park J., Shpilberg O., Raanani P.                           Enhanced adhesion, migration and Pyk2 expression in K562 cells following imatinib treatment                                                                                                            Blood Vol 120 Issue 21 Abstract 4426, 2012

 

41.  Mittelman M., Filanovsky K., Rosenbaum H., Raanani P., Braester A,. Goldschmidt N., Hellman I., Kirgner I., Perri C., Oster H.S.                              

Azacitidine and lenalidomide combination in higher-risk myelodysplastic syndromes-preliminary results of the Vilen-01 protocol

Blood Vol 122 Issue 1 Abstract 1576, 2013

 

42.  Vidal L., Gurion R., Ram R., Shpilberg O., Raanani P., Gafter-Gvili A. CHOP/CHOP-Like-14 Vs. CHOP/CHOP-Like-21 for Patients with aggressive lymphoma - a systematic review and meta-Analysis of randomized controlled trials

Blood Vol 122 Issue 1 Abstract 1798, 2013

 

43.  Gafter-Gvili A., Gurion R., Raanani P., Shpilberg O., Vidal L.                 Bendamustine is not associated with an increase in infections - systematic review and meta-analysis of randomized controlled trials

Blood Vol 122 Issue 21 Abstract 5125, 2013

 

44.  Yeshurun M.,   Shpilberg O.,   Herscovici K.,  Shargian L.,  Dreyer J., Peck A.,  Israeli M., Levy-Assaraf M.,  Gruenewald T.,  Mechoulam R.,  Raanani, P., Ram R.

Cannabidiol for the prevention of graft-versus-host-disease after allogeneic stem cell transplantation: Results of a Phase I/II Study

Biology of blood and marrow transplantation Vol 21 Supplement: 1  pp S353-S354, 2015

 

45.  Abulafia, AS., Raanani P., Lavie  D., Volchek Y., Ram R., Hellmann I.,  Shargian L.,  Gourevietch A.,  Chubar E.,  Ratzon R.,  Rozovski U.

A nationwide observational study of the israeli experience with ponatinib outside clinical trials in chronic myeloid leukemia.

Blood Vol 126 Issue 23, Dec 2015

 

46.  Itchaki G., Wolach O ., Bar-Natan M., Yeshurun M., Ram R., Herscovici C., Douer D ., Tallman M., Shpilberg O., Raanani P.

Very High Dose Cytarabine as Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia in the Setting of Intensified Anthracycline Induction and Post Stem-Cell Transplantation.

Clinical Lymphoma Myeloma & Leukemia Vol 15, pp  S184-S184, June 2015

 

47.  Al-Ali HK., Tavares R., Palumbo GA., Palandri F., Martino B., Liberati AM.,  Ullrich JG., Breccia M., Brittain D., Foltz L., Griesshammer M.,  Raanani P., Gupta V., Giraldo P., Ghosh J., Tannir B.,  Ronco JP., Vannucchi AM., Le Coutre P.

Safety and efficacy of Ruxolitinib in expanded-access JUMP study: an update from a cohort of 1869 patients

Oncology Research And Treatment Vol 39, pp 233-233 (Supplement 3), Oct 2016

 

 

 

 

 

 

 

 

 

 

 

 

E.  ITEMS IN ENCYCLOPEDIAS

{C}1.    Raanani P.

Aplastic anemia

The Israeli Encyclopeida for Medicine

 

{C}2.        Raanani P.

Acute lymphoblastic leukemia

The Israeli Encyclopeida for Medicine

 

 

F.     BOOKS EDITED  
{C}1.    Raanani  P.,  Hochhaus A. -  Editors

           Special issue : Minimal residual disease in hematologic malignancies  

             Acta Haematologica Vol. 112, No. 1-2, 2004

 

 

2.    Raanani P., Skoetz N. – Editors

      Speical Issue: The role of systematic reviews and meta-analyses in the management of hemato-oncological disorders

           Acta Haematologica  Vol 125, No. 1-2, 2011

 

3. Raanani P., Tallman M. - Editors

   Special Issue: Adolescents and young adults with hematological disorders

   challenges and perspectives

   Acta Haematologica Vol 132, No. 3-4, 2014

 

 

{C}G.    OTHER PUBLICATIONS

1.       Shpilberg O., Raanani P., Ben-Bassat I., Ramot B.                                                  Recurrent bilateral parotitis in acute myeloid leukemia (letter to the editor)          Acta Haematologica, Vol. 86 pp. 56, 1991                                                                (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

2.       Raanani P., Bercowicz M., Harden I., Ben-Bassat I.                                            Severe hypophosphataemia in autograft recipients during accelerated leucocyte recovery. (letter to the editor)                                                                                                             British Journal of Haematology, Vol. 91 pp. 1031-1032, 1995                                    (journal IF =  4.490; journal 5-Year IF = 3.733; journal rank = 12 of 63)

 

3.       Raanani P, Hochhaus A. Minimal Residual Disease in Hematological Malignancies  (Editorial.)

         Acta Haematologica, Vol. 112 pp 5-7, 2004

        (journal IF =  1.352; journal 5-Year IF = 1.439; journal rank = 48 of 63)

 

4.      Ben-Bassat I, Raanani P.

         Bracha Ramot (1927-2006).

Blood Cells, Molecules and  Diseases Vol 39, pp 135-139, 2007                             (journal IF =  2.555; journal 5-Year IF = 2.560; journal rank = 30 of 63)

 

5.      Ram R, Raanani P.

     Rituximab - a double-edged sword: can one treatment for thrombocytopenia also
     induce it?

Leukemia and  Lymphoma Vol. 49, pp 2035-2036, 2008                                      (journal IF = 1.512; journal 5-Year IF = 1.461; journal rank = 41 of 63)

 

6.      Raanani P, Gafter-Gvili1 A., Paul M., Ben-Bassat I., Leibovici L., Shpilberg O. Reply to "Prophylactic intravenous immunoglobulin does not have a role in hematopoietic stem cell transplant: Is the evidence clear?" Nishitha Reddy, et. al.

Journal of Clinical Oncology Vol. 27, pp 2297-2298, 2009

(journal IF =  15.484; journal 5-Year IF = 13.753; journal rank = 5 of 132)

 

7.      Ram R, Raanani P.

The role of myeloid colony stimulating factors in the treatment of acute    lymphoblastic leukemia – more questions than answers?

      Leukemia and  Lymphoma  Vol 5, pp 1737-1739, 2009

(journal IF = 1.939; journal 5-Year IF = 1.680; journal rank = 43 of 62)

 

8.      Gurion R., Vidal L., Gafter-Gvili A., Belnik Y., Yeshuru M., Raanani P.,
Shpilberg O.

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - systematic review and meta-analysis (Reply to Kumar et al. and to Herbst et al.)

Haematologica Vol 95, pp. 343-344, 2010

 (journal IF =  5.978; journal 5-Year IF = 5.513; journal rank = 9 of 62)

 

{C}9.      {C}Raanani P., Skoetz N. 
The role of systematic reviews and meta-analyses in the management of hemato-oncological disorders. Introduction.
Acta Haematologica Vol. 125, pp 5-7, 2011

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank   = 62 of 70; Quartile in Category – Q4; no. of citations: 1)

 

10.  Raanani P.                                                                                                    Editorial: Taming of the shrew - overcoming extramedullary blast crisis in the era of    the new tyrosine kinase inhibitors.

       Acta Haematologica Vol. 125, pp 5-7, 2011

 (journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank   = 62 of 70; Quartile in Category – Q4; no. of citations: 2)

 

 

11.  Experts in Chronic Myeloid Leukemia.

Collaborators: Abboud C, Berman E, Cohen A, Cortes J, DeAngelo D, Deininger M, Devine S, Druker B, Fathi A, Jabbour E, Jagasia M, Kantarjian H, Khoury J,

Laneuville P, Larson R, Lipton J, Moore JO, Mughal T, O'Brien S, Pinilla-Ibarz J, Quintas-Cardama A, Radich J, Reddy V, Schiffer C, Shah N, Shami P, Silver RT, Snyder D, Stone R, Talpaz M, Tefferi A, Van Etten RA, Wetzler M, Abruzzese E, Apperley J, Breccia M, Byrne J, Cervantes F, Chelysheva E, Clark R, de Lavallade H, Dyagil I, Gambacorti-Passerini C, Goldman J, Haznedaroglu I, Hjorth-Hansen H, Holyoake T, Huntly B, le Coutre P, Lomaia E, Mahon FX, Marin-Costa D, Martinelli G, Mayer J, Milojkovic D, Olavarria E, Porkka K, Richter J, Rousselot P, Saglio G, Saydam G, Stentoft J, Turkina A, Vigneri P, Zaritskey A, Aguayo A, Ayala M, Bendit I, Bengio RM, Best C, Bullorsky E, Cervera E, DeSouza C, Fanilla E, Gomez-Almaguer D, Hamerschlak N, Lopez J, Magarinos A, Meillon L, Milone J, Moiraghi B, Pasquini R, Pavlovsky C, Ruiz-Arguelles GJ, Spector N, Arthur C, Browett P, Grigg A, Hu J, Huang XJ, Hughes T, Jiang Q, Jootar S, Kim DW, Malhotra H, Malhotra P, Matsumura I, Melo J, Ohnishi K, Ohno R, Saikia T, Schwarer AP, Takahashi N, Tam C, Tauchi T, Usuki K, Wang J, Abdel-Rahman F, Aljurf MD, Bazarbachi A, Ben Yehuda D, Chaudhri N, Durosinmi M, Kamel H, Louw V, Matti BF, Nagler A, Raanani P, Salem Z.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the

unsustainable prices of cancer drugs: from the perspective of a large group of

CML experts.

Blood Vol 121, pp 4439-4442, 2013

(journal IF =  11.841; journal 5-Year IF = 10.233; journal rank = 2 of 70; Quartile in Category – Q4; no. of citations: 104)

 

12.  Raanani P., Tallman MS.

The challenges and perspectives in treating adolescent and young adult patients with hematological malignancies. Introduction.

Acta Haematologica Vol 132, pp 263, 2014

 (journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank   = 62 of 70; Quartile in Category – Q4; no. of citations: 0)

13.  Raanani P.

The Importance of Being Cured: A Chronic Myeloid Leukemia Perspective.                        Acta Haematologica Vol 135, pp 131-132, 2016
     (journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal rank   = 62 of 70; Quartile in Category – Q4; no. of citations: 0)

 

14.  Amitai I., Leader A., Raanani P.

Adherence to tyrosine kinase inhibitors in chronic myeloid leukemia: the challenge that lies ahead

      Acta Haematologica Vol 136, pp 43 - 44, 2016

(journal IF =  1.053; journal 5-Year IF = 0.923; HEMATOLOGY journal        rank= 62 of 70; Quartile in Category – Q4; no. of citations: 0)

 

 

 

 

{C}H.    MEMBER OF EDITORIAL BOARD / REVIEWER                   (International Journals)

 

1. Editorial Board:

1. Cochrane Haematological Malignancies Group (CHMG) –The Cochrane Collaboration (since 2006)

2. ACTA HAEMATOLOGICA (since 2012)

3. The Israel Medical Association Journal (IMAJ) (since 2014)

4. Cardio-Oncology (since 2015)

 

 

2. Reviewer:

1. ACTA HAEMATOLOGICA (since 1999)

2. British Journal of Haematology (since 2003)

3. Leukemia (since 2004)

4. European Journal of Haematology (since 2007)

5. Leukemia and Lymphoma (since 2008)

6. Haematlogica (since 2009)

7. Blood (since 2011)

8. Journal of Cancer (since 2012)

9. Leukemia Research (since 2013)

 

 

 

 

 

 

 

               

 

Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel
UI/UX Basch_Interactive